<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Eylea, INN-Aflibercept</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	line-height:13.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
h3
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:43.9pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char1";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-name:"Caption\,Bayer Caption";
	mso-style-link:"Caption Char\,Bayer Caption Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:45.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Calibri Light",sans-serif;}
span.MsoEndnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	line-height:13.0pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0in;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:31.65pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	line-height:13.0pt;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial Unicode MS",sans-serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin-top:10.0pt;
	margin-right:.6in;
	margin-bottom:8.0pt;
	margin-left:.6in;
	text-align:center;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#404040;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:.25in;
	margin-right:.6in;
	margin-bottom:.25in;
	margin-left:.6in;
	text-align:center;
	line-height:13.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4472C4;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.AHeader1, li.AHeader1, div.AHeader1
	{mso-style-name:"AHeader 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2, li.AHeader2, div.AHeader2
	{mso-style-name:"AHeader 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader3, li.AHeader3, div.AHeader3
	{mso-style-name:"AHeader 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2abc, li.AHeader2abc, div.AHeader2abc
	{mso-style-name:"AHeader 2 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-align:justify;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.AHeader3abc, li.AHeader3abc, div.AHeader3abc
	{mso-style-name:"AHeader 3 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:85.05pt;
	text-align:justify;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Para0s, li.Para0s, div.Para0s
	{mso-style-name:"Para\:0\:s";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Helvetica",sans-serif;}
p.Table120, li.Table120, div.Table120
	{mso-style-name:"Table12\:0";
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Xspace40, li.Xspace40, div.Xspace40
	{mso-style-name:"Xspace4\:0";
	margin:0in;
	font-size:4.0pt;
	font-family:"Times New Roman",serif;}
p.GlobalBayerBodyText, li.GlobalBayerBodyText, div.GlobalBayerBodyText
	{mso-style-name:"Global Bayer Body Text";
	mso-style-link:"Global Bayer Body Text Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
span.GlobalBayerBodyTextChar
	{mso-style-name:"Global Bayer Body Text Char";
	mso-style-link:"Global Bayer Body Text";
	font-family:"Arial",sans-serif;}
p.BayerBodyTextFull, li.BayerBodyTextFull, div.BayerBodyTextFull
	{mso-style-name:"Bayer Body Text Full";
	mso-style-link:"Bayer Body Text Full Zchn";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Para0sb, li.Para0sb, div.Para0sb
	{mso-style-name:"Para\:0\:sb";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-BodyText, li.C-BodyText, div.C-BodyText
	{mso-style-name:"C-Body Text";
	mso-style-link:"C-Body Text Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.C-BodyTextChar
	{mso-style-name:"C-Body Text Char";
	mso-style-link:"C-Body Text";}
p.C-TableHeader, li.C-TableHeader, div.C-TableHeader
	{mso-style-name:"C-Table Header";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-TableText, li.C-TableText, div.C-TableText
	{mso-style-name:"C-Table Text";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BayerTRDASectionHeading3, li.BayerTRDASectionHeading3, div.BayerTRDASectionHeading3
	{mso-style-name:"Bayer TRD_A_Section Heading 3";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:77.95pt;
	text-indent:-56.7pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title  A";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.berarbeitung1, li.berarbeitung1, div.berarbeitung1
	{mso-style-name:berarbeitung1;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.TitleA0, li.TitleA0, div.TitleA0
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	text-indent:-17.85pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.CommentTextChar1
	{mso-style-name:"Comment Text Char1";
	mso-style-link:"Comment Text";}
span.BayerBodyTextFullZchn
	{mso-style-name:"Bayer Body Text Full Zchn";
	mso-style-link:"Bayer Body Text Full";}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	font-family:"Times New Roman",serif;}
p.No-numheading5Agency, li.No-numheading5Agency, div.No-numheading5Agency
	{mso-style-name:"No-num heading 5 \(Agency\)";
	mso-style-link:"No-num heading 5 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.No-numheading5AgencyChar
	{mso-style-name:"No-num heading 5 \(Agency\) Char";
	mso-style-link:"No-num heading 5 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.DocsubtitleAgency, li.DocsubtitleAgency, div.DocsubtitleAgency
	{mso-style-name:"Doc subtitle \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:32.0pt;
	margin-left:0in;
	line-height:18.0pt;
	font-size:12.0pt;
	font-family:"Verdana",sans-serif;}
p.DoctitleAgency, li.DoctitleAgency, div.DoctitleAgency
	{mso-style-name:"Doc title \(Agency\)";
	margin-top:.5in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:18.0pt;
	font-size:16.0pt;
	font-family:"Verdana",sans-serif;
	color:#003399;}
p.HeaderAgency, li.HeaderAgency, div.HeaderAgency
	{mso-style-name:"Header \(Agency\)";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.CarCar2CharCharCarCarCharChar, li.CarCar2CharCharCarCarCharChar, div.CarCar2CharCharCarCarCharChar
	{mso-style-name:" Car Car2 Char Char Car Car Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Car";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.Heading1Agency, li.Heading1Agency, div.Heading1Agency
	{mso-style-name:"Heading 1 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:13.5pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading2Agency, li.Heading2Agency, div.Heading2Agency
	{mso-style-name:"Heading 2 \(Agency\)";
	mso-style-link:"Heading 2 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.Heading3Agency, li.Heading3Agency, div.Heading3Agency
	{mso-style-name:"Heading 3 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading4Agency, li.Heading4Agency, div.Heading4Agency
	{mso-style-name:"Heading 4 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.Heading5Agency, li.Heading5Agency, div.Heading5Agency
	{mso-style-name:"Heading 5 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading6Agency, li.Heading6Agency, div.Heading6Agency
	{mso-style-name:"Heading 6 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:3.0in;
	text-indent:-.25in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading7Agency, li.Heading7Agency, div.Heading7Agency
	{mso-style-name:"Heading 7 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:3.5in;
	text-indent:-.25in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading8Agency, li.Heading8Agency, div.Heading8Agency
	{mso-style-name:"Heading 8 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading9Agency, li.Heading9Agency, div.Heading9Agency
	{mso-style-name:"Heading 9 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.Heading2AgencyChar
	{mso-style-name:"Heading 2 \(Agency\) Char";
	mso-style-link:"Heading 2 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
span.BodytextAgencyCar
	{mso-style-name:"Body text \(Agency\) Car";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.Listenabsatz1, li.Listenabsatz1, div.Listenabsatz1
	{mso-style-name:Listenabsatz1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.CaptionChar
	{mso-style-name:"Caption Char\,Bayer Caption Char";
	mso-style-link:"Caption\,Bayer Caption";
	font-weight:bold;}
p.bayerbodytextfull0, li.bayerbodytextfull0, div.bayerbodytextfull0
	{mso-style-name:bayerbodytextfull;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.BayerTableFootnote, li.BayerTableFootnote, div.BayerTableFootnote
	{mso-style-name:"Bayer Table Footnote";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.C-TableFootnote, li.C-TableFootnote, div.C-TableFootnote
	{mso-style-name:"C-Table Footnote";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.1in;
	text-indent:-.1in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.ListParagraph1, li.ListParagraph1, div.ListParagraph1
	{mso-style-name:"List Paragraph1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:35.4pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Revision1, li.Revision1, div.Revision1
	{mso-style-name:Revision1;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Nottoc-headings, li.Nottoc-headings, div.Nottoc-headings
	{mso-style-name:"Not toc-headings";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.BayerBodyTextFullChar
	{mso-style-name:"Bayer Body Text Full Char";}
p.Listenabsatz2, li.Listenabsatz2, div.Listenabsatz2
	{mso-style-name:Listenabsatz2;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	font-family:"Verdana",sans-serif;}
p.berarbeitung2, li.berarbeitung2, div.berarbeitung2
	{mso-style-name:berarbeitung2;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FooterblueAgency, li.FooterblueAgency, div.FooterblueAgency
	{mso-style-name:"Footer blue \(Agency\)";
	mso-style-link:"Footer blue \(Agency\) Char Char";
	margin:0in;
	font-size:6.5pt;
	font-family:"Times New Roman",serif;
	color:#003399;
	font-weight:bold;}
span.FooterblueAgencyCharChar
	{mso-style-name:"Footer blue \(Agency\) Char Char";
	mso-style-link:"Footer blue \(Agency\)";
	font-family:"Verdana",sans-serif;
	color:#003399;
	font-weight:bold;}
p.BulletBayerBodyText, li.BulletBayerBodyText, div.BulletBayerBodyText
	{mso-style-name:"Bullet Bayer Body Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	color:green;
	font-style:italic;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";
	color:green;
	font-style:normal;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:"Courier New";}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#4472C4;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:"Courier New";}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Calibri Light",sans-serif;
	background:#CCCCCC;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	color:#404040;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Calibri Light",sans-serif;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:842.0pt 595.35pt;
	margin:56.7pt 56.7pt 70.9pt 56.7pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection3
	{page:WordSection3;}
@page WordSection4
	{size:842.0pt 595.35pt;
	margin:.5in .5in .5in .5in;}
div.WordSection4
	{page:WordSection4;}
@page WordSection5
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection5
	{page:WordSection5;}
@page WordSection6
	{size:842.0pt 595.35pt;
	margin:56.7pt 56.7pt 70.9pt 56.7pt;}
div.WordSection6
	{page:WordSection6;}
@page WordSection7
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection7
	{page:WordSection7;}
@page WordSection8
	{size:842.0pt 595.35pt;
	margin:.5in 12.45pt .5in .5in;}
div.WordSection8
	{page:WordSection8;}
@page WordSection9
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection9
	{page:WordSection9;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal><span lang=EN-GB style='font-family:"Calibri",sans-serif;
color:#1F497D'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleA0><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<p class=TitleA0><span lang=EN-GB style='text-transform:none;background:fuchsia;
font-weight:normal'>&nbsp;</span></p>

<p class=TitleA0 align=left style='text-align:left;text-indent:0in'><span
lang=EN-GB style='font-family:"Arial",sans-serif;font-weight:normal'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>1.</span></b><span lang=EN-GB> <b>NAME OF THE
MEDICINAL PRODUCT</b></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Eylea 40&nbsp;mg/mL&nbsp;</span><span lang=EN-GB>solution for
injection in pre-filled syringe.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>2. QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>1 mL solution for
injection contains 40&nbsp;mg aflibercept*.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One pre-filled
syringe contains 90&nbsp;microlitres, equivalent to 3.6&nbsp;mg aflibercept.
This provides a usable amount to deliver a single dose of 50 microlitres
containing 2</span><span lang=EN-GB>&nbsp;mg</span><span lang=EN-GB>
aflibercept.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*Fusion protein
consisting of portions of human VEGF (Vascular Endothelial Growth Factor)
receptors&nbsp;1 and 2 extracellular domains fused to the Fc portion of human
IgG1</span><span lang=EN-GB> and </span><span lang=EN-GB>produced in Chinese
hamster ovary (CHO) K1 cells by recombinant DNA technology.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3. PHARMACEUTICAL <span style='text-transform:
uppercase'>form</span></span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Solution for injection (injection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The solution is a
clear, colourless to pale yellow and iso-osmotic solution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='text-transform:uppercase'>4. Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Eylea </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>is
indicated for adults for the treatment of </span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN-GB>neovascular (wet)
     age-related macular degeneration (AMD) (see section 5.1),</span></li>
</ul>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-10.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>visual impairment due to macular oedema secondary
to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN-GB>visual
     impairment due to diabetic macular oedema (DME) (see section 5.1),</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN-GB>visual
     impairment due to myopic choroidal neovascularisation (myopic CNV) (see section
     5.1).</span></li>
</ul>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.2 Posology
and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Eylea is for
intravitreal injection only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Eylea must only be
administered by a qualified physician experienced in administering intravitreal
injections.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Posology</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><s><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>wet AMD</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The recommended
dose for Eylea is 2&nbsp;mg aflibercept, equivalent to 50&nbsp;microlitres.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Eylea treatment is
initiated with one injection per month for three consecutive doses. The
treatment interval is then extended to two months.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Based on the
physicians judgement of visual and/or anatomic outcomes, the treatment
interval may be maintained at two months or further extended using a
treat-and-extend dosing regimen, where injection intervals are increased in 2- or
4-weekly increments to maintain stable visual and/or anatomic outcomes. If
visual and/or anatomic outcomes deteriorate, the treatment interval should be
shortened accordingly to a minimum of two months during the first 12 months of
treatment.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>There is no
requirement for monitoring between injections. Based on the physicians
judgement the schedule of monitoring visits may be more frequent than the
injection visits.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>Treatment intervals greater than four
months between injections have not been studied (see Section 5.1</span><span
style='font-family:"Times New Roman",serif'>).</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Macular
oedema secondary to </span></i><i><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>RVO (branch RVO or central RVO)</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The recommended
dose for Eylea is 2 mg aflibercept equivalent to 50 microlitres. </span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>After the initial
injection, treatment is given monthly. The interval between two doses should
not be shorter than one month.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>If visual and
anatomic outcomes indicate that the patient is not benefiting from continued
treatment, Eylea should be discontinued.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Monthly treatment
continues until maximum visual acuity is achieved and/or there are no signs of
disease activity. Three or more consecutive, monthly injections may be needed.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Treatment may then
be continued with a treat-and-extend regimen with gradually increased treatment
intervals to maintain stable visual and/or anatomic outcomes, however there are
insufficient data to conclude on the length of these intervals. If visual
and/or anatomic outcomes deteriorate, the treatment interval should be
shortened accordingly.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The monitoring
and treatment schedule should be determined by the treating physician based on
the individual patients response. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Monitoring for
disease activity may include clinical examination, functional testing or
imaging techniques (e.g. optical coherence tomography or fluorescein
angiography).</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Diabetic macular oedema</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The recommended
dose for Eylea is 2 mg aflibercept equivalent to 50 microlitres. </span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Eylea treatment is
initiated with one injection per month for five consecutive doses, followed by
one injection every two months. There is no requirement for monitoring between
injections. </span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>After the first 12
months of treatment with Eylea, and based on visual and/or anatomic outcomes,
the treatment interval may be extended, such as with a treat-and-extend dosing
regimen, where the treatment intervals are gradually increased to maintain
stable visual and/or anatomic outcomes; however there are insufficient data to
conclude on the length of these intervals. If visual and/or anatomic outcomes
deteriorate, the treatment interval should be shortened accordingly.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The schedule for
monitoring should therefore be determined by the treating physician and may be
more frequent than the schedule of injections.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>If visual and
anatomic outcomes indicate that the patient is not benefiting from continued
treatment, Eylea should be discontinued.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Myopic
choroidal neovascularisation</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The recommended
dose for Eylea is a single intravitreal injection of 2 mg aflibercept
equivalent to 50&nbsp;microlitres. </span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Additional doses
may be administered if visual and/or anatomic outcomes indicate that the disease
persists. Recurrences should be treated as a new manifestation of the disease.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The schedule for
monitoring should be determined by the treating physician.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The interval
between two doses should not be shorter than one month.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Special
populations</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hepatic
and/or renal impairment</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>No
specific studies in patients with hepatic and/or renal impairment have been conducted
with </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Eylea</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Available data do
not suggest a need for a dose adjustment with </span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Eylea</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'> in
these patients (see section&nbsp;5.2).</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Elderly population</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>No special
considerations are needed. </span><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>There is limited experience in patients
older than 75 years with DME.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Paediatric
population </span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The safety and
efficacy of Eylea have not been established in children and adolescents. There
is no relevant use of Eylea in the paediatric population for the indications of
wet AMD, CRVO, BRVO, DME and myopic CNV.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Method of
administration</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Intravitreal
injections must be carried out according to medical standards and applicable
guidelines by a qualified physician experienced in administering intravitreal
injections.</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>
In general, adequate anaesthesia and asepsis, including topical broad spectrum
microbicide (e.g. povidone iodine applied to </span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>the periocular
skin, eyelid and ocular surface</span><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>), have to be ensured. </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Surgical
hand disinfection, sterile gloves, a sterile drape, and a sterile eyelid
speculum (or equivalent) are recommended.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The injection
needle should be inserted 3.5-4.0 mm posterior to the limbus into the vitreous
cavity, avoiding the horizontal meridian and aiming towards the centre of the
globe. The injection volume of 0.05 mL is then delivered; a different scleral
site should be used for subsequent injections.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Immediately
following the intravitreal injection, patients should be monitored for elevation
in intraocular pressure. Appropriate monitoring may consist of a check for
perfusion of the optic nerve head or tonometry.</span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'> If required,
sterile equipment for paracentesis should be available.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Following
intravitreal injection </span><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>patients should be instructed to report any
symptoms suggestive of endophthalmitis (e.g. eye pain, redness of the eye,
photophobia, blurring of vision) without delay.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Each pre-filled
syringe should only be used for the treatment of a single eye. Extraction of
multiple doses from a pre-filled syringe may increase the risk of contamination
and subsequent infection.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;color:black'>The pre-filled syringe contains more than
the recommended dose of 2 mg aflibercept. T</span><span lang=EN-GB
style='font-size:11.0pt'>he extractable volume of the syringe (90&nbsp;microlitres)
is not to be used in total. </span><span lang=EN-GB style='font-size:11.0pt;
color:black'>The excess volume should be expelled before injecting.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Injecting the entire volume of the pre-filled syringe
could result in overdose. </span><span lang=EN-GB style='font-size:11.0pt;
color:black'>T</span><span lang=EN-GB style='font-size:11.0pt'>o expel the air
bubble along with excess medicinal product, slowly depress the plunger to align
the cylindrical base of the dome plunger with the black dosing line on the
syringe (equivalent to 50 microlitres i.e. 2 mg aflibercept).</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>After injection any unused product must be discarded.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>For handling of
the medicinal product before administration, see section&nbsp;6.6.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypersensitivity
to the active substance aflibercept or to any of the excipients listed in
section 6.1.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Active or
suspected ocular or periocular infection.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Active severe
intraocular inflammation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4 Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Traceability</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>In order to
improve the traceability of biological medicinal products, the name and the
batch number of the administered product should be clearly recorded.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><a name="OLE_LINK6"><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>Intravitreal injection-related reactions </span></u></a></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Intravitreal injections, including those with
Eylea, have been associated with endophthalmitis, intraocular inflammation,
rhegmatogenous retinal detachment, retinal tear and iatrogenic traumatic
cataract (see section 4.8). Proper aseptic injection techniques must always be
used when administering Eylea. In addition, patients should be monitored during
the week following the injection to permit early treatment if an infection
occurs. Patients should be instructed to report any symptoms suggestive of
endophthalmitis or any of the above mentioned events without delay.</span><i><span
lang=EN-GB> </span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Increases in intraocular pressure have been seen
within 60&nbsp;minutes of intravitreal injection, including those with Eylea (see
section&nbsp;4.8). Special precaution is needed in patients with poorly
controlled glaucoma (do not inject Eylea while the intraocular pressure is
&#8805; 30 mmHg). In all cases, both the intraocular pressure and the perfusion
of the optic nerve head must therefore be monitored and managed appropriately.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt'>Immunogenicity</span></u></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;color:black'>As this is a therapeutic protein, there is
a potential for immunogenicity with Eylea (see section 4.8). Patients should be
instructed to report any signs or symptoms of intraocular inflammation, e.g.
pain, photophobia, or redness, which may be a clinical sign attributable to hypersensitivity.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Systemic effects</span></u></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;color:black'>Systemic adverse events including
non-ocular haemorrhages and arterial thromboembolic events have been reported
following intravitreal injection of VEGF inhibitors </span><span lang=EN-GB
style='font-size:11.0pt;color:black'>and there is a theoretical risk that these
may relate to VEGF inhibition</span><span lang=EN-GB style='font-size:11.0pt;
color:black'>. There are limited data on safety in the treatment of patients
with CRVO, BRVO, DME </span><span lang=EN-GB style='font-size:11.0pt'>or myopic
CNV </span><span lang=EN-GB style='font-size:11.0pt;color:black'>with a history
of stroke or transient ischaemic attacks or myocardial infarction within the
last 6 months. Caution should be exercised when treating such patients.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Other</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>As with other
intravitreal anti-VEGF treatments for AMD, CRVO, BRVO, DME </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>and
myopic CNV </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>the
following also applies:</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:14.2pt'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The safety and efficacy
of Eylea therapy administered to both eyes concurrently have not been
systematically studied (see section 5.1). If bilateral treatment is performed
at the same time this could lead to an increased systemic exposure, which could
increase the risk of systemic adverse events.</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Concomitant use of
other anti-VEGF (vascular endothelial growth factor)</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt'><span lang=EN-GB style='font-size:11.0pt'>There is no
data available on the concomitant use of Eylea with other anti-VEGF medicinal
products (systemic or ocular).</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Risk factors associated
with the development of a retinal pigment epithelial tear after anti-VEGF
therapy for wet AMD, include a large and/or high pigment epithelial retinal
detachment. When initiating Eylea therapy, caution should be used in patients
with these risk factors for retinal pigment epithelial tears.</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Treatment should be
withheld in patients with rhegmatogenous retinal detachment or stage 3 or 4
macular holes.</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>In the event of a retinal
break the dose should be withheld and treatment should not be resumed until the
break is adequately repaired.</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt;color:black'>The dose should be withheld and
treatment should not be resumed earlier than the next scheduled treatment in
the event of:</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:1.0in;text-indent:-.25in'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>a decrease in best-corrected
visual acuity (BCVA) of &#8805;30 letters compared with the last assessment of
visual acuity;</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:1.0in;text-indent:-.25in'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>a subretinal
haemorrhage involving the centre of the fovea, or, if the size of the
haemorrhage is &#8805;50%, of the total lesion area.</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt;color:black'>The dose should be withheld
within the previous or next 28 days in the event of a performed or planned
intraocular surgery.</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Eylea should not be used in pregnancy unless
the potential benefit outweighs the potential risk to the foetus (see section
4.6).</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Women of childbearing potential have to use
effective contraception during treatment and for at least 3 months after the
last intravitreal injection of aflibercept (see section 4.6).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>There is limited experience with treatment of
patients with ischaemic CRVO and BRVO. In patients presenting with clinical
signs of irreversible ischaemic visual function loss, the treatment is not
recommended</span><span lang=EN-GB style='color:black'>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Populations with limited data</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is only
limited experience in the treatment of subjects with DME due to type I diabetes
or in diabetic patients with an HbA1c over 12% or with proliferative diabetic
retinopathy.</span></p>

<p class=MsoNormal><span lang=EN-GB>Eylea has not been studied in patients with
active systemic infections or in patients with concurrent eye conditions such
as retinal detachment or macular hole. There is also no experience of treatment
with Eylea in diabetic patients with uncontrolled hypertension. This lack of
information should be considered by the physician when treating such patients. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In myopic CNV there is no experience with
Eylea in the treatment of non-Asian patients, patients who have previously
undergone treatment for myopic CNV, and patients with extrafoveal lesions. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Information about excipients</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg)
per dosage unit, that is to say essentially sodium-free.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.5 Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>No interaction studies have been performed.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Adjunctive use of verteporfin photodynamic therapy
(PDT) and Eylea has not been studied, therefore, a safety profile is not
established.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6 Fertility, pregnancy
and lactation</span></b></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Women
of childbearing potential</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Women of
childbearing potential have to use effective contraception during treatment and
for at least 3 months after the last intravitreal injection of aflibercept (see
section&nbsp;4.4).</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>Pregnancy</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>There
are no data on the use of aflibercept in pregnant women.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Studies in animals
have shown embryo-foetal toxicity (see section&nbsp;5.3).</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Although the
systemic exposure after ocular administration is very low, Eylea should not be
used during pregnancy unless the potential benefit outweighs the potential risk
to the foetus.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Breast-feeding</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>It is
unknown whether aflibercept is excreted in human milk. A risk to the breast-fed
child cannot be excluded.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Eylea is not
recommended during breast-feeding. A decision must be made whether to
discontinue breast-feeding or to abstain from Eylea therapy </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>taking
into account the benefit of breast-feeding for the child and the benefit of
therapy for the woman</span><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Fertility</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Results from
animal studies with high systemic exposure indicate that aflibercept can impair
male and female fertility (see section 5.3). Such effects are not expected
after ocular administration with very low systemic exposure.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7 Effects on ability
to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Injection
with Eylea has a minor influence on the ability to drive and use machines due
to possible temporary visual disturbances associated either with the injection
or the eye examination. Patients should not drive or use machines until their
visual function has recovered sufficiently.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Summary
of the safety profile</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>A total of 3,102 patients
constituted the safety population in the eight phase&nbsp;III studies. Among
those, 2,501 patients were treated with the recommended dose of 2&nbsp;mg.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Serious ocular adverse
reactions in the study eye related to the injection procedure have occurred in
less than 1&nbsp;in&nbsp;1,900 intravitreal injections with Eylea and included blindness,
endophthalmitis, retinal detachment, cataract traumatic, cataract, vitreous
haemorrhage, vitreous detachment, and intraocular pressure increased (see
section&nbsp;4.4).</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The most
frequently observed adverse reactions (in at least&nbsp;5%&nbsp;of patients
treated with Eylea) were conjunctival haemorrhage&nbsp;(25%), retinal
haemorrhage (11%), visual acuity reduced (11%), eye pain&nbsp;(10%), cataract (8%),
intraocular pressure increased&nbsp;(8%), vitreous detachment&nbsp;(7%), and vitreous
floaters&nbsp;(7%). </span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Tabulated list of
adverse reactions</span></u></p>

<p class=BayerBodyTextFull style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>The safety data described below include all adverse
reactions from the eight phase III studies in the indications wet AMD, CRVO, BRVO,
DME and myopic CNV with a reasonable possibility of causality to the injection
procedure or medicinal product.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>The adverse reactions are listed by system organ class
and frequency using the following convention:</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Very common (&#8805;1/10), common (&#8805;1/100 to
&lt;1/10), uncommon (&#8805;1/1,000 to &lt;1/100), rare (</span><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'></span><span
lang=EN-GB style='font-size:11.0pt'> 1/10,000 to &lt; 1/1,000)</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Within each frequency grouping, adverse drug reactions
are presented in order of decreasing seriousness.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 1:</span></b><span
lang=EN-GB>  </span><span lang=EN-GB>All treatment-emergent adverse drug
reactions reported in patients in phase III studies (pooled data of the phase
III studies for the indications wet AMD, CRVO, BRVO, DME and myopic CNV) or
during post-marketing surveillance</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=603
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=71 style='width:52.9pt;border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-5.3pt;
  margin-bottom:2.0pt;margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>System
  Organ Class</span></b></p>
  </td>
  <td width=100 style='width:74.7pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:2.0pt;margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very
  common</span></b></p>
  </td>
  <td width=206 style='width:154.25pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></b></p>
  </td>
  <td width=142 style='width:106.3pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></b></p>
  </td>
  <td width=85 style='width:63.8pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=71 valign=top style='width:52.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:-5.3pt;
  margin-bottom:0in;margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Immune
  system disorders</span></b></p>
  </td>
  <td width=100 valign=top style='width:74.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=206 valign=top style='width:154.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypersensitivity***<sup>
  </sup></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=71 valign=top style='width:52.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-5.3pt;
  margin-bottom:0in;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Eye disorders</span></b></p>
  </td>
  <td width=100 valign=top style='width:74.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Visual acuity reduced,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Retinal haemorrhage,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Conjunctival haemorrhage,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Eye pain</span></p>
  </td>
  <td width=206 valign=top style='width:154.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Retinal pigment epithelial tear*,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Detachment of the retinal pigment
  epithelium,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Retinal degeneration,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Vitreous haemorrhage,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Cataract,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Cataract cortical,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Cataract nuclear,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Cataract subcapsular,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Corneal erosion, </span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Corneal abrasion,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Intraocular pressure increased,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Vision blurred,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Vitreous floaters,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Vitreous detachment,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Injection site pain,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Foreign body sensation in eyes,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Lacrimation increased,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Eyelid oedema,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Injection site haemorrhage,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Punctate keratitis,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Conjunctival hyperaemia,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Ocular hyperaemia</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Endophthalmitis**,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Retinal detachment,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Retinal tear, </span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Iritis,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Uveitis,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Iridocyclitis,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Lenticular opacities,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Corneal epithelium defect,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Injection site irritation,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Abnormal sensation in eye,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Eyelid irritation,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Anterior chamber flare, </span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Corneal oedema</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Blindness,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Cataract traumatic,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Vitritis,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Hypopyon</span></p>
  </td>
 </tr>
</table>

<p class=BayerBodyTextFull style='margin-top:4.0pt;margin-right:0in;margin-bottom:
0in;margin-left:.25in;text-indent:-.25in'><span lang=EN-GB style='font-size:
10.0pt'>* Conditions known to be associated with wet AMD. Observed in the
wet AMD studies only.</span></p>

<p class=BayerBodyTextFull style='margin-top:4.0pt;margin-right:0in;margin-bottom:
0in;margin-left:.25in;text-indent:-.25in'><span lang=EN-GB style='font-size:
10.0pt'>** Culture positive and culture negative endophthalmitis</span></p>

<p class=BayerBodyTextFull style='margin-top:4.0pt;margin-right:0in;margin-bottom:
0in;margin-left:.25in;text-indent:-.25in'><span lang=EN-GB style='font-size:
10.0pt'>*** During the post-marketing period, reports of hypersensitivity
included rash, pruritus, urticaria, and isolated cases of severe
anaphylactic/anaphylactoid reactions.</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;text-indent:-17.85pt'><i><span lang=EN-GB
style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:black'>Description of selected adverse reactions</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>In the
wet AMD phase III studies, there was an increased incidence of conjunctival haemorrhage
in patients receiving anti-thrombotic agents. This increased incidence was
comparable between patients treated with ranibizumab and Eylea.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Arterial
thromboembolic events (ATEs) are adverse events potentially related to systemic
VEGF inhibition. There is a theoretical risk of arterial thromboembolic events,
including stroke and myocardial infarction, following intravitreal use of VEGF
inhibitors.</span></p>

<p class=BayerBodyTextFull style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt'>A low incidence rate of arterial thromboembolic events
was observed in the Eylea clinical trials in patients with AMD, DME, RVO and
myopic CNV. Across indications no notable difference between the groups treated
with aflibercept and the respective comparator groups were observed.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>As with all therapeutic</span><span
lang=EN-GB> proteins, there is a potential for immunogenicity with Eylea.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Reporting
of suspected adverse reactions</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:silver'>the national reporting
system listed in </span></span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
background:silver'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:silver'>.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.9  Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>In clinical trials, doses of up to 4&nbsp;mg in monthly intervals have
been used and isolated cases of overdoses with 8&nbsp;mg occurred.</span></p>

<p class=MsoNormal style='text-autospace:none'><s><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Overdosing with
increased injection volume may increase intraocular pressure. Therefore, in
case of overdose, intraocular pressure should be monitored and if deemed
necessary by the treating physician, adequate treatment should be initiated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.1  Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: Ophthalmologicals / Antineovascularisation agents</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ATC code:&nbsp;S01LA05</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Aflibercept is a
recombinant fusion protein consisting of portions of human VEGF receptor&nbsp;1
and 2 extracellular domains fused to the Fc portion of human IgG1.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aflibercept is
produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Aflibercept acts
as a soluble decoy receptor that binds VEGF-A and PlGF with higher affinity
than their natural receptors, and thereby can inhibit the binding and
activation of these cognate VEGF receptors. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Mechanism of
action</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Vascular
endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are
members of the VEGF family of angiogenic factors that can act as potent
mitogenic, chemotactic, and vascular permeability factors for endothelial
cells. VEGF acts via two receptor tyrosine kinases; VEGFR-1 and VEGFR-2,
present on the surface of endothelial cells. PlGF binds only to VEGFR-1, which
is also present on the surface of leucocytes. Excessive activation of these
receptors by VEGF-A can result in pathological neovascularisation and excessive
vascular permeability. PlGF can synergize with VEGF-A in these processes, and
is also known to promote leucocyte infiltration and vascular inflammation.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Pharmacodynamic
effects</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>wet AMD</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Wet AMD is
characterised by pathological choroidal neovascularisation (CNV). Leakage of
blood and fluid from CNV may cause retinal thickening or oedema and/or
sub-/intra-retinal haemorrhage, resulting in loss of visual acuity.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>In patients
treated with Eylea (one injection per month for three consecutive months,
followed by one injection every 2&nbsp;months), central retinal thickness [CRT]
decreased soon after treatment initiation, and the mean CNV lesion size was
reduced, consistent with the results seen with ranibizumab 0.5&nbsp;mg every
month.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>In the VIEW1 study
there were mean decreases in CRT on optical coherence tomography (OCT) (-130
and -129 microns at week&nbsp;52 for the Eylea 2&nbsp;mg every two months and
ranibizumab 0.5&nbsp;mg every month study groups, respectively). Also at the
52&nbsp;week time point, in the VIEW2 study there were mean decreases in CRT on
OCT (-149 and -139 microns for the Eylea 2&nbsp;mg every two months and
ranibizumab 0.5&nbsp;mg every month study groups, respectively). The reduction
of CNV size and reduction in CRT were generally maintained in the second year
of the studies.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The ALTAIR study was conducted in Japanese<i>
</i>patients with treatment nave wet AMD, showing similar outcomes to the VIEW
studies using 3 initial monthly Eylea 2 mg injections, followed by one
injection after a further 2 months, and then continued with a treat-and-extend
regimen with variable treatment intervals (2- week or 4- week adjustments) up
to a maximum 16 week interval according to pre-specified criteria. At week 52,
there were mean decreases in central retinal thickness (CRT) on OCT of -134.4
and 126.1 microns for the 2-week adjustment group and the 4-week adjustment
group, respectively.<span style='color:red'> </span>The proportion of patients
without fluid on OCT at week 52 was 68.3% and 69.1% in the 2- and 4-week
adjustment groups, respectively. </span>The reduction in CRT was generally
maintained in both treatment arms in the second year of the ALTAIR study<i><span
style='font-size:12.0pt'>.</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Macular oedema secondary
to </span></i><i><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>CRVO
and BRVO</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>In CRVO and BRVO, retinal ischaemia occurs and signals
the release of VEGF which in turn destabilises the tight junctions, and
promotes endothelial cell proliferation. Up-regulation of VEGF is associated
with the breakdown of the blood retina barrier, increased vascular permeability,
retinal oedema, and neovascularisation complications.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients treated with 6 consecutive
monthly injections of Eylea 2mg, there was a consistent, rapid and robust morphologic
response (as measured by improvements in mean CRT) observed. At week 24, the
reduction in CRT was statistically superior versus control in all three studies
(</span><span lang=EN-GB>COPERNICUS in CRVO: -457 vs. -145 microns; GALILEO in
CRVO: -449 vs. -169 microns; VIBRANT in BRVO: -280 vs. -128 microns). This
decrease from baseline in CRT was maintained to the end of each study, week 100
in COPERNICUS, week 76 in GALILEO, and week 52 in VIBRANT.</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB>Diabetic
macular oedema</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Diabetic
macular oedema is a consequence of diabetic retinopathy and is characterised by
increased vasopermeability and damage to the retinal capillaries which may
result in loss of visual acuity. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-family:"Goudy",serif'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>In patients treated with Eylea, the majority of whom
were classified as having Type II diabetes, a rapid and robust response in
morphology (CRT, DRSS level) was observed. </span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>In the VIVID<sup>DME</sup> and the VISTA<sup>DME </sup>studies,
a statistically significant greater mean decrease in CRT from baseline to week
52 was observed in patients treated with Eylea than with the laser control, -192.4
and -183.1 microns for the 2Q8 Eylea groups and -66.2 and -73.3 microns for the
control groups, respectively. </span><span lang=EN-GB style='font-size:11.0pt'>At
week 100 the decrease was maintained with -195.8 and -191.1&nbsp;microns for
the 2Q8 Eylea groups and </span><span lang=EN-GB style='font-size:11.0pt'>-85.7
</span><span lang=EN-GB style='font-size:11.0pt'>and -83.9 microns for the
control groups, in the VIVID<sup>DME</sup> and VISTA<sup>DME</sup> studies,
respectively.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>A &#8805; 2 step improvement in DRSS was assessed in a
pre-specified manner in VIVID<sup>DME</sup> and VISTA<sup>DME</sup>. The DRSS
score was gradable in </span><span lang=EN-GB style='font-size:11.0pt'>73.7% of
the patients in VIVID<sup>DME</sup> and 98.3% of the patients in VISTA<sup>DME</sup></span><span
lang=EN-GB>.<i> </i></span><span lang=EN-GB style='font-size:11.0pt'>At week
52, 27.7% and 29.1% of the Eylea 2Q8 groups, and 7.5% and 14.3% of the control
groups experienced a &#8805;2&nbsp;step improvement in the DRSS.</span><span
lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:
11.0pt'>At week 100, the respective percentages were 32.6% and 37.1% of the
Eylea 2Q8 groups and 8.2% and 15.6% of the control groups.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Myopic
choroidal neovascularisation </span></i></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Myopic choroidal
neovascularisation (myopic CNV) is a frequent cause of vision loss in adults
with pathologic myopia. It develops as a wound healing mechanism consequent to
Bruchs membrane ruptures and represents the most vision-threatening event in
pathologic myopia. </span></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In patients treated with Eylea in the
MYRROR study (one injection given at start of therapy, with additional
injections given in case of disease persistence or recurrence), CRT decreased
soon after treatment initiation favouring Eylea at week 24 (-79&nbsp;microns
and -4&nbsp;microns for the Eylea 2&nbsp;mg treatment group and the control
group, respectively), which was maintained through week&nbsp;48. In addition, the
mean CNV lesion size decreased. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>wet AMD</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The safety and efficacy of Eylea were assessed in two randomised,
multi-centre, double-masked, active-controlled studies in patients with wet AMD
(VIEW1 and VIEW2) with a total of 2,412&nbsp;patients treated and evaluable for
efficacy (1,817&nbsp;with Eylea). Patient ages ranged from 49 to 99&nbsp;years
with a mean of 76&nbsp;years. </span><span lang=EN-GB>In these clinical
studies, approximately 89%&nbsp;(1,616/1,817) of the patients randomised to
treatment with </span><span lang=EN-GB>Eylea</span><span lang=EN-GB> were
65&nbsp;years of age or older, and approximately 63%&nbsp;(1,139/1,817) were
75&nbsp;years of age or older. </span><span lang=EN-GB>In each study, patients
were randomly assigned in a 1:1:1:1&nbsp;ratio to 1&nbsp;of&nbsp;4 dosing
regimens:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='font-size:12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>1)&nbsp;Eylea administered at </span><span lang=EN-GB>2&nbsp;mg</span><span
lang=EN-GB> every 8 weeks following 3&nbsp;initial monthly doses (Eylea 2Q8);</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>2)&nbsp;Eylea administered at 2&nbsp;mg every 4&nbsp;weeks (Eylea
2Q4);</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>3)&nbsp;Eylea administered at 0.5&nbsp;mg every 4&nbsp;weeks (Eylea&nbsp;0.5Q4);
and</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>4)&nbsp;ranibizumab administered at 0.5&nbsp;mg every 4&nbsp;weeks
(ranibizumab&nbsp;0.5Q4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>In the second year of the studies, patients continued
to receive the initially randomised dosage but on a modified dosing schedule
guided by assessment of visual and anatomic outcomes with a protocol-defined
maximum dosing interval of 12 weeks.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In both studies,
the primary efficacy endpoint was the proportion of patients in the Per
Protocol Set who maintained vision, i.e. losing fewer than 15&nbsp;letters of
visual acuity at week 52&nbsp;from baseline.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>In the VIEW1 study, at week&nbsp;52, 95.1% of patients
in the Eylea 2Q8&nbsp;group maintained vision compared to&nbsp;94.4% patients
in the ranibizumab 0.5Q4&nbsp;group. In the VIEW2 study, at week&nbsp;52, 95.6%
of patients in the Eylea 2Q8&nbsp;group maintained vision compared to 94.4%&nbsp;patients
in the ranibizumab 0.5Q4&nbsp;group. In both studies Eylea was shown to be
non-inferior and clinically equivalent to the ranibizumab 0.5Q4&nbsp;group.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed results
from the combined analysis of both studies are shown in Table&nbsp;2 and Figure&nbsp;1
below.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Table 2:</span></b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>
Efficacy outcomes at week&nbsp;52 (primary analysis) and week 96; combined data
from the VIEW1 and VIEW2 studies</span><sup><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>B)</span></sup></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=600
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=180 rowspan=2 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader style='margin:0in'><span lang=EN-GB>Efficacy Outcome</span></p>
  </td>
  <td width=210 colspan=2 valign=top style='width:157.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='margin:0in;text-align:center'><span
  lang=EN-GB>Eylea&nbsp;</span><span lang=EN-GB>2Q8</span><sup><span
  lang=EN-GB> E)</span></sup></p>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>(Eylea 2&nbsp;mg every 8&nbsp;weeks
  following 3&nbsp;initial monthly doses)</span></p>
  <p class=C-TableHeader align=center style='margin:0in;text-align:center'><span
  lang=EN-GB>(N = 607)</span></p>
  </td>
  <td width=210 colspan=2 valign=top style='width:157.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='margin:0in;text-align:center'><span
  lang=EN-GB>Ranibizumab&nbsp;</span><span lang=EN-GB>0.5Q4</span></p>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>(ranibizumab 0.5&nbsp;mg every
  4&nbsp;weeks)</span></p>
  <p class=C-TableHeader align=center style='margin:0in;text-align:center'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=C-TableHeader align=center style='margin:0in;text-align:center'><span
  lang=EN-GB>(N = 595)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=108 valign=top style='width:81.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-6.15pt;
  margin-bottom:0in;margin-left:-5.4pt;text-align:center;text-indent:.15pt;
  page-break-after:avoid'><span lang=EN-GB>Week 52</span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin-top:0in;margin-right:-6.9pt;margin-bottom:
  0in;margin-left:-4.65pt;page-break-after:avoid'><span lang=EN-GB>Week 96</span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin-top:0in;margin-right:-6.15pt;margin-bottom:
  0in;margin-left:-5.4pt;text-indent:.15pt;page-break-after:avoid'><span
  lang=EN-GB>Week 52</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin-top:0in;margin-right:-6.9pt;margin-bottom:
  0in;margin-left:-4.65pt;page-break-after:avoid'><span lang=EN-GB>Week 96</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>Mean number of injections from baseline </span></p>
  </td>
  <td width=108 style='width:81.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>7.6</span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>11.2</span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>12.3</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>16.5</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>Mean number of injections from Week 52 to 96</span></p>
  </td>
  <td width=108 style='width:81.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-6.15pt;
  margin-bottom:0in;margin-left:-5.4pt;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>4.2</span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>4.</span><span
  lang=EN-GB style='font-size:9.0pt'>7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>Proportion of patients with </span></p>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>&lt; 15 letters loss from baseline ( PPS<sup> A)</sup>)</span></p>
  </td>
  <td width=108 style='width:81.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-6.15pt;
  margin-bottom:0in;margin-left:-5.4pt;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>95.33%<sup>B)</sup></span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>92.42%</span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>94.42%<sup>
  B)</sup></span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>91.60%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>Difference<sup>C)</sup></span></p>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>(95% CI)<sup>D)</sup></span></p>
  </td>
  <td width=108 style='width:81.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-4.55pt;
  margin-bottom:0in;margin-left:-5.4pt;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>0.9%<br>
  (&#8209;1.7, 3.5)<sup>F)</sup></span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-4.55pt;
  margin-bottom:0in;margin-left:-5.4pt;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>0.8%<br>
  (&#8209;2.3, 3.8)<sup>F)</sup></span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>Mean change in BCVA as measured by ETDRS<sup>A)</sup> letter score
  from baseline </span></p>
  </td>
  <td width=108 style='width:81.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>8.40</span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>7.62</span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>8.74</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>7.89</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>Difference in LS<sup> A) </sup>mean change (ETDRS
  letters)<sup>C)</sup></span></p>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>(95% CI)<sup>D)</sup></span></p>
  </td>
  <td width=108 style='width:81.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-4.65pt;
  margin-bottom:0in;margin-left:-5.4pt;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&#8209;0.32<br>
  (&#8209;1.87, 1.23)</span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-6.9pt;
  margin-bottom:0in;margin-left:-7.65pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&#8209;0.25<br>
  (&#8209;1.98, 1.49)</span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>Proportion of patients with &#8805; 15 letters gain from baseline</span></p>
  </td>
  <td width=108 style='width:81.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>30.97%</span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>33.44%</span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>32.44%</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>31.60%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>Difference<sup>C)</sup></span></p>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>(95% CI)<sup>D)</sup></span></p>
  </td>
  <td width=108 style='width:81.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>&#8209;1.5%<br>
  (&#8209;6.8, 3.8)</span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>1.8%<br>
  (&#8209;3.5, 7.1)</span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=GlobalBayerBodyText style='margin:0in'><sup><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></sup></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt'><sup><span lang=EN-GB
style='font-family:"Times New Roman",serif'>A)</span></sup><span lang=EN-GB
style='font-family:"Times New Roman",serif'> BCVA: Best Corrected Visual
Acuity</span></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'> ETDRS: Early Treatment
Diabetic Retinopathy Study</span></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt'><span lang=EN-GB> </span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>LS: Least square means
derived from ANCOVA</span></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'> PPS: Per Protocol Set</span></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt'><sup><span lang=EN-GB
style='font-family:"Times New Roman",serif'>B)</span></sup><span lang=EN-GB
style='font-family:"Times New Roman",serif'> </span><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Full Analysis Set (FAS), Last
Observation Carried Forward (LOCF) for all analyses except proportion of
patients with maintained visual acuity at week 52 which is PPS</span></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt'><sup><span lang=EN-GB
style='font-family:"Times New Roman",serif'>C)</span></sup><span lang=EN-GB
style='font-family:"Times New Roman",serif'> The difference is the value of
the Eylea group minus the value of the ranibizumab group. A positive value
favours Eylea.</span></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt'><sup><span lang=EN-GB
style='font-family:"Times New Roman",serif'>D)</span></sup><span lang=EN-GB
style='font-family:"Times New Roman",serif'> Confidence interval (CI)
calculated by normal approximation</span></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt'><sup><span lang=EN-GB
style='font-family:"Times New Roman",serif'>E)</span></sup><span lang=EN-GB
style='font-family:"Times New Roman",serif'> After treatment initiation with
three monthly doses</span></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt'><sup><span lang=EN-GB
style='font-family:"Times New Roman",serif'>F)</span></sup><span lang=EN-GB
style='font-family:"Times New Roman",serif'> A confidence interval lying
entirely above -10% indicates a non-inferiority of Eylea to ranibizumab</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>Figure 1</span></b><span
lang=EN-GB>. Mean Change in Visual Acuity</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
page-break-after:avoid'><span lang=EN-GB>from Baseline to Week 96 for the
Combined</span></p>

<p class=GlobalBayerBodyText align=center style='margin:0in;text-align:center;
page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>Data from the View1 and View2 Studies</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB><img border=0
width=592 height=272 id="Grafik 1" src="Eylea_IB_007_files/image003.jpg"></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In combined data analysis of VIEW1 and
VIEW2, Eylea demonstrated clinically meaningful changes from baseline in
pre-specified secondary efficacy endpoint National Eye Institute Visual
Function Questionnaire (NEI VFQ-25) without clinically meaningful differences
to ranibizumab. The magnitude of these changes was similar to that seen in
published studies, which corresponded to a&nbsp;15-letter gain in Best
Corrected Visual Acuity (BCVA).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the second
year of the studies, efficacy was generally maintained through the last assessment
at week 96, and 2-4% of patients required all injections on a monthly basis,
and a third of patients required at least one injection with a treatment
interval of only one month.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Decreases in mean CNV area were evident in
all dose groups in both studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Efficacy results
in all evaluable subgroups (e.g. age, gender, race, baseline visual acuity,
lesion type, lesion size) in each study and in the combined analysis were
consistent with the results in the overall populations.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>ALTAIR was a 96&nbsp;week multicentre,
randomised, open-label study in 247 Japanese patients with treatment nave wet
AMD, designed to assess the efficacy and safety of Eylea following two
different adjustment intervals (2- weeks and 4- weeks) of a treat-and-extend
dosing regimen.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>All patients received monthly doses of Eylea
2 mg for 3 months, followed by one injection after a further 2 month interval.
At week 16, patients were randomised 1:1 into two treatment groups: 1) Eylea
treat-and-extend with 2-week adjustments and 2) Eylea treat-and-extend with
4-week adjustments. Extension or shortening of the treatment interval was
decided based on visual and/or anatomic criteria defined by protocol with a
maximum treatment interval of 16 weeks for both groups.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary efficacy endpoint was mean
change in BCVA from baseline to week 52. The secondary efficacy endpoints were
the proportion of patients who did not lose &#8805;15 letters and the
proportion of patients who gained at least 15 letters of BCVA from baseline to
week 52.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>At week 52, patients in the
treat-and-extend arm with 2-week adjustments gained a mean of 9.0 letters from
baseline as compared to 8.4 letters for those in the 4-week adjustment group
[LS mean difference in letters (95% CI): -0.4 (-3.8,3.0), ANCOVA]. The
proportion of patients who did not lose &#8805;15 letters in the two treatment
arms was similar (96.7% in the 2-week and 95.9% in the 4-week adjustment groups).
The proportion of patients who gained &#8805;15 letters at week 52 was 32.5% in
the 2-week adjustment group and 30.9% in the 4-week adjustment group.</span><span
lang=EN-GB> The proportion of patients who extended their treatment interval to
12 weeks or beyond was 42.3% in the 2-week adjustment group and 49.6% in the
4-week adjustment group. Furthermore, in the 4-week adjustment group 40.7% of
patients were extended to 16 week intervals. At the last visit up to week 52,
56.8% and 57.8% of patients in the 2-week and 4-week adjustment groups,
respectively had their next injection scheduled at an interval of 12 weeks or beyond.
</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>In the second year of the study, efficacy was generally
maintained up to and including the last assessment at week&nbsp;96, with a mean
gain from baseline of 7.6&nbsp;letters for the 2-week adjustment group and 6.1&nbsp;letters
for the 4-week adjustment group. The proportion of patients who extended their
treatment interval to 12&nbsp;weeks or beyond was 56.9% in the 2-week adjustment
group and 60.2% in the 4-week adjustment group. At the last visit prior to week
96, 64.9% and 61.2% of patients in the 2-week and 4-week adjustment groups,
respectively had their next injection scheduled at an interval of 12 weeks or
beyond. During the second year of treatment patients in both the 2-week and
4-week adjustment groups received an average of 3.6&nbsp;and 3.7&nbsp;injections,
respectively. Over the 2&nbsp;year treatment period patients received an
average of 10.4&nbsp;injections.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Ocular and systemic safety profiles were
similar to the safety observed in the pivotal studies VIEW1 and VIEW2.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Macular
oedema secondary to </span></i><i><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>CRVO</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>The safety and efficacy of Eylea were assessed in two
randomised, multi-centre, double-masked, sham-controlled studies in patients
with macular oedema secondary to CRVO (COPERNICUS and GALILEO) with a total of
358 patients treated and evaluable for efficacy (217 with Eylea). Patient ages
ranged from 22 to 89 years with a mean of 64&nbsp;years. In the CRVO studies,
approximately 52% (112/217) of the patients randomised to treatment with Eylea
were 65 years of age or older, and approximately 18% (38/217) were 75 years of
age or older. In both studies, patients were randomly assigned in a 3:2 ratio
to either 2&nbsp;mg Eylea administered every 4 weeks (2Q4), or the control
group receiving sham injections every 4 weeks for a total of 6 injections.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>After 6 consecutive monthly injections, patients
received treatment only if they met pre-specified retreatment criteria, except
for patients in the control group in the GALILEO study who continued to receive
sham (control to control)</span><span lang=EN-GB> </span><span lang=EN-GB
style='font-size:11.0pt'>until week 52. From this timepoint all patients were
treated if pre-specified criteria were met.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>In both studies, the primary efficacy endpoint was the
proportion of patients who gained at least 15&nbsp;letters in BCVA at week 24
compared to baseline. A secondary efficacy variable was change in visual acuity
at week 24 compared to baseline.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>The difference between treatment groups was
statistically significant in favour of Eylea in both studies. </span><span
lang=EN-GB style='font-size:11.0pt'>The maximal improvement in visual acuity was
achieved at month&nbsp;3 with subsequent stabilisation of visual acuity and CRT
until month&nbsp;6.</span><b><i><span lang=EN-GB style='font-size:11.0pt'> </span></i></b><span
lang=EN-GB style='font-size:11.0pt'>The statistically significant difference
was maintained through week 52.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Detailed results from the analysis of both studies are
shown in Table&nbsp;3 and Figure&nbsp;2 below.</span></p>

</div>

<i><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></i>

<div class=WordSection2>

<p class=MsoNormal><b><span lang=EN-GB>Table 3:</span></b><span lang=EN-GB>  Efficacy
outcomes at week 24, week 52 and week 76/100 (Full Analysis Set with LOCF<sup>C)</sup>)
in COPERNICUS and GALILEO studies</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=180 rowspan=3 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader><span lang=EN-GB style='font-size:8.0pt;font-weight:
  normal'><br>
  </span><span lang=EN-GB style='font-size:10.0pt'>Efficacy Outcomes</span></p>
  </td>
  <td colspan=6 valign=top style='border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>COPERNICUS</span></p>
  </td>
  <td colspan=6 valign=top style='border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>GALILEO</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td colspan=2 valign=top style='border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>24 Weeks</span></p>
  </td>
  <td colspan=2 valign=top style='border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>52 Weeks</span></p>
  </td>
  <td colspan=2 valign=top style='border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>100 Weeks</span></p>
  </td>
  <td colspan=2 valign=top style='border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>24 Weeks</span></p>
  </td>
  <td colspan=2 valign=top style='border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>52 Weeks</span></p>
  </td>
  <td colspan=2 valign=top style='border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>76 Weeks</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>Eylea</span></p>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>2 mg Q4</span></p>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 114)</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Control</span></b></p>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-.9pt;
  margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N= 73)</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>Eylea</span></p>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>2 mg </span></p>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-1.65pt;
  margin-bottom:3.0pt;margin-left:-3.9pt;text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 114)</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'><b>Control<sup>E)</sup></b></span></p>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N =73)</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>Eylea<sup> F)</sup></span></p>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>2 mg </span></p>
  <p class=C-TableText align=center style='margin-left:-1.65pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N= 114)</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.65pt;
  margin-bottom:3.0pt;margin-left:-1.65pt;text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Control <sup>E,F)</sup></span></b><span
  lang=EN-GB style='font-size:10.0pt'> </span></p>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.65pt;
  margin-bottom:3.0pt;margin-left:-1.65pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(<b>N=73)</b></span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>Eylea</span></p>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>2 mg Q4</span></p>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 103)</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Control</span></b></p>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=C-TableText align=center style='margin-left:-1.65pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 68)</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>Eylea</span></p>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>2 mg</span></p>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.65pt;
  margin-bottom:3.0pt;margin-left:-1.65pt;text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 103)</span></b></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText><b><span lang=EN-GB style='font-size:10.0pt'>Control </span></b></p>
  <p class=C-TableText align=center style='margin-left:-4.65pt;text-align:center'><b><span
  lang=EN-GB style='font-size:10.0pt'>(N = 68)</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>Eylea</span><sup><span lang=EN-GB
  style='font-size:10.0pt'> G</span></sup><sup><span lang=EN-GB
  style='font-size:10.0pt'>)</span></sup></p>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>2 mg</span></p>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.65pt;
  margin-bottom:3.0pt;margin-left:-1.65pt;text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 103)</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Control</span></b><b><sup><span
  lang=EN-GB style='font-size:10.0pt'> G</span></sup></b><b><sup><span
  lang=EN-GB style='font-size:10.0pt'>)</span></sup></b></p>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=C-TableText align=center style='margin-left:-4.65pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 68)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText><span lang=EN-GB style='font-size:9.0pt'>Proportion of
  patients with &#8805;15 letters gain from baseline</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-6.15pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>56%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>12%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>55%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>30%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>49.1%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>23.3%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-3.15pt;
  margin-bottom:3.0pt;margin-left:-2.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>60%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>22%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.65pt;
  margin-bottom:3.0pt;margin-left:-6.9pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>60%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>32%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.65pt;
  margin-bottom:3.0pt;margin-left:-6.9pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>57.3%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>29.4%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  0in;margin-left:12.6pt'><span lang=EN-GB style='font-size:9.0pt'>Weighted
  difference<sup>A,B,E)</sup></span></p>
  <p class=C-TableText style='margin-top:0in;margin-right:0in;margin-bottom:
  3.0pt;margin-left:12.6pt'><span lang=EN-GB style='font-size:9.0pt'>(95% CI)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.55pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>44.8%<br>
  (33.0, 56.6)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.55pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.55pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>25.9%<br>
  (11.8, 40.1)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.55pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td rowspan=2 style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.55pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>26.7%<br>
  (13.1, 40.3)</span></p>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:0in;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p=0.0003</span></p>
  </td>
  <td rowspan=2 style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.55pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.55pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>38.3%<br>
  (24.4, 52.1)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.55pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>27.9%<br>
  (13.0, 42.7)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td rowspan=2 style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>28.0%<br>
  (13.3, 42.6)</span></p>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>p=0.0004</span></p>
  </td>
  <td rowspan=2 style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin-top:0in;margin-right:0in;margin-bottom:
  3.0pt;margin-left:12.6pt'><span lang=EN-GB style='font-size:9.0pt'>p-value</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:0in;
  margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p &lt; 0.0001</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:0in;
  margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:0in;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p = 0.0006</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:0in;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-3.9pt;
  margin-bottom:3.0pt;margin-left:-1.65pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>p &lt; 0.0001</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-3.9pt;
  margin-bottom:3.0pt;margin-left:-1.65pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>p = 0.0004</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText><span lang=EN-GB style='font-size:9.0pt'>Mean change in
  BCVA<sup>C)</sup> as measured by ETDRS<sup>C)</sup> letter score from
  baseline (SD)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>17.3<br>
  (12.8)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&#8209;4.0<br>
  (18.0)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>16.2<br>
  (17.4)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>3.8<br>
  (17.1)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>13.0<br>
  (17.7)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>1.5<br>
  (17.7)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>18.0<br>
  (12.2)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>3.3<br>
  (14.1)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>16.9<br>
  (14.8)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>3.8<br>
  (18.1)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>13.7<br>
  (17.8)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>6.2<br>
  (17.7)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin-left:12.45pt'><span lang=EN-GB
  style='font-size:9.0pt'>Difference in LS mean<sup>A,C,D,E)<br>
  </sup>(95% CI)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-6.8pt;
  margin-bottom:3.0pt;margin-left:-7.65pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>21.7<br>
  (17.4, 26.0)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-6.8pt;
  margin-bottom:3.0pt;margin-left:-7.65pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-2.4pt;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>12.7<br>
  (7.7, 17.7)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-2.4pt;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td rowspan=2 style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-2.4pt;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>11.8<br>
  (6.7, 17.0)</span></p>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-2.4pt;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p &lt; 0.0001</span></p>
  </td>
  <td rowspan=2 style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-2.4pt;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-3.95pt;
  margin-bottom:3.0pt;margin-left:-4.55pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>14.7<br>
  (10.8, 18.7)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-3.95pt;
  margin-bottom:3.0pt;margin-left:-4.55pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>13.2<br>
  (8.2, 18.2)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td rowspan=2 style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>7.6<br>
  (2.1, 13.1)</span></p>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>p=0.0070</span></p>
  </td>
  <td rowspan=2 style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin-top:0in;margin-right:0in;margin-bottom:
  3.0pt;margin-left:12.45pt'><span lang=EN-GB style='font-size:9.0pt'>p-value</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-6.8pt;
  margin-bottom:3.0pt;margin-left:-7.65pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p &lt; 0.0001</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-6.8pt;
  margin-bottom:3.0pt;margin-left:-7.65pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-2.4pt;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p &lt; 0.0001</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-2.4pt;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-3.95pt;
  margin-bottom:3.0pt;margin-left:-4.55pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>p &lt; 0.0001</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-3.95pt;
  margin-bottom:3.0pt;margin-left:-4.55pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>p &lt; 0.0001</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=BayerBodyTextFull style='margin:0in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:8.0pt;color:white'><br>
</span></b><sup><span lang=EN-GB style='font-size:10.0pt'>A) </span></sup><span
lang=EN-GB style='font-size:10.0pt'>Difference is Eylea 2 mg Q4 weeks minus
control</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.0pt;text-indent:-12.0pt;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:10.0pt'>B)</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Difference and confidence interval (CI) are
calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for region
(America vs. rest of the world for COPERNICUS and Europe vs. Asia/Pacific for
GALILEO) and baseline BCVA category (&gt; 20/200 and &#8804; 20/200)</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.0pt;text-indent:-12.0pt;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:10.0pt'>C)</span></sup><span lang=EN-GB
style='font-size:10.0pt'> BCVA: Best Corrected Visual Acuity<br>
ETDRS: Early Treatment Diabetic Retinopathy Study<br>
LOCF: Last Observation Carried Forward<br>
SD: Standard deviation<br>
LS: Least square means derived from ANCOVA</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.0pt;text-indent:-12.0pt;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:10.0pt'>D)</span></sup><span lang=EN-GB
style='font-size:10.0pt'> LS mean difference and confidence interval based on
an ANCOVA model with factors treatment group, region (America vs. rest of the
world for COPERNICUS and Europe vs. Asia/Pacific for GALILEO) and baseline BCVA
category (&gt; 20/200 and &#8804; 20/200)</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:-6.65pt;
margin-bottom:0in;margin-left:14.2pt;text-indent:-14.2pt;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:10.0pt'>E)</span></sup><span lang=EN-GB
style='font-size:10.0pt'> In COPERNICUS study, control group patients could receive
Eylea on an as-needed basis as frequently as every 4 weeks during week 24 to
week 52; patients had visits every 4&nbsp;weeks.</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:-6.65pt;
margin-bottom:0in;margin-left:13.5pt;text-indent:-13.5pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>F</span></sup><sup><span lang=EN-GB
style='font-size:10.0pt'>) </span></sup><span lang=EN-GB style='font-size:
10.0pt'>In COPERNICUS study, both control group and Eylea 2mg patients received
Eylea 2 mg on an as-needed basis as frequently as every 4 weeks starting from week
52 to week&nbsp;96; patients had mandatory quarterly visits but may have been
seen as frequently as every 4 weeks if necessary. </span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:-6.65pt;
margin-bottom:0in;margin-left:12.0pt;text-indent:-12.0pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>G</span></sup><sup><span lang=EN-GB
style='font-size:10.0pt'>) </span></sup><span lang=EN-GB style='font-size:
10.0pt'>In GALILEO study, both control group and Eylea 2mg patients received Eylea
2 mg on an as-needed basis every 8 weeks starting from week 52 to week 68;
patients had mandatory visits every 8 weeks.</span></p>

</div>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Figure 2</span></b><span lang=EN-GB>:  Mean
Change from Baseline to Week 76/100 in Visual Acuity by Treatment Group for the
COPERNICUS and GALILEO Studies (Full Analysis Set)</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><img border=0
width=601 height=759 src="Eylea_IB_007_files/image004.jpg"></span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
background:lime'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>In GALILEO, 86.4% (n=89) of the Eylea group
and 79.4% (n=54) of the sham group had perfused CRVO at baseline. At week 24,
this was 91.8% (n=89) in the Eylea group and 85.5% (n=47) in the sham group.
These proportions were maintained at week 76, with 84.3% (n=75) in the Eylea
group and 84.0% (n=42) in the sham group.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In COPERNICUS, 67.5% (n = 77) of the Eylea
group and 68.5% (n = 50) of the sham group had perfused CRVO at baseline. At
week 24, this was 87.4% (n = 90) in the Eylea group and 58.6% (n = 34) in the
sham group. These proportions were maintained at week 100 with 76.8 % (n = 76)
in the Eylea group and </span><span lang=EN-GB>78% (n = 39) in the sham group.</span><span
lang=EN-GB> Patients in the sham group were eligible to receive Eylea from week
24.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>The beneficial effect of Eylea treatment on visual
function was similar in the baseline subgroups of perfused and non-perfused
patients. Treatment effects in other evaluable subgroups (e.g. age, gender,
race, baseline visual acuity, CRVO duration) in each study were in general
consistent with the results in the overall populations.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In combined data analysis of GALILEO and
COPERNICUS, Eylea demonstrated clinically meaningful changes from baseline in
pre-specified secondary efficacy endpoint National Eye Institute Visual
Function Questionnaire (NEI VFQ-25). The magnitude of these changes was similar
to that seen in published studies, which corresponded to a&nbsp;15-letter gain
in Best Corrected Visual Acuity (BCVA).</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Macular oedema
secondary to </span></i><i><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>BRVO</span></i></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>The safety
and efficacy of Eylea were assessed in a randomised, multi-centre,
double-masked, active-controlled study in patients with macular oedema
secondary to BRVO (VIBRANT) which included Hemi-Retinal Vein Occlusion. A total
of 181 patients were treated and evaluable for efficacy (91 with Eylea).<span
class=MsoEndnoteReference> </span>Patient ages ranged from 42 to 94 years with
a mean of 65&nbsp;years. In the BRVO study, approximately 58% (53/91) of the
patients randomised to treatment with Eylea were 65 years of age or older, and
approximately 23% (21/91) were 75 years of age or older. In the study, patients
were randomly assigned in a 1:1 ratio to either 2&nbsp;mg Eylea administered
every 8 weeks following 6 initial monthly</span><span lang=EN-GB> </span><span
lang=EN-GB style='font-size:11.0pt'>injections</span><span lang=EN-GB> </span><span
lang=EN-GB style='font-size:11.0pt'>or laser photocoagulation administered at
baseline (laser control group). Patients in the laser control group could
receive additional laser photocoagulation (called rescue laser treatment)
beginning at week 12 with a minimum interval of 12 weeks. Based on
pre-specified criteria, patients in the laser group could receive rescue
treatment with Eylea 2mg from week 24, administered every 4 weeks for 3 months
followed by every 8 weeks. </span></p>

<p class=C-BodyText style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>In
the VIBRANT study, the primary efficacy endpoint was the proportion of patients
who gained at least 15 letters in BCVA at week 24 compared to baseline and the
Eylea group was superior to laser control. </span></p>

<p class=C-BodyText style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>A
secondary efficacy endpoint was change in visual acuity at week 24 compared to
baseline, which was statistically significant in</span><span lang=EN-GB> </span><span
lang=EN-GB style='font-size:11.0pt'>favour of Eylea</span><span lang=EN-GB> </span><span
lang=EN-GB style='font-size:11.0pt'>in the VIBRANT study. The course of visual
improvement was rapid and peaked at 3 months with maintenance of the effect until
month 12.</span></p>

<p class=C-BodyText style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>In
the laser group 67 patients received rescue treatment with Eylea beginning at
week 24 (Active Control/ Eylea 2mg group), which resulted in improvement of
visual acuity by about 5 letters from week 24 to 52.</span></p>

<p class=C-BodyText style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:14.0pt'><span lang=EN-GB>Detailed results
from the analysis of the VIBRANT study are shown in Table 4 and Figure 3 below.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:14.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;
margin-left:0in;line-height:14.0pt'><b><span lang=EN-GB>Table 4: </span></b><span
lang=EN-GB> Efficacy outcomes at week 24 and week 52 (Full Analysis Set
with LOCF) in VIBRANT study</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=138 rowspan=2 valign=top style='width:103.45pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in'><b><span lang=EN-GB style='font-size:10.0pt'>Efficacy
  Outcomes</span></b></p>
  </td>
  <td width=481 colspan=4 valign=top style='width:360.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>VIBRANT</span></b></p>
  </td>
 </tr>
 <tr style='height:16.35pt'>
  <td width=219 colspan=2 valign=top style='width:164.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.35pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>24 Weeks</span></b></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.35pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>52 Weeks</span></b></p>
  </td>
 </tr>
 <tr style='height:52.25pt'>
  <td width=138 valign=top style='width:103.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:52.25pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=106 valign=top style='width:79.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:52.25pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>Eylea 2mg Q4</span></b></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>(N = 91)</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:52.25pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>Active Control (laser)</span></b></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>(N = 90)</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:52.25pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>Eylea 2mg Q8</span></b></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>(N = 91)</span></b><b><sup><span lang=EN-GB
  style='font-size:10.0pt;font-family:"Times New Roman Bold",serif'> D)</span></sup></b></p>
  </td>
  <td width=139 valign=top style='width:104.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:52.25pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>Active Control (laser)/Eylea 2mg</span></b><b><sup><span
  lang=EN-GB style='font-size:10.0pt;font-family:"Times New Roman Bold",serif'>E)</span></sup></b></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>(N = 90)</span></b></p>
  </td>
 </tr>
 <tr style='height:19.3pt'>
  <td width=138 valign=top style='width:103.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in'><span lang=EN-GB style='font-size:9.0pt'>Proportion of
  patients with &#8805;15 letters gain from Baseline (%)</span></p>
  </td>
  <td width=106 valign=top style='width:79.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>52.7%</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>26.7%</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>57.1%</span></p>
  </td>
  <td width=139 valign=top style='width:104.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>41.1%</span></p>
  </td>
 </tr>
 <tr style='height:19.3pt'>
  <td width=138 valign=top style='width:103.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=right style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:right'><span lang=EN-GB
  style='font-size:9.0pt'>Weighted Difference <sup>A,B)</sup> (%)</span></p>
  <p class=MsoNormal align=right style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:right'><span lang=EN-GB
  style='font-size:9.0pt'>(95% CI)</span></p>
  <p class=MsoNormal align=right style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:right'><span lang=EN-GB
  style='font-size:9.0pt'>p-value </span></p>
  </td>
  <td width=106 valign=top style='width:79.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;line-height:14.0pt'><span
  lang=EN-GB style='font-size:9.0pt'>26.6%</span></p>
  <p class=MsoNormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;line-height:14.0pt'><span
  lang=EN-GB style='font-size:9.0pt'>(13.0, 40.1)</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p=0.0003</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>16.2%</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(2.0, 30.5)</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p=0.0296</span></p>
  </td>
  <td width=139 valign=top style='width:104.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:19.3pt'>
  <td width=138 valign=top style='width:103.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in'><span lang=EN-GB style='font-size:9.0pt'>Mean change
  in BCVA as measured by ETDRS letter score from Baseline (SD)</span></p>
  </td>
  <td width=106 valign=top style='width:79.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;line-height:14.0pt'><span
  lang=EN-GB style='font-size:9.0pt'>17.0</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(11.9)</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>6.9</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(12.9)</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>17.1</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(13.1)</span></p>
  </td>
  <td width=139 valign=top style='width:104.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>12.2 (11.9)</span></p>
  </td>
 </tr>
 <tr style='height:19.3pt'>
  <td width=138 valign=top style='width:103.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=right style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:right'><span lang=EN-GB
  style='font-size:9.0pt'>Difference in LS mean <sup>A,C)</sup></span></p>
  <p class=MsoNormal align=right style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:right'><span lang=EN-GB
  style='font-size:9.0pt'>(95% CI)</span></p>
  <p class=MsoNormal align=right style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:right'><span lang=EN-GB
  style='font-size:9.0pt'>p-value</span></p>
  </td>
  <td width=106 valign=top style='width:79.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>10.5</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(7.1, 14.0)</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p&lt;0.0001</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>5.2</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(1.7, 8.7)</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p=0.0035<sup>F)</sup></span></p>
  </td>
  <td width=139 valign=top style='width:104.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:24.95pt;text-indent:-17.85pt;line-height:
normal'><sup><span lang=EN-GB style='font-size:10.0pt'>A)<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>Difference is
Eylea 2 mg Q4 weeks minus Laser Control</span></p>

<p class=MsoNormal style='margin-left:24.95pt;text-indent:-17.85pt;line-height:
normal'><sup><span lang=EN-GB style='font-size:10.0pt'>B)<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>Difference and
95% CI are calculated using Mantel-Haenszel weighting scheme adjusted for
region (North America vs. Japan) and baseline BCVA category (&gt;&nbsp;20/200
and &#8804;&nbsp;20/200)</span></p>

<p class=MsoNormal style='margin-left:24.95pt;text-indent:-17.85pt;line-height:
normal'><sup><span lang=EN-GB style='font-size:10.0pt'>C)<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>LS mean
difference and 95% CI based on an ANCOVA model with treatment group, </span><span
lang=EN-GB style='font-size:10.0pt'>baseline BCVA category (&gt;&nbsp;20/200
and &#8804;&nbsp;20/200) </span><span lang=EN-GB style='font-size:10.0pt'>and </span><span
lang=EN-GB style='font-size:10.0pt'>region (North America vs. Japan) </span><span
lang=EN-GB style='font-size:10.0pt'>as fixed effects, and baseline BCVA as
covariate.</span></p>

<p class=MsoNormal style='margin-left:24.95pt;text-indent:-17.85pt;line-height:
normal'><sup><span lang=EN-GB style='font-size:10.0pt'>D)<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>From week 24 on
the treatment interval in the Eylea treatment group was extended for all
subjects from 4 weeks to 8 weeks through week 48.</span></p>

<p class=MsoNormal style='margin-left:24.95pt;text-indent:-17.85pt;line-height:
normal'><sup><span lang=EN-GB style='font-size:10.0pt'>E)<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>Beginning at week
24 subjects in the Laser Group could receive rescue treatment with Eylea, if
they met at least one pre-specified eligibility criterion. At total of 67
subjects in this group received Eylea rescue treatment. The fixed regimen for
Eylea rescue was three times Eylea 2mg every 4 weeks followed by injections
every 8 weeks.</span></p>

<p class=MsoNormal style='margin-left:24.95pt;text-indent:-17.85pt;line-height:
normal'><sup><span lang=EN-GB style='font-size:10.0pt'>F)<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>Nominal p-value</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;
margin-left:0in;line-height:14.0pt;page-break-after:avoid'><b><span lang=EN-GB>Figure
3:  </span></b><span lang=EN-GB>Mean Change in BCVA as Measured by ETDRS
Letter Score from Baseline to Week&nbsp;52 in VIBRANT Study</span></p>

<p class=BayerBodyTextFull style='page-break-after:avoid'><span lang=EN-GB><img
border=0 width=498 height=356 src="Eylea_IB_007_files/image005.jpg"></span></p>

<p class=C-BodyText style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>At
baseline, the proportion of perfused patients in the Eylea and laser groups was
60% and 68%, respectively. At week 24 these proportions were 80% and 67%,
respectively. In the Eylea group the proportion of perfused patients was
maintained through week 52. In the laser group, where patients were eligible
for rescue treatment with Eylea from week 24, the proportion of perfused patients
increased to 78% by week 52. </span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt'>Diabetic macular oedema</span></i></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>The safety and efficacy of Eylea were assessed in two
randomised, multi-centre, double-masked, active-controlled studies in patients
with DME (VIVID<sup>DME</sup> and VISTA<sup>DME</sup>). A total of 862 patients
were treated and evaluable for efficacy, 576 with Eylea. Patient ages ranged
from 23 to 87 years with a mean of 63&nbsp;years. </span><span
class=MsoCommentReference><span lang=EN-GB style='font-size:11.0pt'>In the DME
studies, approximately 47% (268/576) of the patients randomised to treatment
with Eylea were 65 years of age or older, and approximately 9% (52/576) were 75
years<span style='color:#0F243E'> of age or older. </span></span></span><span
lang=EN-GB style='font-size:11.0pt'>The majority of patients in both studies
had Type II diabetes.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>In both studies, patients were randomly assigned in a
1:1:1 ratio to 1 of 3 dosing regimens: </span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>1)&nbsp;Eylea administered 2 mg every 8 weeks
following 5 initial monthly injections (Eylea 2Q8);</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>2) Eylea administered 2 mg every 4 weeks (Eylea 2Q4);
and</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>3) macular laser photocoagulation (active control).</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Beginning at week 24, patients meeting a pre-specified
threshold of vision loss were eligible to receive additional treatment:
patients in the Eylea groups could receive laser and patients in the control group
could receive Eylea. </span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>In both studies, the primary efficacy endpoint was the
mean change from baseline in BCVA at week 52 and both Eylea 2Q8 and Eylea 2Q4
groups demonstrated statistical significance and were superior to the control
group. This benefit was maintained through week 100.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Detailed results from the analysis of the VIVID<sup>DME</sup>
and VISTA<sup>DME</sup> studies are shown in Table 5 and Figure 4 below.</span></p>

</div>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection4>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;
margin-left:1.0in;text-indent:-1.0in;line-height:14.0pt;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;</span></b><b><span lang=EN-GB>5</span></b><b><span
lang=EN-GB>: </span></b><span lang=EN-GB>Efficacy outcomes at week 52
and week 100 (Full Analysis Set with LOCF) in VIVID<sup>DME</sup> and VISTA<sup>DME</sup>
studies</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=1023
 style='margin-left:-.05in;border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:27.6pt'>
   <td width=109 rowspan=3 valign=top style='width:81.85pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:27.6pt'>
   <p class=MsoNormal style='margin-top:.1in;margin-right:0in;margin-bottom:
   .1in;margin-left:0in;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:10.0pt'>Efficacy Outcomes</span></b></p>
   </td>
   <td width=451 colspan=6 valign=top style='width:338.25pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:27.6pt'>
   <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
   margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB>VIVID<sup>DME</sup></span></b></p>
   </td>
   <td width=463 colspan=6 valign=top style='width:347.3pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:27.6pt'>
   <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
   margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB>VISTA<sup>DME</sup></span></b></p>
   </td>
  </tr>
  <tr style='height:7.15pt' style='height:7.15pt !msorm'>
   <td width=224 colspan=3 valign=top style='width:168.15pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
   margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:9.0pt'>52 Weeks</span></b></p>
   </td>
   <td width=227 colspan=3 valign=top style='width:170.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
   margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:9.0pt'>100 Weeks</span></b></p>
   </td>
   <td width=236 colspan=3 valign=top style='width:177.2pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
   margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:9.0pt'>52 Weeks</span></b></p>
   </td>
   <td width=227 colspan=3 valign=top style='width:170.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
   margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:9.0pt'>100 Weeks</span></b></p>
   </td>
  </tr>
  <tr style='height:7.15pt' style='height:7.15pt !msorm'>
   <td width=73 valign=top style='width:54.75pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>Eylea</span></b></p>
   <p class=MsoNormal align=center style='margin-left:-4.65pt;text-align:center;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:9.0pt'>2 mg Q8 </span></b><sup><span
   lang=EN-GB style='font-size:9.0pt'>A</span></sup></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N = 135)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>Eylea</span></b></p>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>2 mg Q4</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N = 136)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Active Control</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(laser)</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N = 132)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>Eylea</span></b></p>
   <p class=MsoNormal align=center style='margin-left:-4.65pt;text-align:center;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:9.0pt'>2 mg Q8 </span></b><sup><span
   lang=EN-GB style='font-size:9.0pt'>A</span></sup></p>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>(N = 135)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Eylea </span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>2mg Q4</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N=136)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Active Control</span></b><b><sup><span
   lang=EN-GB style='font-size:9.0pt;font-family:"Times New Roman Bold",serif'>
   </span></sup></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(laser)</span></b></p>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>(N = 132)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>Eylea</span></b></p>
   <p class=MsoNormal align=center style='margin-left:-4.65pt;text-align:center;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:9.0pt'>2 mg Q8 </span></b><sup><span
   lang=EN-GB style='font-size:9.0pt'>A</span></sup></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N = 151)</span></b></p>
   </td>
   <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>Eylea</span></b></p>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>2 mg Q4</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N = 154)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Active Control</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(laser)</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N = 154)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>Eylea</span></b></p>
   <p class=MsoNormal align=center style='margin-left:-4.65pt;text-align:center;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:9.0pt'>2 mg Q8 </span></b><sup><span
   lang=EN-GB style='font-size:9.0pt'>A</span></sup></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N = 151)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Eylea</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>2 mg Q4</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N=154)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Active Control</span></b><b><sup><span
   lang=EN-GB style='font-size:9.0pt;font-family:"Times New Roman Bold",serif'>
   </span></sup></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(laser)</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N = 154)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:80.65pt' style='height:80.65pt !msorm'>
  <td width=109 style='width:81.85pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;border:solid windowtext 1.0pt !msorm;
  border-top:none !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>Mean change in BCVA as measured by ETDRS</span><sup><span
  lang=EN-GB style='font-size:9.0pt'> E</span></sup><span lang=EN-GB
  style='font-size:9.0pt'> letter score from Baseline</span></p>
  </td>
  <td width=73 style='width:54.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>10.7</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>10.5</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>1.2</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>9.4</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>11.4</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>0.7</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>10.7</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>12.5</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>0.2</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>11.1</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>11.5</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>0.9</span></p>
  </td>
 </tr>
 <tr style='height:44.45pt' style='height:44.45pt !msorm'>
  <td width=109 valign=top style='width:81.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;border:solid windowtext 1.0pt !msorm;
  border-top:none !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>Difference<sup> </sup>in LS <br>
   mean<sup> B,C,E<br>
  </sup> (97.5% CI)</span></p>
  </td>
  <td width=73 style='width:54.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>9.1<sup><br>
  </sup>(6.3, 11.8)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>9.3<sup><br>
  </sup>(6.5, 12.0)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>8.2<sup><br>
  </sup>(5.2, 11.3)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>10.7 (7.6, 13.8)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>10.45<sup><br>
  </sup>(7.7, 13.2)</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>12.19<sup><br>
  </sup>(9.4, 15.0)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>10.1<sup><br>
  </sup>(7.0, 13.3)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>10.6 (7.1, 14.2)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:78.3pt' style='height:78.3pt !msorm'>
  <td width=109 valign=top style='width:81.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;border:solid windowtext 1.0pt !msorm;
  border-top:none !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;height:78.3pt'>
  <p class=MsoNormal style='margin-top:.1in;margin-right:0in;margin-bottom:
  .1in;margin-left:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Proportion of patients with &#8805; 15 letters gain
  from Baseline</span></p>
  </td>
  <td width=73 style='width:54.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>33%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>32%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>9%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>31.1%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>38.2%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>12.1%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>31%</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>42%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>8%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>33.1%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>38.3%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>13.0%</span></p>
  </td>
 </tr>
 <tr style='height:53.7pt' style='height:53.7pt !msorm'>
  <td width=109 valign=top style='width:81.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;border:solid windowtext 1.0pt !msorm;
  border-top:none !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;height:53.7pt'>
  <p class=MsoNormal style='margin-top:.1in;margin-right:0in;margin-bottom:
  .1in;margin-left:0in'><span lang=EN-GB style='font-size:9.0pt'> Adjusted
  <br>
   Difference <sup>D,C,E</sup><br>
   (97.5% CI)</span></p>
  </td>
  <td width=73 style='width:54.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>24%<br>
  (13.5, 34.9)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>23%<br>
  (12.6, 33.9)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>19.0% (8.0, 29.9)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>26.1% (14.8, 37.5)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt;background:aqua'>&nbsp;</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>23%<br>
  (13.5, 33.1)</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>34%<br>
  (24.1, 44.4)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>20.1% (9.6, 30.6)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>25.8% (15.1, 36.6)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=C-TableFootnote style='margin-left:9.05pt;text-indent:-9.05pt'><sup><span
lang=EN-GB>&nbsp;</span></sup></p>

<p class=C-TableFootnote style='margin-left:9.05pt;text-indent:-9.05pt'><sup><span
lang=EN-GB>A </span></sup><span lang=EN-GB>After treatment initiation with 5
monthly injections </span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:9.05pt;text-indent:-9.05pt;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:10.0pt'>B  </span></sup><span lang=EN-GB
style='font-size:10.0pt'>LS mean and CI based on an ANCOVA model with baseline
BCVA measurement as a covariate and a factor for treatment group. Additionally,
region (Europe/Australia vs. Japan) had been included as factor for VIVID<sup>DME</sup>,
and history of MI and/or CVA as a factor for VISTA<sup>DME</sup></span></p>

<p class=C-TableFootnote style='margin-left:9.05pt;text-indent:-9.05pt'><sup><span
lang=EN-GB>C</span></sup><span lang=EN-GB>  </span><span lang=EN-GB>Difference</span><span
lang=EN-GB> is Eylea group minus active control (laser) group</span></p>

<p class=C-BodyText style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:9.05pt;text-indent:-9.05pt;line-height:normal'><sup><span
lang=EN-GB style='font-size:10.0pt'>D </span></sup><sup><span lang=EN-GB
style='font-size:10.0pt'> </span></sup><span lang=EN-GB style='font-size:10.0pt'>Difference
with confidence interval (CI) and statistical test is calculated using
Mantel-Haenszel weighting scheme adjusted by region (Europe/Australia vs.
Japan) for VIVID<sup>DME</sup> and medical history of MI or CVA for VISTA<sup>DME</sup></span></p>

<p class=C-BodyText style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:9.05pt;text-indent:-9.05pt;line-height:normal'><sup><span
lang=EN-GB style='font-size:10.0pt'>E</span></sup><span lang=EN-GB
style='font-size:10.0pt'> BCVA: Best Corrected Visual Acuity</span></p>

<p class=C-BodyText style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:9.05pt;text-indent:-9.05pt;line-height:normal'><span lang=EN-GB
style='font-size:10.0pt'> ETDRS: Early Treatment Diabetic Retinopathy Study<br>
LOCF: Last Observation Carried Forward<br>
LS: Least square means derived from ANCOVA<br>
CI: Confidence interval</span></p>

<p class=C-BodyText style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:9.05pt;text-indent:-9.05pt;line-height:normal'><sup><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></sup></p>

</div>

<span lang=EN-GB style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection5>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:1.0in;text-indent:-1.0in;page-break-after:avoid'><span
class=CaptionChar><span lang=EN-GB style='font-size:11.0pt'>Figure 4:  </span></span><span
lang=EN-GB style='font-size:11.0pt'>Mean Change in BCVA as Measured by ETDRS
Letter Score from Baseline to Week&nbsp;100 in VIVID<sup>DME</sup> and VISTA<sup>DME</sup>
Studies</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.0pt;text-indent:-12.0pt;page-break-after:avoid'><span
class=CaptionChar><span lang=EN-GB style='font-size:11.0pt;font-weight:normal'>&nbsp;</span></span></p>

<p class=BayerBodyTextFull style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull><span lang=EN-GB style='font-size:11.0pt'><img
border=0 width=528 height=556 src="Eylea_IB_007_files/image006.jpg"></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Treatment effects in evaluable subgroups (e.g., age, gender, race,
baseline HbA1c, baseline visual acuity, prior anti-VEGF therapy) in each study
and in the combined analysis were generally consistent with the results in the
overall populations.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>In the VIVID<sup>DME</sup> and VISTA<sup>DME</sup>
studies, 36 (9%) and 197 (43%) patients received prior anti-VEGF therapy,
respectively, with a 3-month or longer washout period. Treatment effects in the
subgroup of patients who had previously been treated with a VEGF inhibitor were
similar to those seen in patients who were VEGF inhibitor nave.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Patients with bilateral disease were eligible to
receive anti-VEGF treatment in their fellow eye if assessed necessary by the
physician. In the VISTA<sup>DME</sup> study, 217 (70.7%) of Eylea patients
received bilateral Eylea injections until week100; in the VIVID<sup>DME</sup> study,
97 (35.8%) of Eylea patients received a different anti-VEGF treatment in their
fellow eye.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>An independent comparative trial (DRCR.net
Protocol T) utilised a dosing regimen based on strict OCT and vision
re-treatment criteria. In the aflibercept treatment group (n = 224) at week 52,
this treatment regimen resulted in patients receiving a mean of 9.2 injections,
which is similar to the administered number of doses in the Eylea 2Q8 group in
VIVID<sup>DME </sup>and VISTA<sup>DME</sup>, while overall efficacy of the
aflibercept treatment group in Protocol T was comparable to the Eylea 2Q8 group
in VIVID<sup>DME</sup> and VISTA<sup>DME</sup>. A 13.3 mean letter gain with
42% of patients gaining at least 15 letters in vision from baseline was
observed in Protocol T. Ocular and systemic safety profiles (including ATEs)
were similar to VIVID<sup>DME</sup> and VISTA<sup>DME</sup></span><span
lang=EN-GB style='font-family:"Calibri",sans-serif'>.</span></p>

<p class=BayerBodyTextFull style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Myopic choroidal
neovascularisation</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=BayerBodyTextFull style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>The safety and efficacy of Eylea were
assessed in a randomised, multi-centre, double-masked, sham-controlled study in
treatment-nave,</span><i><span lang=EN-GB style='font-size:11.0pt'> </span></i><span
lang=EN-GB style='font-size:11.0pt'>Asian patients with myopic CNV. A total of
121&nbsp;patients were treated and evaluable for efficacy (90&nbsp;with Eylea).
Patient ages ranged from 27&nbsp;to 83&nbsp;years with a mean of 58&nbsp;years.</span><span
lang=EN-GB style='font-size:11.0pt'> In the myopic CNV study, approximately 36%
(33/91) of the patients randomised to treatment with Eylea were 65&nbsp;years
of age or older, and approximately 10% (9/91) were 75&nbsp;years of age or
older.</span></p>

<p class=BayerBodyTextFull style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients were randomly assigned in a
3:1&nbsp; ratio to receive either 2&nbsp;mg Eylea </span><span lang=EN-GB>intravitreally</span><span
lang=EN-GB> or sham injections administered once at study start with additional
injections given monthly in case of disease persistence or recurrence until
week 24, when the primary endpoint was assessed. At week 24, patients initially
randomised to sham were eligible to receive the first dose of Eylea. Following
this, patients in both groups continued to be eligible for additional
injections in case of disease persistence or recurrence.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The difference between treatment groups was
statistically significant in favour of Eylea for the primary endpoint (change
in BCVA) and confirmatory secondary efficacy endpoint (proportion of patients
who gained 15 letters in BCVA) at week&nbsp;24 compared to baseline.
Differences for both endpoints were maintained through week&nbsp;48.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed results from the analysis of the
MYRROR study are shown in Table&nbsp;6 and Figure&nbsp;5 below.</span></p>

<u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></u>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:12.0pt;
margin-left:1.0in;text-indent:-1.0in;page-break-after:avoid'><b><span
lang=EN-GB>Table 6:  </span></b><span lang=EN-GB>Efficacy outcomes at
week 24 (primary analysis) and week 48 in MYRROR study (Full Analysis Set with
LOCF<sup>A)</sup>)</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=225 rowspan=3 valign=top style='width:168.45pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:10.0pt'>Efficacy Outcomes</span></b></p>
   </td>
   <td width=421 colspan=4 valign=top style='width:315.7pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>MYRROR</span></b></p>
   </td>
  </tr>
  <tr>
   <td width=208 colspan=2 valign=top style='width:155.9pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>24 Weeks</span></b></p>
   </td>
   <td width=213 colspan=2 valign=top style='width:159.8pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>48 Weeks</span></b></p>
   </td>
  </tr>
  <tr>
   <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Eylea 2mg</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 90)</span></b></p>
   </td>
   <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Sham</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 31)</span></b></p>
   </td>
   <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Eylea 2mg</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 90)</span></b></p>
   </td>
   <td width=109 valign=top style='width:81.85pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Sham/<br>
   Eylea 2mg</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 31)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=225 valign=top style='width:168.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Mean change in BCVA <sup>B)</sup> as measured by
  ETDRS letter score from baseline (SD) <sup>B)</sup></span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>12.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>(8.3)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>-2.0</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>(9.7)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>13.5<br>
  (8.8)</span></p>
  </td>
  <td width=109 style='width:81.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>3.9</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>(14.3)</span></p>
  </td>
 </tr>
 <tr>
  <td width=225 valign=top style='width:168.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>
  Difference in LS mean <sup>C,D,E)</sup></span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'> (95% CI)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>14.1</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(10.8, 17.4)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>9.5</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(5.4, 13.7)</span></p>
  </td>
  <td width=109 style='width:81.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=225 valign=top style='width:168.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>Proportion of
  patients with &#8805;15 letters gain from baseline</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>38.9%</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>9.7%</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>50.0%</span></p>
  </td>
  <td width=109 style='width:81.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>29.0%</span></p>
  </td>
 </tr>
 <tr>
  <td width=225 valign=top style='width:168.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'> Weighted
  difference <sup>D,F)</sup></span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'> (95% CI)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>29.2%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(14.4, 44.0)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>21.0%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(1.9, 40.1)</span></p>
  </td>
  <td width=109 style='width:81.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;text-indent:0in'><sup><span
lang=EN-GB style='font-size:10.0pt'>A)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>LOCF: Last
Observation Carried Forward</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><sup><span
lang=EN-GB style='font-size:10.0pt'>B)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>BCVA: Best
Corrected Visual Acuity</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in'><span lang=EN-GB
style='font-size:10.0pt'>ETDRS: Early&nbsp;Treatment&nbsp;Diabetic&nbsp;Retinopathy&nbsp;Study</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in'><span lang=EN-GB
style='font-size:10.0pt'>SD: Standard Deviation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><sup><span
lang=EN-GB style='font-size:10.0pt'>C)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>LS mean: Least
square means derived from ANCOVA model</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><sup><span
lang=EN-GB style='font-size:10.0pt'>D)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>CI: Confidence
Interval</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><sup><span
lang=EN-GB style='font-size:10.0pt'>E)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>LS mean
difference and 95% CI based on an ANCOVA model with treatment group and country
(country designations) as fixed effects, and baseline BCVA as covariant.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><sup><span
lang=EN-GB style='font-size:10.0pt'>F)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>Difference and
95% CI are calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for
country (country designations)</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in'><span lang=EN-GB
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin-left:1.0in;text-indent:-1.0in;
page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Figure 5</span></b><span
class=CaptionChar><span lang=EN-GB style='font-size:11.0pt;font-weight:normal'>:</span></span><span
class=CaptionChar><span lang=EN-GB style='font-size:11.0pt'>  </span></span><span
lang=EN-GB style='font-size:11.0pt'>Mean </span><span lang=EN-GB
style='font-size:11.0pt'>Change from Baseline to Week 48 in Visual Acuity by Treatment
Group for the MYRROR Study (Full Analysis Set, LOCF)</span></p>

<p class=BayerBodyTextFull style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=BayerBodyTextFull style='page-break-after:avoid'><span lang=EN-GB><img
border=0 width=495 height=293 id="Picture 1"
src="Eylea_IB_007_files/image007.jpg"></span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The European Medicines Agency has waived the obligation to submit
the results of studies with Eylea in all subsets of the paediatric population
in wet AMD, CRVO, BRVO, DME and myopic CNV populations (see section&nbsp;4.2
for information on paediatric use).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.2 Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=GlobalBayerBodyText style='margin:0in'><a name="_Toc168214226"></a><a
name="_Toc168278247"></a><a name="_Toc168282572"></a><a name="_Toc168282693"></a><a
name="_Toc174868069"><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Eylea
is administered directly into the vitreous to exert local effects in the eye.</span></a></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Absorption /
Distribution</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Aflibercept is
slowly absorbed from the eye into the systemic circulation after intravitreal
administration and is predominately observed in the systemic circulation as an
inactive, stable complex with VEGF; however only free aflibercept is able to
bind endogenous VEGF.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>In a
pharmacokinetic sub-study in 6 neovascular wet AMD patients with frequent
sampling, maximum plasma concentrations of free aflibercept (systemic C<sub>max</sub>)
were low, with a mean of approximately 0.02&nbsp;microgram/mL
(range&nbsp;0&nbsp;to&nbsp;0.054) within 1 to 3 days after a 2&nbsp;mg
intravitreal injection, and were undetectable two weeks following dosage in
almost all patients. Aflibercept does not accumulate in the plasma when
administered intravitreally every 4&nbsp;weeks.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The mean maximum
plasma concentration of free aflibercept is approximately 50 to 500&nbsp;times
below the aflibercept concentration required to inhibit the biologic activity
of systemic VEGF by&nbsp;50% in animal models, in which blood pressure changes
were observed after circulating levels of free aflibercept attained
approximately 10 microgram/mL and returned to baseline when levels fell below
approximately 1 microgram/mL. It is estimated that after intravitreal
administration of 2&nbsp;mg to patients, the mean maximum plasma concentration
of free aflibercept is more than 100-fold lower than the concentration of
aflibercept required to half-maximally bind systemic VEGF (2.91 microgram/mL)
in a study of healthy volunteers. Therefore, systemic pharmacodynamic effects
such as blood pressure changes are unlikely.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>In pharmacokinetic sub-studies in patients with CRVO,
BRVO, DME or myopic CNV mean C<sub>max</sub> of free aflibercept in plasma were
similar with values in the range of 0.03 to 0.05 microgram/mL and individual
values not exceeding 0.14 microgram/mL. Thereafter, plasma concentrations of
free aflibercept declined to values below or close to the lower limit of
quantitation generally within one week; undetectable concentrations were
reached before the next administration after 4 weeks in all patients.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Elimination</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>As Eylea is a
protein-based therapeutic, no metabolism studies have been conducted.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Free aflibercept binds VEGF to form a stable, inert
complex. As with other large proteins, both free and bound aflibercept are
expected to be cleared by proteolytic catabolism.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Renal impairment</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>No special studies
in patients with renal impairment have been conducted with Eylea.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Pharmacokinetic
analysis of patients in the VIEW2 study, of which 40% had renal impairment (24%&nbsp;mild,
15%&nbsp;moderate, and 1%&nbsp;severe), revealed no differences with respect to
plasma concentrations of active drug after intravitreal administration every&nbsp;4
or 8&nbsp;weeks.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Similar results
were seen in patients with CRVO in the GALILEO study, in patients with DME in
the VIVID<sup>DME</sup> study, and in patients with myopic CNV in the MYRROR
study.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3 Preclinical safety
data</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Effects in
non-clinical studies on repeated dose toxicity were observed only at systemic
exposures considered substantially in excess of the maximum human exposure
after intravitreal administration at the intended clinical dose indicating
little relevance to clinical use.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Erosions and
ulcerations of the respiratory epithelium in nasal turbinates in monkeys
treated with aflibercept intravitreally were observed at systemic exposures in
excess of the maximum human exposure. The systemic exposure based on C<sub>max</sub>
and AUC for free aflibercept were approximately 200- and 700-fold higher,
respectively, when compared to corresponding values observed in humans after an
intravitreal dose of 2&nbsp;mg. At the No Observed Adverse Effect Level (NOAEL)
of 0.5 mg/eye in monkeys the systemic exposure was 42- and 56-fold higher based
on C<sub>max</sub> and AUC, respectively.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>No studies have
been conducted on the mutagenic or carcinogenic potential of aflibercept.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>An effect of
aflibercept on intrauterine development was shown in embryo-foetal development
studies in pregnant rabbits with intravenous (3 to 60 mg/kg) as well as
subcutaneous (0.1 to 1 mg/kg) administration. The maternal NOAEL was at the
dose of 3 mg/kg or 1 mg/kg, respectively. A developmental NOAEL was not
identified. At the 0.1 mg/kg dose, the systemic exposures based on C<sub>max</sub>
and cumulative AUC for free aflibercept were approximately 17- and 10-fold
higher, respectively, when compared to corresponding values observed in humans
after an intravitreal dose of 2&nbsp;mg.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Effects on male
and female fertility were assessed as part of a 6-month study in monkeys with
intravenous administration of aflibercept at doses ranging from 3&nbsp;to 30&nbsp;mg/kg.
Absent or irregular menses associated with alterations in female reproductive
hormone levels and changes in sperm morphology and motility were observed at
all dose levels. Based on C<sub>max</sub></span><span lang=EN-GB
style='font-family:"Times New Roman",serif'> </span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>and AUC for free
aflibercept observed at the 3&nbsp;mg/kg intravenous dose, the systemic
exposures were approximately 4,900-fold and 1,500-fold higher, respectively, than
the exposure observed in humans after an intravitreal dose of 2&nbsp;mg. All
changes were reversible.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6. PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Polysorbate&nbsp;20
(E&nbsp;432)</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Sodium
dihydrogen phosphate, monohydrate (for pH adjustment)</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Disodium hydrogen
phosphate, heptahydrate (for pH adjustment)</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Sodium chloride</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Sucrose</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Water for
injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the absence
of compatibility studies, this medicinal product must not be mixed with other
medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>2 years</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>6.4 Special
precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Store in a
refrigerator (2C&nbsp;to&nbsp;8C).</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Do not freeze.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Store in the
original package in order to protect from light.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The unopened
blister may be stored outside the refrigerator below 25&nbsp;C for up to <span
style='color:black'>24&nbsp;</span>hours. After opening the blister, proceed
under aseptic conditions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5 Nature and contents
of container </span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>90 microlitres of solution in pre-filled syringe (type I glass)
marked with a black dosing line, with a plunger stopper (elastomeric rubber)
and a Luer lock adaptor with a tip cap (elastomeric rubber). Pack size of 1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><a name="OLE_LINK1"><b><span lang=EN-GB>6.6 Special precautions for
disposal and other handling</span></b></a></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The pre-filled
syringe is for single use in one eye only.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not open the sterile pre-filled blister outside the clean
administration room.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Since the
pre-filled syringe contains more volume (90&nbsp;microlitres) than the
recommended dose (50&nbsp;microlitres), a part of the volume contained in the
syringe has to be discarded prior to the administration.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The solution should be inspected visually
for any foreign particulate matter and/or discolouration or any variation in
physical appearance prior to administration. In the event of either being
observed, discard the medicinal product.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>For the
intravitreal injection, a 30&nbsp;G x&nbsp;&nbsp;inch injection needle should
be used.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><b><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></b></p>

<p class=GlobalBayerBodyText style='margin:0in'><b><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></b></p>

<p class=GlobalBayerBodyText style='margin:0in'><b><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Instructions for
use of pre-filled syringe:</span></i></b></p>

<p class=GlobalBayerBodyText style='margin:0in'><b><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=651
 style='width:488.2pt;border-collapse:collapse'>
 <tr style='height:41.35pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:41.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>1.</span></p>
  </td>
  <td width=617 colspan=2 valign=top style='width:462.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:41.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When ready to
  administer Eylea, open the carton and remove the sterilised blister.
  Carefully peel open the blister ensuring the sterility of its contents. Keep
  the syringe in the sterile tray until you are ready for assembly.</span></p>
  </td>
 </tr>
 <tr style='height:23.45pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:23.45pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>2.</span></p>
  </td>
  <td width=617 colspan=2 valign=top style='width:462.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:23.45pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>Using aseptic technique, remove the
  syringe from the sterilised blister.</span></p>
  </td>
 </tr>
 <tr style='height:157.35pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:157.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>3.</span></p>
  </td>
  <td width=323 valign=top style='width:241.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:157.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>To remove the
  syringe cap, hold the syringe in one hand while using the other hand to grasp
  the syringe cap with the thumb and fore finger. Please note: You should twist
  off (do not snap off) the syringe cap. </span></p>
  </td>
  <td width=294 valign=top style='width:220.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:157.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><img border=0 width=214 height=214 id="Picture 2"
  src="Eylea_IB_007_files/image008.jpg"></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>4.</span></p>
  </td>
  <td width=617 colspan=2 valign=top style='width:462.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>To avoid compromising the sterility of
  the product, do not pull back on the plunger.</span></p>
  </td>
 </tr>
 <tr style='height:158.2pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:158.2pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>5.</span></p>
  </td>
  <td width=323 valign=top style='width:241.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:158.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Using aseptic
  technique, firmly twist the injection needle onto the Luer-lock syringe tip.</span></p>
  </td>
  <td width=294 valign=top style='width:220.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:158.2pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB><img border=0 width=214 height=195
  id="Picture 27" src="Eylea_IB_007_files/image009.jpg"></span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:150.35pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:150.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>6.</span></p>
  </td>
  <td width=323 valign=top style='width:241.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:150.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Holding the
  syringe with the needle pointing up, check the syringe for bubbles. If there
  are bubbles, gently tap the syringe with your finger until the bubbles rise
  to the top.</span></p>
  </td>
  <td width=294 valign=top style='width:220.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:150.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB><img border=0 width=213 height=213
  src="Eylea_IB_007_files/image010.jpg"></span></p>
  </td>
 </tr>
 <tr style='height:50.45pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.45pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>7.</span></p>
  </td>
  <td width=617 colspan=2 valign=top style='width:462.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.45pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Eliminate all bubbles and expel excess medicinal product by slowly
  depressing the plunger rod to align the cylindrical base of the plunger dome
  edge with the black dosing line on the syringe (equivalent to
  50&nbsp;microlitres).</span></p>
  </td>
 </tr>
 <tr style='height:179.9pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:179.9pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=323 valign=top style='width:241.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:179.9pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><img border=0 width=212
  height=212 id="Grafik 32" src="Eylea_IB_007_files/image011.jpg"></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=294 valign=top style='width:220.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:179.9pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span style='position:absolute;z-index:251657216;
  margin-left:0px;margin-top:0px;width:180px;height:179px'><img width=180
  height=179 src="Eylea_IB_007_files/image012.gif"></span><img border=0
  width=79 height=79 src="Eylea_IB_007_files/image013.gif"></p>
  </td>
 </tr>
 <tr style='height:50.45pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.45pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>8. </span></p>
  </td>
  <td width=617 colspan=2 valign=top style='width:462.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.45pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The pre-filled
  syringe is for single use only. Extraction of multiple doses from a
  pre-filled syringe may increase the risk of contamination and subsequent
  infection.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
  medicinal product or waste material should be disposed of in accordance with
  local requirements.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7. MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Bayer AG</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>51368 Leverkusen</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>8. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/12/797/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: 22 November 2012</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal: 13 July 2017</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>10. DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product is available on the
website of the European Medicines Agency <span style='color:blue'><a
href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span><span
style='color:black'>.</span></span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>1.</span></b><span
lang=EN-GB> <b>NAME OF THE MEDICINAL PRODUCT </b></span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Eylea 40&nbsp;mg/mL&nbsp;</span><span lang=EN-GB>solution for
injection in a vial.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>2. QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>1 mL solution for
injection contains 40&nbsp;mg aflibercept*. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains 100&nbsp;microlitres, equivalent to 4&nbsp;mg aflibercept. This
provides a usable amount to deliver a single dose of 50 microlitres containing
2&nbsp;mg aflibercept.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*Fusion protein
consisting of portions of human VEGF (Vascular Endothelial Growth Factor)
receptors&nbsp;1 and 2 extracellular domains fused to the Fc portion of human
IgG1</span><span lang=EN-GB> and </span><span lang=EN-GB>produced in Chinese
hamster ovary (CHO) K1 cells by recombinant DNA technology.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3. PHARMACEUTICAL <span style='text-transform:
uppercase'>form</span></span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Solution for injection (injection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The solution is a
clear, colourless to pale yellow and iso-osmotic solution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='text-transform:uppercase'>4. Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Eylea </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>is
indicated for adults for the treatment of </span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN-GB>neovascular
     (wet) age-related macular degeneration (AMD) (see section 5.1),</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN-GB>visual
     impairment due to macular oedema secondary to retinal vein occlusion
     (branch RVO or central RVO) (see section 5.1),</span></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>visual impairment due to diabetic macular oedema
(DME) (see section 5.1),</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN-GB>visual
     impairment due to myopic choroidal neovascularisation (myopic CNV) (see
     section 5.1).</span></li>
</ul>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.2 Posology
and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Eylea is for
intravitreal injection only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Eylea must only be
administered by a qualified physician experienced in administering intravitreal
injections.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Posology</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><s><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>wet AMD</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The recommended
dose for Eylea is 2&nbsp;mg aflibercept, equivalent to 50&nbsp;microlitres.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Eylea treatment is
initiated with one injection per month for three consecutive doses. </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
treatment interval is then extended to two months.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Based on the
physicians judgement of visual and/or anatomic outcomes, the treatment
interval may be maintained at two months or further extended using a
treat-and-extend dosing regimen, where injection intervals are increased in 2-
or 4-weekly increments to maintain stable visual and/or anatomic outcomes.. If
visual and/or anatomic outcomes deteriorate, the treatment interval should be
shortened accordingly to a minimum of two months during the first 12 months of
treatment.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>There is no
requirement for monitoring between injections. Based on the physicians
judgement the schedule of monitoring visits may be more frequent than the injection
visits..</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>Treatment intervals greater than four
months between injections have not been studied (see Section&nbsp;5.1</span><span
style='font-family:"Times New Roman",serif'>).</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Macular
oedema secondary to </span></i><i><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>RVO (branch RVO or central RVO)</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The recommended
dose for Eylea is 2 mg aflibercept equivalent to 50 microlitres. </span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>After the initial
injection, treatment is given monthly. The interval between two doses should
not be shorter than one month.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>If visual and
anatomic outcomes indicate that the patient is not benefiting from continued
treatment, Eylea should be discontinued.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Monthly treatment
continues until maximum visual acuity is achieved and/or there are no signs of
disease activity. Three or more consecutive, monthly injections may be needed.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Treatment may then
be continued with a treat-and-extend regimen with gradually increased treatment
intervals to maintain stable visual and/or anatomic outcomes, however there are
insufficient data to conclude on the length of these intervals. If visual
and/or anatomic outcomes deteriorate, the treatment interval should be
shortened accordingly.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The monitoring
and treatment schedule should be determined by the treating physician based on
the individual patients response. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Monitoring for
disease activity may include clinical examination, functional testing or
imaging techniques (e.g. optical coherence tomography or fluorescein
angiography).</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Diabetic macular oedema</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The recommended
dose for Eylea is 2 mg aflibercept equivalent to 50 microlitres. </span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Eylea treatment is
initiated with one injection per month for five consecutive doses, followed by
one injection every two months. There is no requirement for monitoring between
injections.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>After the first 12
months of treatment with Eylea, and based on visual and/or anatomic outcomes,
the treatment interval may be extended, such as with a treat-and-extend dosing
regimen, where the treatment intervals are gradually increased to maintain
stable visual and/or anatomic outcomes; however there are insufficient data to
conclude on the length of these intervals. If visual and/or anatomic outcomes
deteriorate, the treatment interval should be shortened accordingly.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The schedule for
monitoring should therefore be determined by the treating physician and may be
more frequent than the schedule of injections.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>If visual and
anatomic outcomes indicate that the patient is not benefiting from continued
treatment, Eylea should be discontinued.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Myopic
choroidal neovascularisation</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The recommended
dose for Eylea is a single intravitreal injection of 2 mg aflibercept
equivalent to 50&nbsp;microlitres. </span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Additional doses
may be administered if visual and/or anatomic outcomes indicate that the
disease persists. Recurrences should be treated as a new manifestation of the
disease.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The schedule for
monitoring should be determined by the treating physician.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The interval
between two doses should not be shorter than one month.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Special
populations</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hepatic
and/or renal impairment</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>No
specific studies in patients with hepatic and/or renal impairment have been
conducted with </span><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>Eylea</span><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Available data do
not suggest a need for a dose adjustment with </span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Eylea</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'> in
these patients (see section&nbsp;5.2).</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Elderly population</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>No special
considerations are needed. There is limited experience in patients older than
75 years with DME.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Paediatric
population</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The safety and
efficacy of Eylea have not been established in children and adolescents. There
is no relevant use of Eylea in the paediatric population for the indications of
wet AMD, CRVO, BRVO, DME and myopic CNV.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Method of
administration</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Intravitreal
injections must be carried out according to medical standards and applicable
guidelines by a qualified physician experienced in administering intravitreal
injections.</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>
In general, adequate anaesthesia and asepsis, including topical broad spectrum
microbicide (e.g. povidone iodine applied to </span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>the periocular
skin, eyelid and ocular surface</span><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>), have to be ensured. </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Surgical
hand disinfection, sterile gloves, a sterile drape, and a sterile eyelid
speculum (or equivalent) are recommended.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The injection
needle should be inserted 3.5-4.0 mm posterior to the limbus into the vitreous
cavity, avoiding the horizontal meridian and aiming towards the centre of the
globe. The injection volume of 0.05 mL is then delivered; a different scleral
site should be used for subsequent injections.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Immediately following
the intravitreal injection, patients should be monitored for elevation in
intraocular pressure. Appropriate monitoring may consist of a check for
perfusion of the optic nerve head or tonometry.</span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'> If required,
sterile equipment for paracentesis should be available.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Following
intravitreal injection </span><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>patients should be instructed to report
any symptoms suggestive of endophthalmitis (e.g. eye pain, redness of the eye,
photophobia, blurring of vision) without delay.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Each vial should
only be used for the treatment of a single eye. Extraction of multiple doses
from a single vial may increase the risk of contamination and subsequent
infection.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;color:black'>The vial contains more than the
recommended dose of 2 mg aflibercept. T</span><span lang=EN-GB
style='font-size:11.0pt'>he extractable volume of the vial (100&nbsp;microlitres)
is not to be used in total. </span><span lang=EN-GB style='font-size:11.0pt;
color:black'>The excess volume should be expelled before injecting.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Injecting the entire volume of the vial could result
in overdose. </span><span lang=EN-GB style='font-size:11.0pt;color:black'>T</span><span
lang=EN-GB style='font-size:11.0pt'>o expel the air bubble along with excess
medicinal product, slowly depress the plunger to align the cylindrical base of
the dome plunger with the black dosing line on the syringe (equivalent to 50
microlitres i.e. 2 mg aflibercept).</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>After injection any unused product must be discarded.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>For handling of
the medicinal product before administration, see section&nbsp;6.6.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypersensitivity
to the active substance aflibercept or to any of the excipients listed in
section 6.1.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Active or
suspected ocular or periocular infection.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Active severe
intraocular inflammation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4 Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Traceability</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>In order to improve the traceability of
biological medicinal products, the name and the batch number</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>of the administered
product should be clearly recorded.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Intravitreal
injection-related reactions </span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Intravitreal injections, including those with
Eylea, have been associated with endophthalmitis, intraocular inflammation,
rhegmatogenous retinal detachment, retinal tear and iatrogenic traumatic
cataract (see section 4.8). Proper aseptic injection techniques must always be used
when administering Eylea. In addition, patients should be monitored during the
week following the injection to permit early treatment if an infection occurs. Patients
should be instructed to report any symptoms suggestive of endophthalmitis or
any of the above mentioned events without delay.</span><i><span lang=EN-GB> </span></i></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Increases in intraocular pressure have been seen
within 60&nbsp;minutes of intravitreal injection, including those with Eylea
(see section&nbsp;4.8). Special precaution is needed in patients with poorly
controlled glaucoma (do not inject Eylea while the intraocular pressure is
&#8805; 30 mmHg). In all cases, both the intraocular pressure and the perfusion
of the optic nerve head must therefore be monitored and managed appropriately.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt'>Immunogenicity</span></u></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;color:black'>As this is a therapeutic protein, there is
a potential for immunogenicity with Eylea (see section 4.8). Patients should be
instructed to report any signs or symptoms of intraocular inflammation, e.g.
pain, photophobia, or redness, which may be a clinical sign attributable to
hypersensitivity.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Systemic effects</span></u></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;color:black'>Systemic adverse events including
non-ocular haemorrhages and arterial thromboembolic events have been reported
following intravitreal injection of VEGF inhibitors </span><span lang=EN-GB
style='font-size:11.0pt;color:black'>and there is a theoretical risk that these
may relate to VEGF inhibition</span><span lang=EN-GB style='font-size:11.0pt;
color:black'>. There are limited data on safety in the treatment of patients
with CRVO, BRVO, DME or myopic CNV with a history of stroke or transient
ischaemic attacks or myocardial infarction within the last 6 months. Caution
should be exercised when treating such patients.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Other</span></u></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>As with other intravitreal anti-VEGF treatments for
AMD, CRVO, BRVO, DME and myopic CNV the following also applies:</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The safety and efficacy
of Eylea therapy administered to both eyes concurrently have not been
systematically studied (see section 5.1). If bilateral treatment is performed
at the same time this could lead to an increased systemic exposure, which could
increase the risk of systemic adverse events.</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Concomitant use of
other anti-VEGF (vascular endothelial growth factor)</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>There is no data
available on the concomitant use of Eylea with other anti-VEGF medicinal
products (systemic or ocular).</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Risk factors associated
with the development of a retinal pigment epithelial tear after anti-VEGF
therapy for wet AMD, include a large and/or high pigment epithelial retinal
detachment. When initiating Eylea therapy, caution should be used in patients
with these risk factors for retinal pigment epithelial tears.</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Treatment should be
withheld in patients with rhegmatogenous retinal detachment or stage 3 or 4
macular holes.</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>In the event of a
retinal break the dose should be withheld and treatment should not be resumed
until the break is adequately repaired<b>.</b></span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt;color:black'>The dose should be withheld and
treatment should not be resumed earlier than the next scheduled treatment in
the event of:</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:1.0in;text-indent:-.25in'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>a decrease in
best-corrected visual acuity (BCVA) of &#8805;30 letters compared with the last
assessment of visual acuity;</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:1.0in;text-indent:-.25in'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>a subretinal
haemorrhage involving the centre of the fovea, or, if the size of the
haemorrhage is &#8805;50%, of the total lesion area.</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt;color:black'>The dose should be withheld
within the previous or next 28 days in the event of a performed or planned
intraocular surgery.</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Eylea should not be used in pregnancy unless
the potential benefit outweighs the potential risk to the foetus (see section
4.6).</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-14.15pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Women of childbearing potential have to use
effective contraception during treatment and for at least 3 months after the
last intravitreal injection of aflibercept (see section 4.6).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>There is limited experience with treatment of
patients with ischaemic CRVO and BRVO. In patients presenting with clinical
signs of irreversible ischaemic visual function loss, the treatment is not
recommended</span><span lang=EN-GB style='color:black'>.</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt'><span lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Populations with limited data</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is only
limited experience in the treatment of subjects with DME due to type I diabetes
or in diabetic patients with an HbA1c over 12% or with proliferative diabetic
retinopathy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Eylea has not
been studied in patients with active systemic infections or in patients with
concurrent eye conditions such as retinal detachment or macular hole. There is
also no experience of treatment with Eylea in diabetic patients with
uncontrolled hypertension. This lack of information should be considered by the
physician when treating such patients. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In myopic CNV
there is no experience with Eylea in the treatment of non-Asian patients,
patients who have previously undergone treatment for myopic CNV, and patients
with extrafoveal lesions. </span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Information about excipients</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg)
per dosage unit, that is to say essentially sodium-free.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.5 Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>No interaction studies have been performed.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Adjunctive use of verteporfin photodynamic therapy
(PDT) and Eylea has not been studied, therefore, a safety profile is not
established.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6 Fertility, pregnancy
and lactation</span></b></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Women
of childbearing potential</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Women of
childbearing potential have to use effective contraception during treatment and
for at least 3 months after the last intravitreal injection of aflibercept (see
section&nbsp;4.4).</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>Pregnancy</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>There
are no data on the use of aflibercept in pregnant women.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Studies in animals
have shown embryo-foetal toxicity (see section&nbsp;5.3).</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Although the
systemic exposure after ocular administration is very low, Eylea should not be
used during pregnancy unless the potential benefit outweighs the potential risk
to the foetus.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Breast-feeding</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>It is
unknown whether aflibercept is excreted in human milk. A risk to the breast-fed
child cannot be excluded.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Eylea is not
recommended during breast-feeding. A decision must be made whether to
discontinue breast-feeding or to abstain from Eylea therapy </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>taking
into account the benefit of breast-feeding for the child and the benefit of
therapy for the woman</span><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Fertility</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Results
from animal studies with high systemic exposure indicate that aflibercept can
impair male and female fertility (see section 5.3). Such effects are not
expected after ocular administration with very low systemic exposure.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7 Effects on ability
to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Injection with
Eylea has a minor influence on the ability to drive and use machines due to
possible temporary visual disturbances associated either with the injection or
the eye examination. Patients should not drive or use machines until their
visual function has recovered sufficiently.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Summary
of the safety profile</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>A total of 3,102 patients
constituted the safety population in the eight phase&nbsp;III studies. Among
those, 2,501 patients were treated with the recommended dose of 2&nbsp;mg.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Serious ocular adverse
reactions in the study eye related to the injection procedure have occurred in
less than 1&nbsp;in&nbsp;1,900 intravitreal injections with Eylea and included
blindness, endophthalmitis, retinal detachment, cataract traumatic, cataract, vitreous
haemorrhage, vitreous detachment, and intraocular pressure increased (see
section&nbsp;4.4).</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The most
frequently observed adverse reactions (in at least&nbsp;5%&nbsp;of patients
treated with Eylea) were conjunctival haemorrhage&nbsp;(25%), retinal
haemorrhage (11%), visual acuity reduced (11%), eye pain&nbsp;(10%), cataract (8%),
intraocular pressure increased&nbsp;(8%), vitreous detachment&nbsp;(7%), and vitreous
floaters&nbsp;(7%). </span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'></span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Tabulated list of
adverse reactions</span></u></p>

<p class=BayerBodyTextFull style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>The safety data described below include all adverse
reactions from the eight phase III studies in the indications wet AMD, CRVO,
BRVO, DME and myopic CNV with a reasonable possibility of causality to the
injection procedure or medicinal product.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>The adverse reactions are listed by system organ class
and frequency using the following convention:</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Very common (&#8805;1/10), common (&#8805;1/100 to
&lt;1/10), uncommon (&#8805;1/1,000 to &lt;1/100), rare (</span><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'></span><span
lang=EN-GB style='font-size:11.0pt'> 1/10,000 to &lt; 1/1,000)</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Within each frequency grouping, adverse drug reactions
are presented in order of decreasing seriousness.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Table 1</span></b><span lang=EN-GB>:  </span><span
lang=EN-GB>All treatment-emergent adverse drug reactions reported in patients
in phase III studies (pooled data of the phase III studies for the indications
wet AMD, CRVO, BRVO, DME and myopic CNV) or during post-marketing surveillance</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=71 style='width:52.9pt;border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText align=center style='margin-top:2.0pt;margin-right:
  -5.3pt;margin-bottom:2.0pt;margin-left:0in;text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>System
  Organ Class</span></b></p>
  </td>
  <td width=109 style='width:81.8pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText align=center style='margin-top:2.0pt;margin-right:
  -7.35pt;margin-bottom:2.0pt;margin-left:0in;text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very
  common</span></b></p>
  </td>
  <td width=198 style='width:148.8pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText align=center style='margin-top:2.0pt;margin-right:
  0in;margin-bottom:2.0pt;margin-left:0in;text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></b></p>
  </td>
  <td width=142 style='width:106.35pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText align=center style='margin-top:2.0pt;margin-right:
  0in;margin-bottom:2.0pt;margin-left:0in;text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></b></p>
  </td>
  <td width=85 style='width:63.75pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText align=center style='margin-top:2.0pt;margin-right:
  0in;margin-bottom:2.0pt;margin-left:0in;text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=71 valign=top style='width:52.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:-5.3pt;
  margin-bottom:0in;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Immune system disorders</span></b></p>
  </td>
  <td width=109 valign=top style='width:81.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypersensitivity***<sup>
  </sup></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=71 valign=top style='width:52.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-5.3pt;
  margin-bottom:0in;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Eye disorders</span></b></p>
  </td>
  <td width=109 valign=top style='width:81.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Visual acuity reduced,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Retinal haemorrhage,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Conjunctival haemorrhage,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Eye pain</span></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Retinal pigment epithelial tear*,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Detachment of the retinal pigment
  epithelium,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Retinal degeneration,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Vitreous haemorrhage,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Cataract,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Cataract cortical,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Cataract nuclear,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Cataract subcapsular, </span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Corneal erosion, </span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Corneal abrasion,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Intraocular pressure increased,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Vision blurred,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Vitreous floaters,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Vitreous detachment,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Injection site pain,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Foreign body sensation in eyes,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Lacrimation increased,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Eyelid oedema,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Injection site haemorrhage,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Punctate keratitis,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Conjunctival hyperaemia,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Ocular hyperaemia</span></p>
  </td>
  <td width=142 valign=top style='width:106.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Endophthalmitis**,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Retinal detachment,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Retinal tear,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Iritis,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Uveitis,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Iridocyclitis,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Lenticular opacities,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Corneal epithelium defect,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Injection site irritation,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Abnormal sensation in eye,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Eyelid irritation,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Anterior chamber flare,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Corneal oedema</span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Blindness,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Cataract traumatic,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Vitritis,</span></p>
  <p class=GlobalBayerBodyText style='margin-top:2.0pt;margin-right:-7.35pt;
  margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Hypopyon</span></p>
  </td>
 </tr>
</table>

<p class=BayerBodyTextFull style='margin-top:4.0pt;margin-right:0in;margin-bottom:
0in;margin-left:.25in;text-indent:-.25in'><span lang=EN-GB style='font-size:
10.0pt'>*<sup> </sup>Conditions known to be associated with wet AMD.
Observed in the wet AMD studies only.</span></p>

<p class=BayerBodyTextFull style='margin-top:4.0pt;margin-right:0in;margin-bottom:
0in;margin-left:.25in;text-indent:-.25in'><span lang=EN-GB style='font-size:
10.0pt'>** Culture positive and culture negative endophthalmitis</span></p>

<p class=BayerBodyTextFull style='margin-top:4.0pt;margin-right:0in;margin-bottom:
0in;margin-left:.25in;text-indent:-.25in'><span lang=EN-GB style='font-size:
10.0pt'>*** During the post-marketing period, reports of hypersensitivity
included rash, pruritus, urticaria, and isolated cases of severe
anaphylactic/anaphylactoid reactions.</span></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:11.9pt;text-indent:-11.9pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:black'>Description of selected adverse reactions</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>In the
wet AMD phase III studies, there was an increased incidence of conjunctival haemorrhage
in patients receiving anti-thrombotic agents. This increased incidence was
comparable between patients treated with ranibizumab and Eylea.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Arterial
thromboembolic events (ATEs) are adverse events potentially related to systemic
VEGF inhibition. There is a theoretical risk of arterial thromboembolic events,
including stroke and myocardial infarction, following intravitreal use of VEGF
inhibitors.</span></p>

<p class=BayerBodyTextFull style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt'>A low incidence rate of arterial thromboembolic events
was observed in the Eylea clinical trials in patients with AMD, DME, RVO and
myopic CNV. Across indications no notable difference between the groups treated
with aflibercept and the respective comparator groups were observed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>As with all therapeutic</span><span
lang=EN-GB> proteins, there is a potential for immunogenicity with Eylea.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Reporting
of suspected adverse reactions</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:silver'>the national reporting
system listed in </span></span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
background:silver'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:silver'>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.9  Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In clinical
trials, doses of up to 4&nbsp;mg in monthly intervals have been used and
isolated cases of overdoses with 8&nbsp;mg occurred.</span></p>

<p class=MsoNormal style='text-autospace:none'><s><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Overdosing with
increased injection volume may increase intraocular pressure. Therefore, in
case of overdose, intraocular pressure should be monitored and if deemed
necessary by the treating physician, adequate treatment should be initiated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.1  Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: Ophthalmologicals / Antineovascularisation agents</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ATC
code:&nbsp;S01LA05</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Aflibercept is a
recombinant fusion protein consisting of portions of human VEGF receptor&nbsp;1
and 2 extracellular domains fused to the Fc portion of human IgG1.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aflibercept is
produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Aflibercept acts
as a soluble decoy receptor that binds VEGF-A and PlGF with higher affinity
than their natural receptors, and thereby can inhibit the binding and
activation of these cognate VEGF receptors. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Mechanism of
action</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Vascular
endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are
members of the VEGF family of angiogenic factors that can act as potent
mitogenic, chemotactic, and vascular permeability factors for endothelial
cells. VEGF acts via two receptor tyrosine kinases; VEGFR-1 and VEGFR-2,
present on the surface of endothelial cells. PlGF binds only to VEGFR-1, which
is also present on the surface of leucocytes. Excessive activation of these
receptors by VEGF-A can result in pathological neovascularisation and excessive
vascular permeability. PlGF can synergize with VEGF-A in these processes, and
is also known to promote leucocyte infiltration and vascular inflammation.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Pharmacodynamic
effects</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>wet AMD</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Wet AMD is
characterised by pathological choroidal neovascularisation (CNV). Leakage of
blood and fluid from CNV may cause retinal thickening or oedema and/or
sub-/intra-retinal haemorrhage, resulting in loss of visual acuity.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>In patients
treated with Eylea (one injection per month for three consecutive months,
followed by one injection every 2&nbsp;months), central retinal thickness [CRT]
decreased soon after treatment initiation, and the mean CNV lesion size was
reduced, consistent with the results seen with ranibizumab 0.5&nbsp;mg every
month.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>In the VIEW1 study
there were mean decreases in CRT on optical coherence tomography (OCT) (-130
and -129 microns at week&nbsp;52 for the Eylea 2&nbsp;mg every two months and
ranibizumab 0.5&nbsp;mg every month study groups, respectively). Also at the
52&nbsp;week time point, in the VIEW2 study there were mean decreases in CRT on
OCT (-149 and -139 microns for the Eylea 2&nbsp;mg every two months and
ranibizumab 0.5&nbsp;mg every month study groups, respectively). The reduction
of CNV size and reduction in CRT were generally maintained in the second year
of the studies.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;
margin-left:0in'><span lang=EN-GB>The ALTAIR study was conducted in Japanese patients
with treatment nave wet AMD, showing similar outcomes to the VIEW studies
using 3&nbsp;initial monthly Eylea 2&nbsp;mg injections, followed by one
injection after a further 2&nbsp;months, and then continued with a
treat-and-extend regimen with variable treatment intervals (2-week or 4-week
adjustments) up to a maximum 16&nbsp;week interval according to pre-specified
criteria. At week&nbsp;52, there were mean decreases in central retinal
thickness (CRT) on OCT of -134.4 and 126.1&nbsp;microns for the 2-week
adjustment group and the 4-week adjustment group, respectively. The proportion
of patients without fluid on OCT at week 52 was 68.3% and 69.1% in the 2- and
4-week adjustment groups, respectively. </span>The reduction in CRT was
generally maintained in both treatment arms in the second year of the ALTAIR
study<i><span style='font-size:12.0pt'>.</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Macular oedema secondary
to </span></i><i><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>CRVO
and BRVO</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>In CRVO and BRVO, retinal ischaemia occurs and signals
the release of VEGF which in turn destabilises the tight junctions, and
promotes endothelial cell proliferation. Up-regulation of VEGF is associated
with the breakdown of the blood retina barrier, increased vascular permeability,
retinal oedema, and neovascularisation complications.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>In patients treated with 6 consecutive monthly
injections of Eylea 2mg, there was a consistent, rapid and robust morphologic response
(as measured by improvements in mean CRT) observed. At week 24, the reduction
in CRT was statistically superior versus control in all three studies (</span><span
lang=EN-GB style='font-size:11.0pt'>COPERNICUS in CRVO: -457 vs. -145 microns;
GALILEO in CRVO: -449 vs. -169 microns; VIBRANT in BRVO: -280 vs. -128
microns). This decrease from baseline in CRT was maintained to the end of each
study, week 100 in COPERNICUS, week 76 in GALILEO, and week 52 in VIBRANT.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB>Diabetic
macular oedema</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Diabetic
macular oedema is a consequence of diabetic retinopathy and is characterised by
increased vasopermeability and damage to the retinal capillaries which may
result in loss of visual acuity. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In patients
treated with Eylea, the majority of whom were classified as having Type II
diabetes,<i> </i>a rapid and robust response in morphology (CRT, DRSS level)
was observed. </span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>In the VIVID<sup>DME </sup>and the VISTA<sup>DME</sup>
studies, a statistically significant greater mean decrease in CRT from baseline
to week 52 was observed in patients treated with Eylea than with the laser control,
-192.4 and -183.1 microns for the 2Q8 Eylea groups </span><span lang=EN-GB
style='font-size:11.0pt'></span><span lang=EN-GB style='font-size:11.0pt'>and
-66.2 and -73.3 microns for the control groups, respectively. </span><span
lang=EN-GB style='font-size:11.0pt'>At week 100 the decrease was maintained
with -195.8 and -191.1&nbsp;microns for the 2Q8 Eylea groups and </span><span
lang=EN-GB style='font-size:11.0pt'>-85.7 </span><span lang=EN-GB
style='font-size:11.0pt'>and -83.9 microns for the control groups, in the VIVID<sup>DME</sup>
and VISTA<sup>DME</sup> studies, respectively.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>A &#8805; 2 step improvement in DRSS was assessed in a pre-specified
manner in VIVID<sup>DME</sup> and VISTA<sup>DME</sup>. The DRSS score was
gradable in</span><span lang=EN-GB> 73.7% of the patients in VIVID<sup>DME</sup>
and 98.3% of the patients in VISTA<sup>DME</sup></span><span lang=EN-GB>. At
week 52, 27.7% and 29.1% of the Eylea 2Q8 groups, and 7.5% and 14.3% of the
control groups experienced a &#8805;2&nbsp;step improvement in the DRSS.</span><span
lang=EN-GB> </span><span lang=EN-GB>At week 100, the respective percentages
were 32.6% and 37.1% of the Eylea 2Q8 groups and 8.2% and 15.6% of the control
groups.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Myopic
choroidal neovascularisation </span></i></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Myopic choroidal
neovascularisation (myopic CNV) is a frequent cause of vision loss in adults
with pathologic myopia. It develops as a wound healing mechanism consequent to
Bruchs membrane ruptures and represents the most vision-threatening event in
pathologic myopia. </span></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In patients treated with Eylea in the
MYRROR study (one injection given at start of therapy, with additional
injections given in case of disease persistence or recurrence), CRT decreased
soon after treatment initiation favouring Eylea at week 24 (-79&nbsp;microns
and -4&nbsp;microns for the Eylea 2&nbsp;mg treatment group and the control
group, respectively), which was maintained through week&nbsp;48. In addition, the
mean CNV lesion size decreased. </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>wet AMD</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The safety and
efficacy of Eylea were assessed in two randomised, multi-centre, double-masked,
active-controlled studies in patients with wet AMD (VIEW1 and VIEW2) with a.
total of 2,412&nbsp;patients treated and evaluable for efficacy
(1,817&nbsp;with Eylea). Patient ages ranged from 49 to 99&nbsp;years with a
mean of 76&nbsp;years. </span><span lang=EN-GB>In these clinical studies,
approximately 89%&nbsp;(1,616/1,817) of the patients randomised to treatment
with </span><span lang=EN-GB>Eylea</span><span lang=EN-GB> were 65&nbsp;years
of age or older, and approximately 63%&nbsp;(1,139/1,817) were 75&nbsp;years of
age or older. </span><span lang=EN-GB>In each study, patients were randomly
assigned in a 1:1:1:1&nbsp;ratio to 1&nbsp;of&nbsp;4 dosing regimens:</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>1)&nbsp;Eylea administered at </span><span lang=EN-GB>2&nbsp;mg</span><span
lang=EN-GB> every 8 weeks following 3&nbsp;initial monthly doses (Eylea 2Q8);</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>2)&nbsp;Eylea administered at 2&nbsp;mg every 4&nbsp;weeks (Eylea
2Q4);</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>3)&nbsp;Eylea administered at 0.5&nbsp;mg every 4&nbsp;weeks
(Eylea&nbsp;0.5Q4); and</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>4)&nbsp;ranibizumab administered at 0.5&nbsp;mg every 4&nbsp;weeks
(ranibizumab&nbsp;0.5Q4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>In the second year of the studies, patients continued
to receive the initially randomised dosage but on a modified dosing schedule
guided by assessment of visual and anatomic outcomes with a protocol-defined
maximum dosing interval of 12 weeks.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In both studies,
the primary efficacy endpoint was the proportion of patients in the Per
Protocol Set who maintained vision, i.e. losing fewer than 15&nbsp;letters of
visual acuity at week 52&nbsp;from baseline. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>In the VIEW1 study, at week&nbsp;52, 95.1% of patients
in the Eylea 2Q8&nbsp;group maintained vision compared to&nbsp;94.4% patients
in the ranibizumab 0.5Q4&nbsp;group. In the VIEW2 study, at week&nbsp;52, 95.6%
of patients in the Eylea 2Q8&nbsp;group maintained vision compared to
94.4%&nbsp;patients in the ranibizumab 0.5Q4&nbsp;group. In both studies Eylea
was shown to be non-inferior and clinically equivalent to the ranibizumab
0.5Q4&nbsp;group.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed results
from the combined analysis of both studies are shown in Table&nbsp;2 and Figure&nbsp;1
below.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 2</span></b><span
lang=EN-GB>: Efficacy outcomes at week&nbsp;52 (primary analysis) and week 96;
combined data from the VIEW1 and VIEW2 studies<sup>B)</sup></span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></sup></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=600
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=180 rowspan=2 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader style='margin:0in'><span lang=EN-GB>Efficacy Outcome</span></p>
  </td>
  <td width=210 colspan=2 valign=top style='width:157.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='margin:0in;text-align:center'><span
  lang=EN-GB>Eylea&nbsp;</span><span lang=EN-GB>2Q8</span><sup><span
  lang=EN-GB> E)</span></sup></p>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>(Eylea 2&nbsp;mg every 8&nbsp;weeks
  following 3&nbsp;initial monthly doses)</span></p>
  <p class=C-TableHeader align=center style='margin:0in;text-align:center'><span
  lang=EN-GB>(</span><span lang=EN-GB style='font-size:10.0pt;font-weight:normal'>N
  </span><span lang=EN-GB>= 607)</span></p>
  </td>
  <td width=210 colspan=2 valign=top style='width:157.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='margin:0in;text-align:center'><span
  lang=EN-GB>Ranibizumab&nbsp;</span><span lang=EN-GB>0.5Q4</span></p>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>(ranibizumab 0.5&nbsp;mg every
  4&nbsp;weeks)</span></p>
  <p class=C-TableHeader align=center style='margin:0in;text-align:center'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=C-TableHeader align=center style='margin:0in;text-align:center'><span
  lang=EN-GB>(</span><span lang=EN-GB style='font-size:10.0pt;font-weight:normal'>N
  </span><span lang=EN-GB>= 595)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=108 style='width:81.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-6.15pt;
  margin-bottom:0in;margin-left:-5.4pt;text-align:center;text-indent:.15pt;
  page-break-after:avoid'><span lang=EN-GB>Week 52</span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-6.9pt;
  margin-bottom:0in;margin-left:-4.65pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Week 96</span><sup><span lang=EN-GB> </span></sup></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-6.15pt;
  margin-bottom:0in;margin-left:-5.4pt;text-align:center;text-indent:.15pt;
  page-break-after:avoid'><span lang=EN-GB>Week 52</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-6.9pt;
  margin-bottom:0in;margin-left:-4.65pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Week 96</span><sup><span lang=EN-GB> </span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>Mean number of injections from baseline</span></p>
  </td>
  <td width=108 style='width:81.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>7.6</span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>11.2</span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>12.3</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>16.5</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>Mean number of injections from Week 52 to 96</span></p>
  </td>
  <td width=108 style='width:81.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-6.15pt;
  margin-bottom:0in;margin-left:-5.4pt;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>4.2</span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>4.7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>Proportion of patients with </span></p>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>&lt; 15 letters loss from baseline (PPS<sup> A)</sup>)</span></p>
  </td>
  <td width=108 style='width:81.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-6.15pt;
  margin-bottom:0in;margin-left:-5.4pt;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>95.33%<sup>B)</sup></span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>92.42%</span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>94.42%<sup>
  B)</sup></span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>91.60%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>Difference<sup>C)</sup></span></p>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>(95% CI)<sup>D)</sup></span></p>
  </td>
  <td width=108 style='width:81.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-4.55pt;
  margin-bottom:0in;margin-left:-5.4pt;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>0.9%<br>
  (&#8209;1.7, 3.5)<sup>F)</sup></span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-4.55pt;
  margin-bottom:0in;margin-left:-5.4pt;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>0.8%<br>
  (&#8209;2.3, 3.8)<sup>F)</sup></span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>Mean change in BCVA as measured by ETDRS<sup>A)</sup> letter score
  from baseline </span></p>
  </td>
  <td width=108 style='width:81.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>8.40</span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>7.62</span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>8.74</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>7.89</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>Difference in LS<sup> A) </sup>mean change (ETDRS
  letters)<sup>C)</sup></span></p>
  <p class=C-TableText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:24.1pt;page-break-after:avoid'><span lang=EN-GB>(95% CI)<sup>D)</sup></span></p>
  </td>
  <td width=108 style='width:81.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-4.65pt;
  margin-bottom:0in;margin-left:-5.4pt;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&#8209;0.32<br>
  (&#8209;1.87, 1.23)</span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-6.9pt;
  margin-bottom:0in;margin-left:-7.65pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&#8209;0.25<br>
  (&#8209;1.98, 1.49)</span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>Proportion of patients with &#8805; 15 letters gain from baseline</span></p>
  </td>
  <td width=108 style='width:81.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>30.97%</span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>33.44%</span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>32.44%</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>31.60%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>Difference<sup>C)</sup></span></p>
  <p class=C-TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>(95% CI)<sup>D)</sup></span></p>
  </td>
  <td width=108 style='width:81.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>&#8209;1.5%<br>
  (&#8209;6.8, 3.8)</span></p>
  </td>
  <td width=102 style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>1.8%<br>
  (&#8209;3.5, 7.1)</span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></sup></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt;page-break-after:avoid'><sup><span
lang=EN-GB style='font-family:"Times New Roman",serif'>A)</span></sup><span
lang=EN-GB style='font-family:"Times New Roman",serif'> BCVA: Best Corrected
Visual Acuity</span></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'> ETDRS: Early
Treatment Diabetic Retinopathy Study</span></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'> LS</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>: Least square means
derived from ANCOVA</span></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'> </span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>PPS: Per Protocol Set</span></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt;page-break-after:avoid'><sup><span
lang=EN-GB style='font-family:"Times New Roman",serif'>B)</span></sup><span
lang=EN-GB style='font-family:"Times New Roman",serif'> </span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Full Analysis Set (FAS),
Last Observation Carried Forward (LOCF) for all analyses except proportion of
patients with maintained visual acuity at week 52 which is PPS</span></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt;page-break-after:avoid'><sup><span
lang=EN-GB style='font-family:"Times New Roman",serif'>C)</span></sup><span
lang=EN-GB style='font-family:"Times New Roman",serif'> The difference is the
value of the Eylea group minus the value of the ranibizumab group. A positive
value favours Eylea.</span></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt;page-break-after:avoid'><sup><span
lang=EN-GB style='font-family:"Times New Roman",serif'>D)</span></sup><span
lang=EN-GB style='font-family:"Times New Roman",serif'> Confidence interval
(CI) calculated by normal approximation</span></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt;page-break-after:avoid'><sup><span
lang=EN-GB style='font-family:"Times New Roman",serif'>E)</span></sup><span
lang=EN-GB style='font-family:"Times New Roman",serif'> After treatment
initiation with three monthly doses</span></p>

<p class=GlobalBayerBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.75pt;text-indent:-12.75pt;page-break-after:avoid'><sup><span
lang=EN-GB style='font-family:"Times New Roman",serif'>F)</span></sup><span
lang=EN-GB style='font-family:"Times New Roman",serif'> A confidence interval
lying entirely above -10% indicates a non-inferiority of Eylea to ranibizumab</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif'><br
clear=all>
</span></b>

<p class=GlobalBayerBodyText align=center style='margin:0in;text-align:center'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Figure
1</span></b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>.
Mean Change in Visual Acuity</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
page-break-after:avoid'><span lang=EN-GB>from Baseline to Week 96 for the
Combined</span></p>

<p class=GlobalBayerBodyText align=center style='margin:0in;text-align:center;
page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>Data from the View1 and View2 Studies</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB><img border=0
width=592 height=272 src="Eylea_IB_007_files/image014.jpg"></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In combined data analysis of VIEW1 and
VIEW2 Eylea demonstrated clinically meaningful changes from baseline in
pre-specified secondary efficacy endpoint National Eye Institute Visual
Function Questionnaire (NEI VFQ-25) without clinically meaningful differences
to ranibizumab. The magnitude of these changes was similar to that seen in
published studies, which corresponded to a&nbsp;15-letter gain in Best
Corrected Visual Acuity (BCVA).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the second
year of the studies, efficacy was generally maintained through the last
assessment at week 96, and 2-4% of patients required all injections on a
monthly basis, and a third of patients required at least one injection with a
treatment interval of only one month.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Decreases in mean CNV area were evident in
all dose groups in both studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Efficacy results
in all evaluable subgroups (e.g. age, gender, race, baseline visual acuity,
lesion type, lesion size) in each study and in the combined analysis were
consistent with the results in the overall populations.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>ALTAIR was a 96&nbsp;week multicentre,
randomised, open-label study in 247&nbsp;Japanese patients with treatment nave
wet AMD, designed to assess the efficacy and safety of Eylea following two
different adjustment intervals (2-weeks and 4-weeks) of a treat-and-extend
dosing regimen.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>All patients received monthly doses of Eylea
2&nbsp;mg for 3 months, followed by one injection after a further 2&nbsp;month
interval. At week&nbsp;16, patients were randomised 1:1 into two treatment
groups: 1) Eylea treat-and-extend with 2-week adjustments and 2) Eylea
treat-and-extend with 4-week adjustments. Extension or shortening of the treatment
interval was decided based on visual and/or anatomic criteria defined by
protocol with a maximum treatment interval of 16&nbsp;weeks for both groups.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary efficacy endpoint was mean
change in BCVA from baseline to week&nbsp;52. The secondary efficacy endpoints were
the proportion of patients who did not lose &#8805;15&nbsp;letters and the
proportion of patients who gained at least 15&nbsp;letters of BCVA from
baseline to week&nbsp;52.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>At week&nbsp;52, patients in the treat-and-extend arm with 2-week
adjustments gained a mean of 9.0&nbsp;letters from baseline as compared to 8.4&nbsp;letters
for those in the 4-week adjustment group [LS mean difference in letters (95%
CI): -0.4 (-3.8,3.0), ANCOVA]. The proportion of patients who did not lose
&#8805;15&nbsp;letters in the two treatment arms was similar (96.7% in the
2-week and 95.9% in the 4-week adjustment groups). The proportion of patients
who gained &#8805;15 letters at week 52 was 32.5% in the 2-week adjustment
group and 30.9% in the 4-week adjustment group. The proportion of patients who
extended their treatment interval to 12&nbsp;weeks or beyond was 42.3% in the
2-week adjustment group and 49.6 % in the 4-week adjustment group. Furthermore,
in the 4-week adjustment group 40.7% of patients were extended to 16&nbsp;week
intervals. At the last visit up to week&nbsp;52, 56. 8% and 57.8% of patients
in the 2-week and 4-week adjustment groups, respectively had their next
injection scheduled at an interval of 12&nbsp;weeks or beyond. </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>In the second year of the study, efficacy was generally
maintained up to and including the last assessment at week&nbsp;96, with a mean
gain from baseline of 7.6&nbsp;letters for the 2-week adjustment group and 6.1&nbsp;letters
for the 4-week adjustment group. The proportion of patients who extended their
treatment interval to 12&nbsp;weeks or beyond was 56.9% in the 2-week adjustment
group and 60.2% in the 4-week adjustment group. At the last visit prior to week&nbsp;96,
64.9% and 61.2% of patients in the 2-week and 4-week adjustment groups,
respectively had their next injection scheduled at an interval of 12&nbsp;weeks
or beyond. During the second year of treatment patients in both the 2-week and
4-week adjustment groups received an average of 3.6&nbsp;and 3.7&nbsp;injections,
respectively. Over the 2&nbsp;year treatment period patients received an
average of 10.4&nbsp;injections.</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Ocular and systemic safety profiles were similar to the safety
observed in the pivotal studies VIEW1 and VIEW2.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Macular oedema secondary
to </span></i><i><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>CRVO</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>The safety and efficacy of Eylea were assessed in two
randomised, multi-centre, double-masked, sham-controlled studies in patients
with macular oedema secondary to CRVO (COPERNICUS and GALILEO) with a total of
358 patients treated and evaluable for efficacy (217 with Eylea). Patient ages
ranged from 22 to 89 years with a mean of 64&nbsp;years. In the CRVO studies,
approximately 52% (112/217) of the patients randomised to treatment with Eylea
were 65 years of age or older, and approximately 18% (38/217) were 75 years of
age or older. In both studies, patients were randomly assigned in a 3:2 ratio
to either 2&nbsp;mg Eylea administered every 4 weeks (2Q4), or the control
group receiving sham injections every 4 weeks for a total of 6 injections.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After 6 consecutive monthly injections,
patients received treatment only if they met pre-specified retreatment
criteria, except for patients in the control group in the GALILEO study who
continued to receive sham (control to control) </span><span lang=EN-GB>until
week 52. From this timepoint all patients were treated if pre-specified
criteria were met</span><span lang=EN-GB>.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>In both studies, the primary efficacy endpoint was the
proportion of patients who gained at least 15&nbsp;letters in BCVA at week 24
compared to baseline. A secondary efficacy variable was change in visual acuity
at week 24 compared to baseline.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>The difference between treatment groups was
statistically significant in favour of Eylea in both studies. </span><span
lang=EN-GB style='font-size:11.0pt'>The maximal improvement in visual acuity was
achieved at month&nbsp;3 with subsequent stabilisation of visual acuity and CRT
until month&nbsp;6.</span><b><i><span lang=EN-GB style='font-size:11.0pt'> </span></i></b><span
lang=EN-GB style='font-size:11.0pt'>The statistically significant difference
was maintained through week 52.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Detailed results from the analysis of both studies are
shown in Table&nbsp;3 and Figure&nbsp;2 below.</span></p>

<p class=BayerBodyTextFull><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

</div>

<u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></u>

<div class=WordSection6>

<p class=MsoNormal><b><span lang=EN-GB>Table 3:</span></b><span lang=EN-GB>  Efficacy
outcomes at week 24, week 52 and week 76/100 (Full Analysis Set with LOCF<sup>C)</sup>)
in COPERNICUS and GALILEO studies</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:8.0pt'>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=180 rowspan=3 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader><span lang=EN-GB style='font-size:10.0pt'>Efficacy
  Outcomes</span></p>
  </td>
  <td colspan=6 valign=top style='border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>COPERNICUS</span></p>
  </td>
  <td colspan=6 valign=top style='border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>GALILEO</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td colspan=2 valign=top style='border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>24 Weeks</span></p>
  </td>
  <td colspan=2 valign=top style='border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>52 Weeks</span></p>
  </td>
  <td colspan=2 valign=top style='border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>100 Weeks</span></p>
  </td>
  <td colspan=2 valign=top style='border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>24 Weeks</span></p>
  </td>
  <td colspan=2 valign=top style='border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>52 Weeks</span></p>
  </td>
  <td colspan=2 valign=top style='border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>76 Weeks</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>Eylea</span></p>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>2 mg Q4</span></p>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 114)</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Control</span></b></p>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-.9pt;
  margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N= 73)</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>Eylea</span></p>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>2 mg </span></p>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-1.65pt;
  margin-bottom:3.0pt;margin-left:-3.9pt;text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 114)</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'><b>Control<sup>E)</sup></b></span></p>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N =73)</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>Eylea<sup> F)</sup></span></p>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>2 mg </span></p>
  <p class=C-TableText align=center style='margin-left:-1.65pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N= 114)</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.65pt;
  margin-bottom:3.0pt;margin-left:-1.65pt;text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Control <sup>E,F)</sup></span></b><span
  lang=EN-GB style='font-size:10.0pt'> </span></p>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.65pt;
  margin-bottom:3.0pt;margin-left:-1.65pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(<b>N=73)</b></span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>Eylea</span></p>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>2 mg Q4</span></p>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 103)</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Control</span></b></p>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=C-TableText align=center style='margin-left:-1.65pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 68)</span></b></p>
  </td>
  <td width=59 valign=top style='width:44.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>Eylea</span></p>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>2 mg</span></p>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.65pt;
  margin-bottom:3.0pt;margin-left:-1.65pt;text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 103)</span></b></p>
  </td>
  <td width=59 style='width:44.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText><b><span lang=EN-GB style='font-size:10.0pt'>Control </span></b></p>
  <p class=C-TableText align=center style='margin-left:-4.65pt;text-align:center'><b><span
  lang=EN-GB style='font-size:10.0pt'>(N = 68)</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>Eylea</span><sup><span lang=EN-GB
  style='font-size:10.0pt'> G</span></sup><sup><span lang=EN-GB
  style='font-size:10.0pt'>)</span></sup></p>
  <p class=C-TableHeader align=center style='margin-top:3.0pt;margin-right:
  -.9pt;margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span
  lang=EN-GB style='font-size:10.0pt'>2 mg</span></p>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.65pt;
  margin-bottom:3.0pt;margin-left:-1.65pt;text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 103)</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Control</span></b><b><sup><span
  lang=EN-GB style='font-size:10.0pt'> G</span></sup></b><b><sup><span
  lang=EN-GB style='font-size:10.0pt'>)</span></sup></b></p>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=C-TableText align=center style='margin-left:-4.65pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 68)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText><span lang=EN-GB style='font-size:9.0pt'>Proportion of
  patients with&#8805;15 letters gain from baseline</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-6.15pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>56%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>12%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>55%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>30%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>49.1%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>23.3%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-3.15pt;
  margin-bottom:3.0pt;margin-left:-2.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>60%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>22%</span></p>
  </td>
  <td width=59 style='width:44.1pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.65pt;
  margin-bottom:3.0pt;margin-left:-6.9pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>60%</span></p>
  </td>
  <td width=59 style='width:44.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>32%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.65pt;
  margin-bottom:3.0pt;margin-left:-6.9pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>57.3%</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>29.4%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  0in;margin-left:12.6pt'><span lang=EN-GB style='font-size:9.0pt'>Weighted
  difference<sup>A,B,E)</sup></span></p>
  <p class=C-TableText style='margin-top:0in;margin-right:0in;margin-bottom:
  3.0pt;margin-left:12.6pt'><span lang=EN-GB style='font-size:9.0pt'>(95% CI)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.55pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>44.8%<br>
  (33.0, 56.6)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.55pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.55pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>25.9%<br>
  (11.8, 40.1)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.55pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td rowspan=2 style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.55pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>26.7%<br>
  (13.1, 40.3)</span></p>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.55pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p=0.0003</span></p>
  </td>
  <td rowspan=2 style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.55pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.55pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>38.3%<br>
  (24.4, 52.1)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-4.55pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=59 style='width:44.1pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>27.9%<br>
  (13.0, 42.7)</span></p>
  </td>
  <td width=59 style='width:44.15pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td rowspan=2 style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>28.0%<br>
  (13.3, 42.6)</span></p>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>p=0.0004</span></p>
  </td>
  <td rowspan=2 style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin-top:0in;margin-right:0in;margin-bottom:
  3.0pt;margin-left:12.6pt'><span lang=EN-GB style='font-size:9.0pt'>p-value</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:0in;
  margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p &lt; 0.0001</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:0in;
  margin-bottom:3.0pt;margin-left:-4.65pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:0in;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p = 0.0006</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:0in;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-3.9pt;
  margin-bottom:3.0pt;margin-left:-1.65pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>p &lt; 0.0001</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-3.9pt;
  margin-bottom:3.0pt;margin-left:-1.65pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=59 style='width:44.1pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>p = 0.0004</span></p>
  </td>
  <td width=59 style='width:44.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText><span lang=EN-GB style='font-size:9.0pt'>Mean change in
  BCVA<sup> C)</sup> as measured by ETDRS<sup>C)</sup> letter score from
  baseline (SD)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>17.3<br>
  (12.8)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&#8209;4.0<br>
  (18.0)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>16.2<br>
  (17.4)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>3.8<br>
  (17.1)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>13.0<br>
  (17.7)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>1.5<br>
  (17.7)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>18.0<br>
  (12.2)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>3.3<br>
  (14.1)</span></p>
  </td>
  <td width=59 style='width:44.1pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>16.9<br>
  (14.8)</span></p>
  </td>
  <td width=59 style='width:44.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>3.8<br>
  (18.1)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>13.7<br>
  (17.8)</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>6.2<br>
  (17.7)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin-left:12.45pt'><span lang=EN-GB
  style='font-size:9.0pt'>Difference in LS mean<sup>A,C,D,E)<br>
  </sup>(95% CI)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-6.8pt;
  margin-bottom:3.0pt;margin-left:-7.65pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>21.7<br>
  (17.4, 26.0)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-6.8pt;
  margin-bottom:3.0pt;margin-left:-7.65pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-2.4pt;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>12.7<br>
  (7.7, 17.7)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-2.4pt;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td rowspan=2 style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-2.4pt;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>11.8<br>
  (6.7, 17.0)</span></p>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-2.4pt;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p &lt; 0.0001</span></p>
  </td>
  <td rowspan=2 style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-2.4pt;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-3.95pt;
  margin-bottom:3.0pt;margin-left:-4.55pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>14.7<br>
  (10.8, 18.7)</span></p>
  </td>
  <td style='border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-3.95pt;
  margin-bottom:3.0pt;margin-left:-4.55pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=59 style='width:44.1pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>13.2<br>
  (8.2, 18.2)</span></p>
  </td>
  <td width=59 style='width:44.15pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td rowspan=2 style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>7.6<br>
  (2.1, 13.1)</span></p>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>p=0.0070</span></p>
  </td>
  <td rowspan=2 style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:3.0pt;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=180 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText style='margin-top:0in;margin-right:0in;margin-bottom:
  3.0pt;margin-left:12.45pt'><span lang=EN-GB style='font-size:9.0pt'>p-value</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-6.8pt;
  margin-bottom:3.0pt;margin-left:-7.65pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p &lt; 0.0001</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-6.8pt;
  margin-bottom:3.0pt;margin-left:-7.65pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-2.4pt;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p &lt; 0.0001</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-2.4pt;
  margin-bottom:3.0pt;margin-left:-3.15pt;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-3.95pt;
  margin-bottom:3.0pt;margin-left:-4.55pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>p &lt; 0.0001</span></p>
  </td>
  <td style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-3.95pt;
  margin-bottom:3.0pt;margin-left:-4.55pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=59 style='width:44.1pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>p &lt; 0.0001</span></p>
  </td>
  <td width=59 style='width:44.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=C-TableText align=center style='margin-top:0in;margin-right:-5.4pt;
  margin-bottom:3.0pt;margin-left:-5.4pt;text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=BayerBodyTextFull style='margin:0in'><b><span lang=EN-GB
style='font-size:8.0pt;color:white'><br>
</span></b><sup><span lang=EN-GB style='font-size:10.0pt'>A) </span></sup><span
lang=EN-GB style='font-size:10.0pt'>Difference is Eylea 2 mg Q4 weeks minus
control</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.0pt;text-indent:-12.0pt;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:10.0pt'>B)</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Difference and confidence interval (CI) are
calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for region
(America vs. rest of the world for COPERNICUS and Europe vs. Asia/Pacific for
GALILEO) and baseline BCVA category (&gt; 20/200 and &#8804; 20/200)</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.0pt;text-indent:-12.0pt;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:10.0pt'>C)</span></sup><span lang=EN-GB
style='font-size:10.0pt'> BCVA: Best Corrected Visual Acuity<br>
ETDRS: Early Treatment Diabetic Retinopathy Study<br>
LOCF: Last Observation Carried Forward<br>
SD: Standard deviation<br>
LS: Least square means derived from ANCOVA</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.0pt;text-indent:-12.0pt;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:10.0pt'>D)</span></sup><span lang=EN-GB
style='font-size:10.0pt'> LS mean difference and confidence interval based on
an ANCOVA model with factors treatment group, region (America vs. rest of the
world for COPERNICUS and Europe vs. Asia/Pacific for GALILEO) and baseline BCVA
category (&gt; 20/200 and &#8804; 20/200)</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:-6.65pt;
margin-bottom:0in;margin-left:17.85pt;text-indent:-17.85pt;page-break-after:
avoid'><sup><span lang=EN-GB style='font-size:10.0pt'>E)</span></sup><span
lang=EN-GB style='font-size:10.0pt'> In COPERNICUS study, control group
patients could receive Eylea on an as-needed basis as frequently as every 4
weeks during week 24 to week 52; patients had visits every 4&nbsp;weeks.</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:-6.65pt;
margin-bottom:0in;margin-left:13.5pt;text-indent:-13.5pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>F</span></sup><sup><span lang=EN-GB
style='font-size:10.0pt'>) </span></sup><span lang=EN-GB style='font-size:
10.0pt'>In COPERNICUS study, both control group and Eylea 2mg patients received
Eylea 2 mg on an as-needed basis as frequently as every 4 weeks starting from week
52 to week&nbsp;96; patients had mandatory quarterly visits but may have been
seen as frequently as every 4 weeks if necessary. </span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:-6.65pt;
margin-bottom:0in;margin-left:13.5pt;text-indent:-13.5pt;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:10.0pt'>G</span></sup><sup><span lang=EN-GB
style='font-size:10.0pt'>) </span></sup><span lang=EN-GB style='font-size:
10.0pt'>In GALILEO study, both control group and Eylea 2mg patients received Eylea
2 mg on an as-needed basis every 8 weeks starting from week 52 to week 68;
patients had mandatory visits every 8 weeks.</span></p>

</div>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection7>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin-top:12.0pt;margin-right:0in;
margin-bottom:6.0pt;margin-left:1.0in;text-indent:-1.0in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Figure 2:</span></b><span lang=EN-GB
style='font-size:11.0pt'>  Mean Change from Baseline to Week 76/100 in Visual
Acuity by Treatment Group for the COPERNICUS and GALILEO Studies (Full Analysis
Set)</span></p>

<p class=BayerBodyTextFull style='margin-bottom:12.0pt'><span lang=EN-GB
style='font-size:11.0pt'><img border=0 width=601 height=759
src="Eylea_IB_007_files/image015.jpg"></span></p>

<p class=MsoNormal><span lang=EN-GB>In GALILEO, 86.4% (n=89) of the Eylea group
and 79.4% (n=54) of the sham group had perfused CRVO at baseline. At week 24,
this was 91.8% (n=89) in the Eylea group and 85.5% (n=47) in the sham group.
These proportions were maintained at week 76, with 84.3% (n=75) in the Eylea
group and 84.0% (n=42) in the sham group.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In COPERNICUS, 67.5% (n = 77) of the Eylea
group and 68.5% (n = 50) of the sham group had perfused CRVO at baseline. At
week 24, this was 87.4% (n = 90) in the Eylea group and 58.6% (n = 34) in the
sham group. These proportions were maintained at week 100 with 76.8 % (n = 76)
in the Eylea group and </span><span lang=EN-GB>78% (n = 39) in the sham group.</span><span
lang=EN-GB> Patients in the sham group were eligible to receive Eylea from week
24.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The beneficial effect of Eylea treatment on
visual function was similar in the baseline subgroups of perfused and
non-perfused patients. Treatment effects in other evaluable subgroups (e.g.
age, gender, race, baseline visual acuity, CRVO duration) in each study were in
general consistent with the results in the overall populations.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In combined data analysis of GALILEO and
COPERNICUS, Eylea demonstrated clinically meaningful changes from baseline in
pre-specified secondary efficacy endpoint National Eye Institute Visual
Function Questionnaire (NEI VFQ-25). The magnitude of these changes was similar
to that seen in published studies, which corresponded to a&nbsp;15-letter gain
in Best Corrected Visual Acuity (BCVA).</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Macular oedema
secondary to </span></i><i><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>BRVO</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>The safety
and efficacy of Eylea were assessed in a randomised, multi-centre,
double-masked, active-controlled study in patients with macular oedema
secondary to BRVO (VIBRANT) which included Hemi-Retinal Vein Occlusion. A total
of 181 patients were treated and evaluable for efficacy (91 with Eylea).
Patient ages ranged from 42 to 94 years with a mean of 65&nbsp;years. In the
BRVO study, approximately 58% (53/91) of the patients randomised to treatment
with Eylea were 65 years of age or older, and approximately 23% (21/91) were 75
years of age or older.<span class=MsoEndnoteReference> </span>In the study, patients
were randomly assigned in a 1:1 ratio to either 2&nbsp;mg Eylea administered
every 8 weeks following 6 initial monthly injections or laser photocoagulation
administered at baseline (laser control group). Patients in the laser control
group could receive additional laser photocoagulation (called rescue laser
treatment) beginning at week 12 with a minimum interval of 12 weeks. Based on
pre-specified criteria, patients in the laser group could receive rescue
treatment with Eylea 2mg from week 24, administered every 4 weeks for 3 months
followed by every 8 weeks. </span></p>

<p class=C-BodyText style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>In
the VIBRANT study, the primary efficacy endpoint was the proportion of patients
who gained at least 15 letters in BCVA at week 24 compared to baseline and the
Eylea group was superior to laser control. </span></p>

<p class=C-BodyText style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>A
secondary efficacy endpoint was change in visual acuity at week 24 compared to
baseline, which was statistically significant in</span><span lang=EN-GB> </span><span
lang=EN-GB style='font-size:11.0pt'>favour of Eylea in the VIBRANT study. The
course of visual improvement was rapid and peaked at 3 months with maintenance of
the effect until month 12.</span></p>

<p class=C-BodyText style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>In
the laser group 67 patients received rescue treatment with Eylea beginning at
week 24 (Active Control/ Eylea 2mg group), which resulted in improvement of
visual acuity by about 5 letters from week 24 to 52.</span></p>

<p class=C-BodyText style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:14.0pt'><span lang=EN-GB>Detailed results
from the analysis of the VIBRANT study are shown in Table 4 and Figure 3 below.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:14.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;
margin-left:0in;line-height:14.0pt'><b><span lang=EN-GB>Table 4: </span></b><span
lang=EN-GB> Efficacy outcomes at week 24 and week 52 (Full Analysis Set
with LOCF) in VIBRANT study</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=138 rowspan=2 valign=top style='width:103.45pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in'><b><span lang=EN-GB style='font-size:10.0pt'>Efficacy
  Outcomes</span></b></p>
  </td>
  <td width=481 colspan=4 valign=top style='width:360.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>VIBRANT</span></b></p>
  </td>
 </tr>
 <tr style='height:52.25pt'>
  <td width=263 colspan=2 valign=top style='width:197.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:52.25pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>24 Weeks</span></b></p>
  </td>
  <td width=218 colspan=2 valign=top style='width:163.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:52.25pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>52 Weeks</span></b></p>
  </td>
 </tr>
 <tr style='height:52.25pt'>
  <td width=138 valign=top style='width:103.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:52.25pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:52.25pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>Eylea 2mg Q4</span></b></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>(N = 91)</span></b></p>
  </td>
  <td width=131 valign=top style='width:98.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:52.25pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>Active Control (laser)</span></b></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>(N = 90)</span></b></p>
  </td>
  <td width=109 valign=top style='width:81.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:52.25pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>Eylea 2mg Q8</span></b></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>(N = 91)</span></b><b><sup><span lang=EN-GB
  style='font-size:10.0pt;font-family:"Times New Roman Bold",serif'>D)</span></sup></b></p>
  </td>
  <td width=109 valign=top style='width:81.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:52.25pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>Active Control (laser)/Eylea 2mg<sup>E)</sup></span></b></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:10.0pt'>(N = 90)</span></b></p>
  </td>
 </tr>
 <tr style='height:19.3pt'>
  <td width=138 valign=top style='width:103.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in'><span lang=EN-GB style='font-size:9.0pt'>Proportion of
  patients with &#8805;15 letters gain from Baseline (%)</span></p>
  </td>
  <td width=132 valign=top style='width:99.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>52.7%</span></p>
  </td>
  <td width=131 valign=top style='width:98.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>26.7%</span></p>
  </td>
  <td width=109 valign=top style='width:81.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>57.1%</span></p>
  </td>
  <td width=109 valign=top style='width:81.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>41.1%</span></p>
  </td>
 </tr>
 <tr style='height:19.3pt'>
  <td width=138 valign=top style='width:103.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=right style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:right'><span lang=EN-GB
  style='font-size:9.0pt'>Weighted Difference <sup>A,B)</sup> (%)</span></p>
  <p class=MsoNormal align=right style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:right'><span lang=EN-GB
  style='font-size:9.0pt'>(95% CI)</span></p>
  <p class=MsoNormal align=right style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:right'><span lang=EN-GB
  style='font-size:9.0pt'>p-value </span></p>
  </td>
  <td width=132 valign=top style='width:99.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;line-height:14.0pt'><span
  lang=EN-GB style='font-size:9.0pt'>26.6%</span></p>
  <p class=MsoNormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;line-height:14.0pt'><span
  lang=EN-GB style='font-size:9.0pt'>(13.0, 40.1)</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p=0.0003</span></p>
  </td>
  <td width=131 valign=top style='width:98.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=109 valign=top style='width:81.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>16.2%</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(2.0, 30.5)</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p=0.0296</span></p>
  </td>
  <td width=109 valign=top style='width:81.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:19.3pt'>
  <td width=138 valign=top style='width:103.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in'><span lang=EN-GB style='font-size:9.0pt'>Mean change
  in BCVA as measured by ETDRS letter score from Baseline (SD)</span></p>
  </td>
  <td width=132 valign=top style='width:99.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;line-height:14.0pt'><span
  lang=EN-GB style='font-size:9.0pt'>17.0</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(11.9)</span></p>
  </td>
  <td width=131 valign=top style='width:98.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>6.9</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(12.9)</span></p>
  </td>
  <td width=109 valign=top style='width:81.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>17.1</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(13.1)</span></p>
  </td>
  <td width=109 valign=top style='width:81.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>12.2 (11.9)</span></p>
  </td>
 </tr>
 <tr style='height:19.3pt'>
  <td width=138 valign=top style='width:103.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=right style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:right'><span lang=EN-GB
  style='font-size:9.0pt'>Difference in LS mean <sup>A,C)</sup></span></p>
  <p class=MsoNormal align=right style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:right'><span lang=EN-GB
  style='font-size:9.0pt'>(95% CI)</span></p>
  <p class=MsoNormal align=right style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:right'><span lang=EN-GB
  style='font-size:9.0pt'>p-value</span></p>
  </td>
  <td width=132 valign=top style='width:99.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>10.5</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(7.1, 14.0)</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>p&lt;0.0001</span></p>
  </td>
  <td width=131 valign=top style='width:98.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=109 valign=top style='width:81.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>5.2</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(1.7, 8.7)</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>p=0.0035<sup>F)</sup></span></p>
  </td>
  <td width=109 valign=top style='width:81.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:24.95pt;text-indent:-17.85pt;line-height:
normal'><sup><span lang=EN-GB style='font-size:9.0pt'>A)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Difference is
Eylea 2 mg Q4 weeks minus Laser Control</span></p>

<p class=MsoNormal style='margin-left:24.95pt;text-indent:-17.85pt;line-height:
normal'><sup><span lang=EN-GB style='font-size:9.0pt'>B)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Difference and 95%
CI are calculated using Mantel-Haenszel weighting scheme adjusted for region
(North America vs. Japan) and baseline BCVA category (&gt;&nbsp;20/200 and
&#8804;&nbsp;20/200)</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:24.95pt;text-indent:-17.85pt'><sup><span lang=EN-GB
style='font-size:11.0pt'>C)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>LS mean difference
and 95% CI based on an ANCOVA model with treatment group, </span><span
lang=EN-GB style='font-size:9.0pt'>baseline BCVA category (&gt;&nbsp;20/200 and
&#8804;&nbsp;20/200) </span><span lang=EN-GB style='font-size:9.0pt'>and </span><span
lang=EN-GB style='font-size:9.0pt'>region (North America vs. Japan) </span><span
lang=EN-GB style='font-size:9.0pt'>as fixed effects, and baseline BCVA as
covariate.</span></p>

<p class=MsoNormal style='margin-left:24.95pt;text-indent:-17.85pt;line-height:
normal'><sup><span lang=EN-GB style='font-size:9.0pt'>D)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>From week 24 on
the treatment interval in the Eylea treatment group was extended for all
subjects from 4 weeks to 8 weeks through week 48.</span></p>

<p class=MsoNormal style='margin-left:24.95pt;text-indent:-17.85pt;line-height:
normal'><sup><span lang=EN-GB style='font-size:9.0pt'>E)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Beginning at week 24
subjects in the Laser Group could receive rescue treatment with Eylea, if they
met at least one pre-specified eligibility criterion. At total of 67 subjects
in this group received Eylea rescue treatment. The fixed regimen for Eylea
rescue was three times Eylea 2mg every 4 weeks followed by injections every 8
weeks.</span></p>

<p class=MsoNormal style='margin-left:24.95pt;text-indent:-17.85pt;line-height:
normal'><sup><span lang=EN-GB style='font-size:9.0pt'>F)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Nominal p-value</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;
margin-left:.35in;line-height:14.0pt'><sup><span lang=EN-GB style='font-size:
9.0pt'>&nbsp;</span></sup></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;
margin-left:56.7pt;text-indent:-56.7pt;line-height:14.0pt;page-break-after:
avoid'><b><span lang=EN-GB>Figure 3:  </span></b><span lang=EN-GB>Mean
Change in BCVA as Measured by ETDRS Letter Score from Baseline to Week&nbsp;52 in
VIBRANT Study</span></p>

<p class=BayerBodyTextFull style='page-break-after:avoid'><span lang=EN-GB><img
border=0 width=498 height=356 src="Eylea_IB_007_files/image016.jpg"></span></p>

<p class=C-BodyText style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>At
baseline, the proportion of perfused patients in the Eylea and laser groups was
60% and 68%, respectively. At week 24 these proportions were 80% and 67%,
respectively. In the Eylea group the proportion of perfused patients was maintained
through week 52. In the laser group, where patients were eligible for rescue
treatment with Eylea from week 24, the proportion of perfused patients
increased to 78% by week 52. </span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt'>Diabetic macular oedema</span></i></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>The safety and efficacy of Eylea were assessed in two
randomised, multi-centre, double-masked, active-controlled studies in patients
with DME (VIVID<sup>DME</sup> and VISTA<sup>DME</sup>). A total of 862 patients
were treated and evaluable for efficacy, 576 with Eylea. Patient ages ranged
from 23 to 87 years with a mean of 63&nbsp;years. In the DME studies,
approximately 47% (268/576) of the patients randomised to treatment with Eylea
were 65 years of age or older, and approximately 9% (52/576) were 75 years of
age or older. The majority of patients in both studies had Type II diabetes. </span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>In both studies, patients were randomly assigned in a
1:1:1 ratio to 1 of 3 dosing regimens:</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>1)&nbsp;Eylea administered 2 mg every 8 weeks
following 5 initial monthly injections (Eylea 2Q8);</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>2) Eylea administered 2 mg every 4 weeks (Eylea 2Q4);
and</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>3) macular laser photocoagulation (active control). </span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Beginning at week 24, patients meeting a pre-specified
threshold of vision loss were eligible to receive additional treatment:
patients in the Eylea groups could receive laser and patients in the control group
could receive Eylea.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>In both studies, the primary efficacy endpoint was the
mean change from baseline in BCVA at week 52 and both Eylea 2Q8 and Eylea 2Q4
groups demonstrated statistical significance and were superior to the control
group. This benefit was maintained through week 100.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Detailed results from the analysis of the VIVID<sup>DME</sup>
and VISTA<sup>DME</sup> studies are shown in Table 5 and Figure 4 below.</span></p>

</div>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection8>

<p class=BayerBodyTextFull><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;
margin-left:1.0in;text-indent:-1.0in;line-height:14.0pt;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;</span></b><b><span lang=EN-GB>5</span></b><b><span
lang=EN-GB>: </span></b><span lang=EN-GB>Efficacy outcomes at week 52
and week 100 (Full Analysis Set with LOCF) in VIVID<sup>DME</sup> and VISTA<sup>DME</sup>
studies</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=1023
 style='margin-left:-.05in;border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:27.6pt'>
   <td width=109 rowspan=3 valign=top style='width:81.85pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:27.6pt'>
   <p class=MsoNormal style='margin-top:.1in;margin-right:0in;margin-bottom:
   .1in;margin-left:0in;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:10.0pt'>Efficacy Outcomes</span></b></p>
   </td>
   <td width=451 colspan=6 valign=top style='width:338.25pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:27.6pt'>
   <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
   margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB>VIVID<sup>DME</sup></span></b></p>
   </td>
   <td width=463 colspan=6 valign=top style='width:347.3pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:27.6pt'>
   <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
   margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB>VISTA<sup>DME</sup></span></b></p>
   </td>
  </tr>
  <tr style='height:7.15pt' style='height:7.15pt !msorm'>
   <td width=224 colspan=3 valign=top style='width:168.15pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
   margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:9.0pt'>52 Weeks</span></b></p>
   </td>
   <td width=227 colspan=3 valign=top style='width:170.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
   margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:9.0pt'>100 Weeks</span></b></p>
   </td>
   <td width=236 colspan=3 valign=top style='width:177.2pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
   margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:9.0pt'>52 Weeks</span></b></p>
   </td>
   <td width=227 colspan=3 valign=top style='width:170.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
   margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:9.0pt'>100 Weeks</span></b></p>
   </td>
  </tr>
  <tr style='height:7.15pt' style='height:7.15pt !msorm'>
   <td width=73 valign=top style='width:54.75pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>Eylea</span></b></p>
   <p class=MsoNormal align=center style='margin-left:-4.65pt;text-align:center;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:9.0pt'>2 mg Q8 </span></b><sup><span
   lang=EN-GB style='font-size:9.0pt'>A</span></sup></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N = 135)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>Eylea</span></b></p>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>2 mg Q4</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N = 136)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Active Control</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(laser)</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N = 132)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>Eylea</span></b></p>
   <p class=MsoNormal align=center style='margin-left:-4.65pt;text-align:center;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:9.0pt'>2 mg Q8 </span></b><sup><span
   lang=EN-GB style='font-size:9.0pt'>A</span></sup></p>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>(N = 135)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Eylea </span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>2mg Q4</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N=136)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Active Control</span></b><b><sup><span
   lang=EN-GB style='font-size:9.0pt;font-family:"Times New Roman Bold",serif'>
   </span></sup></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(laser)</span></b></p>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>(N = 132)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>Eylea</span></b></p>
   <p class=MsoNormal align=center style='margin-left:-4.65pt;text-align:center;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:9.0pt'>2 mg Q8 </span></b><sup><span
   lang=EN-GB style='font-size:9.0pt'>A</span></sup></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N = 151)</span></b></p>
   </td>
   <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>Eylea</span></b></p>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>2 mg Q4</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N = 154)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Active Control</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(laser)</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N = 154)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='margin-right:-.9pt;margin-left:-4.65pt;
   text-align:center;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:9.0pt'>Eylea</span></b></p>
   <p class=MsoNormal align=center style='margin-left:-4.65pt;text-align:center;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:9.0pt'>2 mg Q8 </span></b><sup><span
   lang=EN-GB style='font-size:9.0pt'>A</span></sup></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N = 151)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Eylea</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>2 mg Q4</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N=154)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
   border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
   padding:0in 5.4pt 0in 5.4pt !msorm;height:7.15pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Active Control</span></b><b><sup><span
   lang=EN-GB style='font-size:9.0pt;font-family:"Times New Roman Bold",serif'>
   </span></sup></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(laser)</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>(N = 154)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:80.65pt' style='height:80.65pt !msorm'>
  <td width=109 style='width:81.85pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;border:solid windowtext 1.0pt !msorm;
  border-top:none !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>Mean change in BCVA as measured by ETDRS</span><sup><span
  lang=EN-GB style='font-size:9.0pt'> E</span></sup><span lang=EN-GB
  style='font-size:9.0pt'> letter score from Baseline</span></p>
  </td>
  <td width=73 style='width:54.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>10.7</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>10.5</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>1.2</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>9.4</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>11.4</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>0.7</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>10.7</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>12.5</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>0.2</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>11.1</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>11.5</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:80.65pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>0.9</span></p>
  </td>
 </tr>
 <tr style='height:44.45pt' style='height:44.45pt !msorm'>
  <td width=109 valign=top style='width:81.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;border:solid windowtext 1.0pt !msorm;
  border-top:none !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>Difference<sup> </sup>in LS <br>
   mean<sup> B,C,E<br>
  </sup> (97.5% CI)</span></p>
  </td>
  <td width=73 style='width:54.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>9.1<sup><br>
  </sup>(6.3, 11.8)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>9.3<sup><br>
  </sup>(6.5, 12.0)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>8.2<sup><br>
  </sup>(5.2, 11.3)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>10.7 (7.6, 13.8)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>10.45<sup><br>
  </sup>(7.7, 13.2)</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>12.19<sup><br>
  </sup>(9.4, 15.0)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>10.1<sup><br>
  </sup>(7.0, 13.3)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>10.6 (7.1, 14.2)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:44.45pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:78.3pt' style='height:78.3pt !msorm'>
  <td width=109 valign=top style='width:81.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;border:solid windowtext 1.0pt !msorm;
  border-top:none !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;height:78.3pt'>
  <p class=MsoNormal style='margin-top:.1in;margin-right:0in;margin-bottom:
  .1in;margin-left:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Proportion of patients with &#8805; 15 letters gain
  from Baseline</span></p>
  </td>
  <td width=73 style='width:54.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>33%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>32%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>9%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>31.1%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>38.2%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>12.1%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>31%</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>42%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>8%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>33.1%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>38.3%</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:78.3pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>13.0%</span></p>
  </td>
 </tr>
 <tr style='height:53.7pt' style='height:53.7pt !msorm'>
  <td width=109 valign=top style='width:81.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;border:solid windowtext 1.0pt !msorm;
  border-top:none !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;height:53.7pt'>
  <p class=MsoNormal style='margin-top:.1in;margin-right:0in;margin-bottom:
  .1in;margin-left:0in'><span lang=EN-GB style='font-size:9.0pt'> Adjusted
  <br>
   Difference <sup>D,C,E</sup><br>
   (97.5% CI)</span></p>
  </td>
  <td width=73 style='width:54.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>24%<br>
  (13.5, 34.9)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>23%<br>
  (12.6, 33.9)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>19.0% (8.0, 29.9)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>26.1% (14.8, 37.5)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt;background:aqua'>&nbsp;</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>23%<br>
  (13.5, 33.1)</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>34%<br>
  (24.1, 44.4)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>20.1% (9.6, 30.6)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>25.8% (15.1, 36.6)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  border-top:none !msorm;border-left:none !msorm;border-bottom:solid windowtext 1.0pt !msorm;
  border-right:solid windowtext 1.0pt !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;
  height:53.7pt'>
  <p class=MsoNormal align=center style='margin-top:.1in;margin-right:0in;
  margin-bottom:.1in;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=C-TableFootnote style='margin-left:9.05pt;text-indent:-9.05pt'><sup><span
lang=EN-GB>&nbsp;</span></sup></p>

<p class=C-TableFootnote style='margin-left:9.05pt;text-indent:-9.05pt'><sup><span
lang=EN-GB>A </span></sup><span lang=EN-GB>After treatment initiation with 5
monthly injections </span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:9.05pt;text-indent:-9.05pt;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:10.0pt'>B  </span></sup><span lang=EN-GB
style='font-size:10.0pt'>LS mean and CI based on an ANCOVA model with baseline
BCVA measurement as a covariate and a factor for treatment group. Additionally,
region (Europe/Australia vs. Japan) had been included as factor for VIVID<sup>DME</sup>,
and history of MI and/or CVA as a factor for VISTA<sup>DME</sup>.</span></p>

<p class=C-TableFootnote style='margin-left:9.05pt;text-indent:-9.05pt'><sup><span
lang=EN-GB>C</span></sup><span lang=EN-GB>  </span><span lang=EN-GB>Difference</span><span
lang=EN-GB> is Eylea group minus active control (laser) group</span></p>

<p class=C-BodyText style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:9.05pt;text-indent:-9.05pt;line-height:normal'><sup><span
lang=EN-GB style='font-size:10.0pt'>D </span></sup><sup><span lang=EN-GB
style='font-size:10.0pt'> </span></sup><span lang=EN-GB style='font-size:10.0pt'>Difference
with confidence interval (CI) and statistical test is calculated using
Mantel-Haenszel weighting scheme adjusted by region (Europe/Australia vs.
Japan) for VIVID<sup>DME</sup> and medical history of MI or CVA for VISTA<sup>DME</sup></span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:7.1pt;text-indent:-7.1pt;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:10.0pt'>E </span></sup><span lang=EN-GB
style='font-size:10.0pt'>BCVA: Best Corrected Visual Acuity</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:7.1pt;page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>ETDRS: Early Treatment Diabetic Retinopathy Study<br>
LOCF: Last Observation Carried Forward<br>
LS: Least square means derived from ANCOVA<br>
CI: Confidence interval</span></p>

</div>

<span lang=EN-GB style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection9>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:1.0in;text-indent:-1.0in;page-break-after:avoid'><span
class=CaptionChar><span lang=EN-GB style='font-size:11.0pt'>Figure 4:  </span></span><span
lang=EN-GB style='font-size:11.0pt'>Mean Change in BCVA as Measured by ETDRS
Letter Score from Baseline to Week&nbsp;100 in VIVID<sup>DME</sup> and VISTA<sup>DME</sup>
Studies</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.0pt;text-indent:-12.0pt;page-break-after:avoid'><span
class=CaptionChar><span lang=EN-GB style='font-size:11.0pt;font-weight:normal'>&nbsp;</span></span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.0pt;text-indent:-12.0pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:12.0pt;text-indent:-12.0pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'><img border=0 width=528 height=556
src="Eylea_IB_007_files/image017.jpg"></span></p>

<p class=BayerBodyTextFull style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Treatment effects in evaluable subgroups
(e.g., age, gender, race, baseline HbA1c, baseline visual acuity, prior
anti-VEGF therapy) in each study and in the combined analysis were generally
consistent with the results in the overall populations.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>In the VIVID<sup>DME</sup> and VISTA<sup>DME</sup>
studies, 36 (9%) and 197 (43%) patients received prior anti-VEGF therapy,
respectively, with a 3-month or longer washout period. Treatment effects in the
subgroup of patients who had previously been treated with a VEGF inhibitor were
similar to those seen in patients who were VEGF inhibitor nave.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Patients with bilateral disease were eligible to
receive anti-VEGF treatment in their fellow eye if assessed necessary by the
physician. In the VISTA<sup>DME</sup> study, 217 (70.7%) of Eylea patients
received bilateral Eylea injections until week100; in the VIVID<sup>DME</sup> study,
97 (35.8%) of Eylea patients received a different anti-VEGF treatment in their
fellow eye.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>An independent comparative trial (DRCR.net
Protocol T) utilised a dosing regimen based on strict OCT and vision
re-treatment criteria. In the aflibercept treatment group (n = 224) at week 52,
this treatment regimen resulted in patients receiving a mean of 9.2 injections,
which is similar to the administered number of doses in the Eylea 2Q8 group in
VIVID<sup>DME </sup>and VISTA<sup>DME</sup>, while overall efficacy of the
aflibercept treatment group in Protocol T was comparable to the Eylea 2Q8 group
in VIVID<sup>DME</sup> and VISTA<sup>DME</sup>. A 13.3 mean letter gain with
42% of patients gaining at least 15 letters in vision from baseline was
observed in Protocol T. Ocular and systemic safety profiles (including ATEs)
were similar to VIVID<sup>DME</sup> and VISTA<sup>DME</sup></span><span
lang=EN-GB style='font-family:"Calibri",sans-serif'>.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Myopic choroidal
neovascularisation</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of Eylea were
assessed in a randomised, multi-centre, double-masked, sham-controlled study in
treatment-nave, Asian patients with myopic CNV. A total of 121&nbsp;patients
were treated and evaluable for efficacy (90&nbsp;with Eylea). Patient ages
ranged from 27&nbsp;to 83&nbsp;years with a mean of 58&nbsp;years. </span><span
lang=EN-GB>In the myopic CNV study, approximately 36% (33/91) of the patients
randomised to treatment with Eylea were 65&nbsp;years of age or older, and
approximately 10% (9/91) were 75&nbsp;years of age or older.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients were randomly assigned in a
3:1&nbsp;ratio to receive either 2&nbsp;mg Eylea </span><span lang=EN-GB>intravitreally</span><span
lang=EN-GB> or sham injections administered once at study start with additional
injections given monthly in case of disease persistence or recurrence until
week 24, when the primary endpoint was assessed. At week 24, patients initially
randomised to sham were eligible to receive the first dose of Eylea. Following
this, patients in both groups continued to be eligible for additional
injections in case of disease persistence or recurrence.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The difference between treatment groups was
statistically significant in favour of Eylea for the primary endpoint (change in
BCVA) and confirmatory secondary efficacy endpoint (proportion of patients who
gained 15 letters in BCVA) at week&nbsp;24 compared to baseline. Differences
for both endpoints were maintained through week&nbsp;48.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed results from the analysis of the
MYRROR study are shown in Table&nbsp;6 and Figure&nbsp;5 below.</span></p>

<p class=MsoNormal style='margin-left:1.0in;text-indent:-1.0in;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:12.0pt;
margin-left:1.0in;text-indent:-1.0in;page-break-after:avoid'><b><span
lang=EN-GB>Table 6:  </span></b><span lang=EN-GB>Efficacy outcomes at
week 24 (primary analysis) and week 48 in MYRROR study (Full Analysis Set with
LOCF<sup>A)</sup>)</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=225 rowspan=3 valign=top style='width:168.45pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:10.0pt'>Efficacy Outcomes</span></b></p>
   </td>
   <td width=421 colspan=4 valign=top style='width:315.7pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>MYRROR</span></b></p>
   </td>
  </tr>
  <tr>
   <td width=208 colspan=2 valign=top style='width:155.9pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>24 Weeks</span></b></p>
   </td>
   <td width=213 colspan=2 valign=top style='width:159.8pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>48 Weeks</span></b></p>
   </td>
  </tr>
  <tr>
   <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Eylea 2mg</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 90)</span></b></p>
   </td>
   <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Sham</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 31)</span></b></p>
   </td>
   <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Eylea 2mg</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 90)</span></b></p>
   </td>
   <td width=109 valign=top style='width:81.85pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Sham/<br>
   Eylea 2mg</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(N = 31)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=225 valign=top style='width:168.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Mean change in BCVA <sup>B)</sup> as measured by
  ETDRS letter score from baseline (SD) <sup>B)</sup></span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>12.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>(8.3)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>-2.0</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>(9.7)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>13.5<br>
  (8.8)</span></p>
  </td>
  <td width=109 style='width:81.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>3.9</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>(14.3)</span></p>
  </td>
 </tr>
 <tr>
  <td width=225 valign=top style='width:168.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>
  Difference in LS mean <sup>C,D,E)</sup></span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'> (95% CI)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>14.1</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(10.8, 17.4)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>9.5</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(5.4, 13.7)</span></p>
  </td>
  <td width=109 style='width:81.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=225 valign=top style='width:168.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>Proportion of
  patients with &#8805;15 letters gain from baseline</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>38.9%</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>9.7%</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>50.0%</span></p>
  </td>
  <td width=109 style='width:81.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>29.0%</span></p>
  </td>
 </tr>
 <tr>
  <td width=225 valign=top style='width:168.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'> Weighted
  difference <sup>D, F)</sup></span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'> (95% CI)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>29.2%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(14.4, 44.0)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>21.0%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>(1.9, 40.1)</span></p>
  </td>
  <td width=109 style='width:81.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><sup><span
lang=EN-GB style='font-size:10.0pt'>A)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>LOCF: Last
Observation Carried Forward</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><sup><span
lang=EN-GB style='font-size:10.0pt'>B)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>BCVA: Best
Corrected Visual Acuity</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in'><span lang=EN-GB
style='font-size:10.0pt'>ETDRS: Early&nbsp;Treatment&nbsp;Diabetic&nbsp;Retinopathy&nbsp;Study</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in'><span lang=EN-GB
style='font-size:10.0pt'>SD: Standard Deviation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><sup><span
lang=EN-GB style='font-size:10.0pt'>C)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>LS mean: Least
square means derived from ANCOVA model</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><sup><span
lang=EN-GB style='font-size:10.0pt'>D)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>CI: Confidence
Interval</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><sup><span
lang=EN-GB style='font-size:10.0pt'>E)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>LS mean
difference and 95% CI based on an ANCOVA model with treatment group and country
(country designations) as fixed effects, and baseline BCVA as covariant.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.25in;text-indent:-.25in'><sup><span
lang=EN-GB style='font-size:10.0pt'>F)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:10.0pt'>Difference and
95% CI are calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for
country (country designations)</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin-left:1.0in;text-indent:-1.0in;
page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Figure 5</span></b><span
class=CaptionChar><span lang=EN-GB style='font-size:11.0pt;font-weight:normal'>:</span></span><span
class=CaptionChar><span lang=EN-GB style='font-size:11.0pt'>  </span></span><span
lang=EN-GB style='font-size:11.0pt'>Mean </span><span lang=EN-GB
style='font-size:11.0pt'>Change from Baseline to Week 48 in Visual Acuity by
Treatment Group for the MYRROR Study (Full Analysis Set, LOCF)</span></p>

<p class=BayerBodyTextFull style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=BayerBodyTextFull style='page-break-after:avoid'><span lang=EN-GB><img
border=0 width=495 height=293 src="Eylea_IB_007_files/image018.jpg"></span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The European Medicines Agency has waived the obligation to submit
the results of studies with Eylea in all subsets of the paediatric population
in wet AMD, CRVO, BRVO, DME and myopic CNV populations (see section&nbsp;4.2
for information on paediatric use).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.2 Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Eylea is
administered directly into the vitreous to exert local effects in the eye.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Absorption / Distribution</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Aflibercept is
slowly absorbed from the eye into the systemic circulation after intravitreal
administration and is predominately observed in the systemic circulation as an
inactive, stable complex with VEGF; however only free aflibercept is able to
bind endogenous VEGF.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>In a
pharmacokinetic sub-study in 6 neovascular wet AMD patients with frequent
sampling, maximum plasma concentrations of free aflibercept (systemic C<sub>max</sub>)
were low, with a mean of approximately 0.02&nbsp;microgram/mL
(range&nbsp;0&nbsp;to&nbsp;0.054) within 1 to 3 days after a 2&nbsp;mg
intravitreal injection, and were undetectable two weeks following dosage in
almost all patients. Aflibercept does not accumulate in the plasma when
administered intravitreally every 4&nbsp;weeks.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The mean maximum
plasma concentration of free aflibercept is approximately 50 to 500&nbsp;times
below the aflibercept concentration required to inhibit the biologic activity
of systemic VEGF by&nbsp;50% in animal models, in which blood pressure changes
were observed after circulating levels of free aflibercept attained
approximately 10 microgram/mL and returned to baseline when levels fell below
approximately 1 microgram/mL. It is estimated that after intravitreal
administration of 2&nbsp;mg to patients, the mean maximum plasma concentration
of free aflibercept is more than 100-fold lower than the concentration of
aflibercept required to half-maximally bind systemic VEGF (2.91 microgram/mL)
in a study of healthy volunteers. Therefore, systemic pharmacodynamic effects
such as blood pressure changes are unlikely.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>In pharmacokinetic sub-studies in patients with CRVO,
BRVO, DME or myopic CNV mean C<sub>max </sub>of free aflibercept in plasma were
similar with values in the range of 0.03 to 0.05 microgram/mL and individual
values not exceeding 0.14 microgram/mL. Thereafter, plasma concentrations of
free aflibercept declined to values below or close to the lower limit of
quantitation generally within one week; undetectable concentrations were
reached before the next administration after 4 weeks in all patients.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Elimination</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>As Eylea is a
protein-based therapeutic, no metabolism studies have been conducted.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Free aflibercept binds VEGF to form a stable, inert
complex. As with other large proteins, both free and bound aflibercept are
expected to be cleared by proteolytic catabolism.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Renal impairment</span></u></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>No special studies
in patients with renal impairment have been conducted with Eylea.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Pharmacokinetic
analysis of patients in the VIEW2 study, of which 40% had renal impairment
(24%&nbsp;mild, 15%&nbsp;moderate, and 1%&nbsp;severe), revealed no differences
with respect to plasma concentrations of active drug after intravitreal
administration every&nbsp;4 or 8&nbsp;weeks.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Similar results
were seen in patients with CRVO in the GALILEO study, in patients with DME in
the VIVID<sup>DME</sup> study, and in patients with myopic CNV in the MYRROR
study.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3 Preclinical safety data</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Effects in
non-clinical studies on repeated dose toxicity were observed only at systemic
exposures considered substantially in excess of the maximum human exposure
after intravitreal administration at the intended clinical dose indicating
little relevance to clinical use.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Erosions and
ulcerations of the respiratory epithelium in nasal turbinates in monkeys
treated with aflibercept intravitreally were observed at systemic exposures in
excess of the maximum human exposure. The systemic exposure based on C<sub>max</sub>
and AUC for free aflibercept were approximately 200- and 700-fold higher,
respectively, when compared to corresponding values observed in humans after an
intravitreal dose of 2&nbsp;mg. At the No Observed Adverse Effect Level (NOAEL)
of 0.5 mg/eye in monkeys the systemic exposure was 42- and 56-fold higher based
on C<sub>max</sub> and AUC, respectively.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>No studies have
been conducted on the mutagenic or carcinogenic potential of aflibercept.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>An effect of
aflibercept on intrauterine development was shown in embryo-foetal development
studies in pregnant rabbits with intravenous (3 to 60 mg/kg) as well as
subcutaneous (0.1 to 1 mg/kg) administration. The maternal NOAEL was at the
dose of 3 mg/kg or 1 mg/kg, respectively. A developmental NOAEL was not
identified. At the 0.1 mg/kg dose, the systemic exposures based on C<sub>max</sub>
and cumulative AUC for free aflibercept were approximately 17- and 10-fold
higher, respectively, when compared to corresponding values observed in humans
after an intravitreal dose of 2 mg.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Effects on male
and female fertility were assessed as part of a 6-month study in monkeys with
intravenous administration of aflibercept at doses ranging from 3&nbsp;to
30&nbsp;mg/kg. Absent or irregular menses associated with alterations in female
reproductive hormone levels and changes in sperm morphology and motility were
observed at all dose levels. Based on C<sub>max</sub> and AUC for free
aflibercept observed at the 3&nbsp;mg/kg intravenous dose, the systemic
exposures were approximately 4,900-fold and 1,500-fold higher, respectively, than
the exposure observed in humans after an intravitreal dose of 2&nbsp;mg. All
changes were reversible.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6. PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Polysorbate
20 (E&nbsp;432)</span></p>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Sodium
dihydrogen phosphate, monohydrate (for pH adjustment)</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Disodium hydrogen
phosphate, heptahydrate (for pH adjustment)</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Sodium chloride</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Sucrose</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Water for
injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the absence
of compatibility studies, this medicinal product must not be mixed with other
medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>2 years</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>6.4 Special
precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Store in a
refrigerator (2C&nbsp;to&nbsp;8C).</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Do not freeze.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Store in the
original package in order to protect from light.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The unopened vial
may be stored outside the refrigerator below 25C for up to 24&nbsp;hours.
After opening the vial, proceed under aseptic conditions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5 Nature and contents
of container</span></b></p>

<p class=BayerBodyTextFull style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>100 microlitres of solution in a vial (type I glass) with a stopper
(elastomeric rubber), and an 18 G&nbsp;filter needle. Pack size of 1 vial + 1
filter needle.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.6 Special precautions for disposal and other
handling</span></b></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The vial is for
single use in one eye only.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Since the vial
contains more volume (100&nbsp;microlitres) than the recommended dose
(50&nbsp;microlitres), a part of the volume contained in the vial has to be
discarded prior to the administration.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The solution should be inspected visually
for any foreign particulate matter and/or discolouration or any variation in
physical appearance prior to administration. In the event of either being
observed, discard the medicinal product.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Filter needle:</span></u></p>

<p class=MsoNormal><span lang=EN-GB>BD Blunt Filter (Fill) Needle, not for skin
injection.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not autoclave the BD Blunt Filter (Fill)
Needle.</span></p>

<p class=MsoNormal><span lang=EN-GB>The filter needle is non-pyrogenic. Do not
use it if individual packaging is damaged.</span></p>

<p class=MsoNormal><span lang=EN-GB>Discard the used BD Blunt Filter (Fill)
Needle in approved sharps collector.</span></p>

<p class=MsoNormal><span lang=EN-GB>Caution: Re-use of the filter needle may
lead to infection or other illness/injury.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the intravitreal injection, a 30&nbsp;G&nbsp;x&nbsp;&nbsp;inch
injection needle should be used.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><i><span lang=EN-GB>Instructions for use of
vial:</span></i></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=642
 style='width:481.85pt;border-collapse:collapse'>
 <tr style='height:148.45pt'>
  <td width=34 valign=top style='width:25.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:148.45pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>1.</span></p>
  </td>
  <td width=335 valign=top style='width:251.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:148.45pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Remove the plastic cap and disinfect the outer part of the rubber
  stopper of the vial.</span></p>
  </td>
  <td width=250 valign=top style='width:187.3pt;padding:0in 5.4pt 0in 5.4pt;
  height:148.45pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB><img border=0
  width=234 height=194 id="Picture 8" src="Eylea_IB_007_files/image019.gif"></span></p>
  </td>
 </tr>
 <tr style='height:157.35pt'>
  <td width=34 valign=top style='width:25.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:157.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>2.</span></p>
  </td>
  <td width=335 valign=top style='width:251.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:157.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Attach the
  18&nbsp;G, 5-micron filter needle supplied in the carton to a 1-mL sterile,
  Luer-lock syringe.</span></p>
  </td>
  <td width=250 valign=top style='width:187.3pt;padding:0in 5.4pt 0in 5.4pt;
  height:157.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB><img border=0 width=234 height=201
  id="Picture 9" src="Eylea_IB_007_files/image020.gif"></span></p>
  </td>
 </tr>
 <tr>
  <td width=34 valign=top style='width:25.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>3.</span></p>
  </td>
  <td width=585 colspan=2 valign=top style='width:438.75pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Push the
  filter needle into the centre of the vial stopper until the needle is completely
  inserted into the vial and the tip touches the bottom or bottom edge of the
  vial.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:141.3pt'>
  <td width=34 valign=top style='width:25.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:141.3pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>4.</span></p>
  </td>
  <td width=335 valign=top style='width:251.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:141.3pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Using aseptic
  technique withdraw all of the Eylea vial contents into the syringe, keeping
  the vial in an upright position, slightly inclined to ease complete withdrawal.
  </span><span lang=EN-GB>To deter the introduction of air, ensure the bevel of
  the filter needle is submerged into the liquid. Continue to tilt the vial
  during withdrawal keeping the bevel of the filter needle submerged in the
  liquid.</span></p>
  </td>
  <td width=250 valign=top style='width:187.3pt;padding:0in 5.4pt 0in 5.4pt;
  height:141.3pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:29.55pt'>
  <td width=34 valign=top style='width:25.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:29.55pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=585 colspan=2 valign=top style='width:438.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:29.55pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:#990099'><img border=0 width=236 height=207
  src="Eylea_IB_007_files/image021.jpg"> <img
  border=0 width=236 height=208 src="Eylea_IB_007_files/image022.jpg"></span></p>
  </td>
 </tr>
 <tr style='height:29.55pt'>
  <td width=34 valign=top style='width:25.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:29.55pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>5.</span></p>
  </td>
  <td width=585 colspan=2 valign=top style='width:438.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:29.55pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ensure that the
  plunger rod is drawn sufficiently back when emptying the vial in order to
  completely empty the filter needle.</span></p>
  </td>
 </tr>
 <tr style='height:32.75pt'>
  <td width=34 valign=top style='width:25.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:32.75pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>6.</span></p>
  </td>
  <td width=585 colspan=2 valign=top style='width:438.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:32.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Remove the
  filter needle and properly dispose of it.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Note: Filter
  needle is not to be used for intravitreal injection.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:149.4pt'>
  <td width=34 valign=top style='width:25.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:149.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>7.</span></p>
  </td>
  <td width=335 valign=top style='width:251.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:149.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Using aseptic
  technique, firmly twist a 30&nbsp;G x  inch injection needle onto the
  Luer-lock syringe tip.</span></p>
  </td>
  <td width=250 valign=top style='width:187.3pt;padding:0in 5.4pt 0in 5.4pt;
  height:149.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB><img border=0 width=234 height=188
  id="Picture 11" src="Eylea_IB_007_files/image023.gif"></span></p>
  </td>
 </tr>
 <tr style='height:20.85pt'>
  <td width=34 valign=top style='width:25.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:20.85pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=585 colspan=2 valign=top style='width:438.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:20.85pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:142.5pt'>
  <td width=34 valign=top style='width:25.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:142.5pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>8.</span></p>
  </td>
  <td width=335 valign=top style='width:251.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:142.5pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Holding the
  syringe with the needle pointing up, check the syringe for bubbles. If there
  are bubbles, gently tap the syringe with your finger until the bubbles rise
  to the top.</span></p>
  </td>
  <td width=250 valign=top style='width:187.3pt;padding:0in 5.4pt 0in 5.4pt;
  height:142.5pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB><img border=0
  width=235 height=199 src="Eylea_IB_007_files/image024.jpg"></span></p>
  </td>
 </tr>
 <tr style='height:33.85pt'>
  <td width=34 valign=top style='width:25.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:33.85pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>9.</span></p>
  </td>
  <td width=585 colspan=2 valign=top style='width:438.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:33.85pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Eliminate all
  bubbles and expel excess medicinal product by slowly depressing the plunger
  so that the plunger tip aligns with the line that marks 0.05 mL on the
  syringe.</span></p>
  </td>
 </tr>
 <tr style='height:169.3pt'>
  <td width=34 valign=top style='width:25.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:169.3pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=335 valign=top style='width:251.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:169.3pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB><img border=0 width=231 height=215
  src="Eylea_IB_007_files/image025.jpg"></span></p>
  </td>
  <td width=250 valign=top style='width:187.3pt;padding:0in 5.4pt 0in 5.4pt;
  height:169.3pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB><img border=0 width=240 height=219
  src="Eylea_IB_007_files/image026.jpg"></span></p>
  </td>
 </tr>
 <tr style='height:29.95pt'>
  <td width=34 valign=top style='width:25.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:29.95pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>10.</span></p>
  </td>
  <td width=608 colspan=2 valign=top style='width:456.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:29.95pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The vial is for
  single use only. Extraction of multiple doses from a single vial may
  increase the risk of contamination and subsequent infection.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
  medicinal product or waste material should be disposed of in accordance with
  local requirements.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>7. MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Bayer AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>51368 Leverkusen</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8. MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/12/797/002</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: 22 November 2012</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal: 13 July 2017</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>10. DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product is available on the
website of the European Medicines Agency </span><span lang=EN-GB></span><span
lang=EN-GB style='color:blue'><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span><span
lang=EN-GB style='color:black'>.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all>
</span>

<p class=MsoNormal style='line-height:normal'></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center'><span
lang=EN-GB style='font-family:"Times New Roman",serif;text-transform:uppercase'>Annex
II</span></p>

<p class=BodytextAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=No-numheading3Agency style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>A. <span style='text-transform:
uppercase'>ManufactureR of the biological active substance and manufacturer
responsible for batch release</span></span><span lang=EN-GB style='font-family:
"Times New Roman",serif;text-transform:uppercase;font-weight:normal'> </span></p>

<p class=BodytextAgency style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=No-numheading3Agency style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:"Times New Roman",serif;text-transform:uppercase'>B. Conditions
or restrictions regarding supply and use</span></p>

<p class=No-numheading3Agency style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:"Times New Roman",serif;text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:"Times New Roman",serif;text-transform:uppercase'>C. Other
conditions and requirements of the marketing authorisation</span></p>

<p class=BodytextAgency><span lang=EN-GB>&nbsp;</span></p>

<p class=No-numheading3Agency style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:"Times New Roman",serif;text-transform:uppercase'>D. CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</span></p>

<p class=BodytextAgency><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB><span lang=EN-GB>A. MANUFACTURER OF THE BIOLOGICAL ACTIVE
SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Name
and address of the manufacturer of the biological active substance </span></u></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Regeneron
Pharmaceuticals, Inc.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>81
Columbia Turnpike</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rensselaer,
New York 12144</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>USA</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>Name and address of the manufacturer responsible for
batch release</span></u></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=DE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Bayer AG</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=DE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Mllerstrae
178</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=DE style='font-size:11.0pt;font-family:"Times New Roman",serif'>13353
Berlin</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=DE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Germany</span></p>

<p class=NormalAgency><span lang=DE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>The printed package leaflet of the medicinal product
must state the name and address of the manufacturer responsible for the release
of the concerned batch.</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>B. Conditions or restrictions regarding
supply and use</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Medicinal
product subject to restricted medical prescription (see Annex I: Summary of
Product Characteristics, section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>C.  Other conditions and requirements of the
Marketing Authorisation </span></p>

<p class=NormalAgency style='line-height:12.0pt'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic safety update reports (PSURs)</span></b></p>

<p class=NormalAgency style='line-height:12.0pt'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=NormalAgency style='line-height:12.0pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The requirements for
submission of PSURs for this medicinal product are set out in the list of Union
reference dates (EURD list) provided for under Article&nbsp;107c(7) of Directive&nbsp;2001/83/EC
and any subsequent updates published on the European medicines web-portal.</span></p>

<p class=NormalAgency style='line-height:12.0pt'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=NormalAgency style='line-height:12.0pt'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=TitleB><span lang=EN-GB>D. CONDITIONS OR RESTRICTIONS WITH REGARD TO
THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT </span></p>

<p class=MsoNormal style='margin-right:-.05pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk management plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>The marketing
authorisation holder (MAH) shall perform the required pharmacovigilance
activities and interventions detailed in the agreed RMP presented in Module
1.8.2 of the marketing authorisation and any agreed subsequent updates of the
RMP.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>An updated RMP
should be submitted:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-10.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>If the dates
for submission of a PSUR and the update of a RMP coincide, they can be
submitted at the same time.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=NormalAgency style='line-height:12.0pt;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Pharmacovigilance
system</span></u></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:12.0pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The MAH
must ensure that the system of pharmacovigilance presented in Module 1.8.1. of
the Marketing Authorisation is in place and functioning before and whilst the
medicinal product is on the market.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Additional risk minimisation measures</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:12.0pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:12.0pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The MAH
has agreed to provide EU educational material for Eylea. Prior to launch and
during the products lifecycle in each Member State the MAH will agree the
final educational material with the National Competent Authority.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:12.0pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The MAH
ensures that, following discussions and agreement with the National Competent
Authorities in each Member State where Eylea is marketed, ophthalmological
clinics where Eylea is expected to be used are provided with an updated
physician information pack containing the following elements:</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Physician information </span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Intravitreal injection
procedure video </span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Intravitreal injection
procedure pictogram </span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Patient information
packs </span></p>

<p class=Default style='line-height:12.0pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Default style='line-height:12.0pt'><span lang=EN-GB style='font-size:
11.0pt'>The physician information in the educational material contains the
following key elements: </span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The Summary of Product
Characteristics </span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Who should be treated
with Eylea</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Sterile techniques, including
periocular and ocular disinfection to minimise the risk of infection </span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Use of antibiotics
according to national guidelines</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Use of povidone iodine
or equivalent</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Techniques for the
intravitreal injection </span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Confirmation that the
vial is for single use only</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The need to expel
excess volume of the syringe before injecting Eylea to avoid overdose</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Patient monitoring
after intravitreal injection including monitoring for visual acuity and
increase of intraocular pressure post-injection</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Key signs and symptoms
of intravitreal injection related adverse events including endophthalmitis,
increased intraocular pressure, retinal pigment epithelial tear and cataract</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Management of
intravitreal injection related adverse events</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Female patients of
childbearing potential have to use effective contraception and pregnant women
should not use Eylea </span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Eylea is not
recommended during breast-feeding. A decision must be made whether to
discontinue breast-feeding or t</span><span style='font-size:11.0pt'>o abstain
from Eylea therapy taking into account the benefit of breast-feeding for the
child and the benefit of therapy for the woman</span></p>

<p class=Default style='line-height:12.0pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Default style='line-height:12.0pt'><span lang=EN-GB style='font-size:
11.0pt'>The patient information pack of the educational material includes a
patient information booklet and an audio-CD that contain following key
elements: </span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Patient information
leaflet</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Who should be treated
with Eylea</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>How to prepare for
Eylea treatment </span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>What are the steps
following treatment with Eylea </span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Key signs and symptoms
of serious adverse events including endophthalmitis, intraocular pressure
increased, retinal pigment epithelial tear and cataract</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>When to seek urgent
attention from their health care provider </span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Female patients of
childbearing potential have to use effective contraception and pregnant women
should </span>not use Eylea </p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:12.0pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Obligation to conduct post-authorisation
measures </span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The MAH
shall complete, within the stated timeframe, the below measures:</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
layout-grid-mode:line'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=495 valign=top style='width:371.2pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BodytextAgency style='margin-bottom:0in'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Description</span></b></p>
  </td>
  <td width=124 valign=top style='width:93.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BodytextAgency style='margin-bottom:0in'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Due date</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=495 valign=top style='width:371.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Post-authorisation efficacy study (PAES)</span></p>
  <p class=MsoNormal><span lang=EN-GB>To perform a post-authorisation
  randomised study in patients with neovascular (wet) AMD with the primary
  objective of comparing the standard regime of injections every 8 weeks with a
  reactive regimen based on visual and anatomic outcomes, based on a CHMP
  approved protocol.</span></p>
  </td>
  <td width=124 valign=top style='width:93.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Final study report submission: 30
  November 2021 </span></p>
  </td>
 </tr>
 <tr>
  <td width=495 valign=top style='width:371.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Post-authorisation efficacy study (PAES)</span></p>
  <p class=MsoNormal><span lang=EN-GB>To perform an interventional
  post-authorisation efficacy study in patients with diabetic macular oedema
  with the primary objective of comparing, after the first initial year of
  Eylea treatment, the standard regime of injections every 8 weeks with
  alternative treatment regimens, i.e. extended treatment intervals based on
  visual and anatomic outcomes (PRN and treat-and-extend).</span></p>
  </td>
  <td width=124 valign=top style='width:93.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB>Final study
  report submission: </span></p>
  <p class=MsoNormal><span lang=EN-GB>November 2020</span></p>
  </td>
 </tr>
</table>

<p class=BodytextAgency style='margin-bottom:0in;line-height:12.0pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;line-height:12.0pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='line-height:12.0pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:green'>&nbsp;</span></i></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleA0><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>Pre-filled syringe</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Eylea 40&nbsp;mg/mL </span><span lang=EN-GB>solution for injection
in pre-filled syringe</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>aflibercept</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>2. STATEMENT
OF ACTIVE SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>1&nbsp;pre-filled
syringe contains 3.6&nbsp;mg aflibercept in 0.09&nbsp;mL solution <span
style='background:silver'>(40&nbsp;mg/mL)</span>.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:black'>&nbsp;</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Excipients: E&nbsp;432</span><span
lang=DE style='font-size:11.0pt;font-family:"Times New Roman",serif'>; </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>sodium
dihydrogen phosphate, monohydrate</span><span lang=DE style='font-size:11.0pt;
font-family:"Times New Roman",serif'>;</span><span lang=DE style='font-size:
11.0pt;font-family:"Times New Roman",serif'> </span><span lang=DE
style='font-size:11.0pt;font-family:"Times New Roman",serif'>d</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>isodium
hydrogen phosphate, heptahydrate; sodium chloride; sucrose; water for
injections.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Solution for injection</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>1&nbsp;pre-filled
syringe contains 3.6&nbsp;mg aflibercept in 0.09&nbsp;mL solution </span><span
lang=EN-GB style='background:silver'>(40&nbsp;mg/mL)</span><span lang=EN-GB
style='background:silver'> .</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Delivers 1&nbsp;single
dose of 2&nbsp;mg/0.05&nbsp;mL.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Intravitreal
use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For single use
only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Open the sterile
blister in clean administration room only.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>Excess volume to be expelled before injecting.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Store in a refrigerator&nbsp;</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>(2C&nbsp;-&nbsp;8C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The unopened
blister may be stored outside the refrigerator below 25C for up to
24&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Bayer AG</span></p>

<p class=MsoNormal><span lang=EN-GB>51368 Leverkusen</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/12/797/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>16. INFORMATION IN <span
style='color:black'>BRAILLE</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:silver'>Justification for not including Braille accepted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='display:none'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC </span></p>

<p class=MsoNormal><span lang=EN-GB>SN </span></p>

<p class=MsoNormal><span lang=EN-GB>NN </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></u></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE BLISTER FOIL </span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>Pre-filled syringe</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Eylea 40&nbsp;mg/mL </span><span lang=EN-GB>solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>aflibercept</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF
ACTIVE SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>1&nbsp;pre-filled
syringe contains 3.6&nbsp;mg aflibercept in 0.09&nbsp;mL solution <span
style='background:silver'>(40&nbsp;mg/mL)</span>. </p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>1&nbsp;pre-filled
syringe contains 3.6&nbsp;mg aflibercept in 0.09&nbsp;mL solution </span><span
lang=EN-GB style='background:silver'>(40&nbsp;mg/mL)</span><span lang=EN-GB> .</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Delivers 1&nbsp;single
dose of 2&nbsp;mg/0.05&nbsp;mL.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Intravitreal
use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For single use
only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Open the sterile blister in clean administration room only.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>Excess volume to be expelled before injecting.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=GlobalBayerBodyText style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Store in a refrigerator&nbsp;</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>(2C&nbsp;-&nbsp;8C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The unopened
blister may be stored outside the refrigerator below 25C for up to 24&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Bayer AG</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>51368 Leverkusen</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/12/797/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></u></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>LABEL</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>Pre-filled syringe</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Eylea 40&nbsp;mg/mL </span><span lang=EN-GB>injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>aflibercept</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravitreal use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2. METHOD OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Extractable volume 0.09&nbsp;mL</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all>
</span>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>Vial</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Eylea 40&nbsp;mg/mL </span><span lang=EN-GB>solution for injection in
a vial</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>aflibercept</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>2. STATEMENT
OF ACTIVE SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black'>1&nbsp;vial
contains 4&nbsp;mg aflibercept in 0.1&nbsp;mL solution <span style='background:
#BFBFBF'>(40&nbsp;mg/mL)</span></span>.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:black'>&nbsp;</span></i></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Excipients: E&nbsp;432;
sodium dihydrogen phosphate, monohydrate; </span><span lang=DE
style='font-size:11.0pt;font-family:"Times New Roman",serif'>d</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>isodium
hydrogen phosphate, heptahydrate, sodium chloride;</span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>sucrose;
water for injections.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Solution for injection</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='color:black;
background:silver'>1&nbsp;vial contains 4&nbsp;mg aflibercept in 0.1&nbsp;mL</span><span
style='color:black'> <span style='background:silver'>solution (4</span><span
style='background:#BFBFBF'>0&nbsp;mg/mL)</span></span>.</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>18G filter
needle</span></p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Delivers 1&nbsp;single dose of 2&nbsp;mg/0.05&nbsp;mL.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Intravitreal use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For single use
only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Excess volume to be expelled before injecting.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='color:black'>Store
in a refrigerator (2 C - 8 C).</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='color:black'>Do not
freeze.</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='color:black'>Store
in the original package in order</span> to protect from light. </p>

<p class=MsoNormal style='line-height:normal'><span style='color:black'>The
unopened vial may be stored outside the refrigerator below 25&nbsp;C for up to
24&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Bayer AG</span></p>

<p class=MsoNormal><span lang=EN-GB>51368 Leverkusen</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/12/797/002</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16. INFORMATION IN <span style='color:black'>BRAILLE</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Justification for not including Braille accepted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all>
</span>

<p class=MsoNormal style='page-break-after:avoid'></p>

<p class=MsoNormal><span lang=EN-GB style='display:none'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>PC </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>SN </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>NN </span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></u></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>LABEL</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>Vial</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Eylea 40&nbsp;mg/mL </span><span lang=EN-GB>injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>aflibercept</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravitreal use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2. METHOD OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Extractable volume 0.1 mL</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleA0><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
Leaflet: <span style='color:black'>Information for the patient</span></span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><i><span
lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB style='color:black'>Eylea 40&nbsp;mg/mL solution for injection</span></b><b><span
lang=EN-GB> in a pre-filled syringe</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>aflibercept</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you are given this medicine because it contains
important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor. This includes any possible side effects not listed in this leaflet. See
section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. What Eylea is and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. What you need to know before you are given
Eylea </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. How you will be given Eylea </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Possible side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>How to store Eylea </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What Eylea is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Eylea is a solution which is injected into the eye to treat eye
conditions in adults called </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>neovascular (wet) age-related macular
degeneration (wet AMD), </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>impaired vision due to macular oedema secondary
to retinal vein occlusion (branch RVO (BRVO) or central RVO (CRVO)),</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>impaired vision due to diabetic macular oedema
(DME),</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>impaired vision due to myopic choroidal
neovascularisation (myopic CNV).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Aflibercept, the active substance in Eylea, blocks the activity of a
group of factors, known as Vascular Endothelial Growth Factor A (VEGF-A) and Placental
Growth Factor (PlGF). </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In patients with wet AMD and myopic CNV, these factors, in excess
are involved in the abnormal formation of new blood vessels in the eye. These
new blood vessels can cause the leak of blood components into the eye and
eventual damage to tissues in the eye responsible for vision. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In patients with CRVO, a blockage occurs in the main blood vessel
that transports blood away from the retina. VEGF levels are elevated in
response causing the leakage of fluid into the retina and thereby causing a swelling
of the macula, (the portion of the retina responsible for fine vision), which
is called macular oedema. When the macula swells with fluid, central vision
becomes blurry.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In patients with BRVO, one or more branches of the main blood vessel
that transports blood away from the retina is blocked. VEGF levels are elevated
in response causing the leakage of fluid into the retina and thereby causing
macular oedema.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>Diabetic macular oedema is a swelling of the retina
occurring in patients with diabetes due to leaking of fluid from blood vessels
within the macula. The macula is the portion of retina responsible for fine
vision. When the macula swells with fluid, central vision becomes blurry.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Eylea has been shown to stop the growth of new abnormal blood
vessels in the eye </span><span lang=EN-GB>which often leak fluid or bleed</span><span
lang=EN-GB>. Eylea can help to stabilise, and in many cases, improve the vision
loss related to wet AMD, CRVO, BRVO, DME and myopic CNV.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What you need to know before you are given
Eylea</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>You will not be given Eylea</span></b></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to aflibercept or any of the
other ingredients of this medicine (listed in section&nbsp;6&nbsp;).</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have an active or suspected infection in
or around the eye (ocular or periocular infection).</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have severe inflammation of the eye
(indicated by pain or redness). </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Talk to your
doctor before you are given Eylea:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have glaucoma.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a history of seeing flashes of light
or floaters and if you have a sudden increase of size and number of floaters.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if surgery was performed or is planned on your
eye within the previous or next four weeks.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a severe form of CRVO or BRVO
(ischaemic CRVO or BRVO), treatment with Eylea is not recommended.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Furthermore, it is important for you to know that:</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>the safety and efficacy of Eylea when administered
to both eyes at the same time has not been <span style='color:black'>studied </span></span><span
lang=EN-GB style='color:black'>and if used in this way may lead to an increased
risk of experiencing side effects.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>injections with Eylea may</span><span
lang=EN-GB> cause an increase in eye pressure (intraocular pressure) in some
patients within 60&nbsp;minutes of the injection. </span><span lang=EN-GB>Your
doctor will monitor this after each injection.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you develop an infection or inflammation
inside the eye (endophthalmitis) or other complications, you may have eye pain
or increased discomfort, worsening eye redness, blurred or decreased vision,
and increased sensitivity to light. It is important to have any symptoms
diagnosed and treated as soon as possible. </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>your doctor will check whether you have other
risk factors that may increase the chance of a tear or detachment of one of the
layers at the back of the eye (retinal detachment or tear, and retinal pigment
epithelial detachment or tear), in which case Eylea must be given with caution.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Eylea should not be used in pregnancy unless the
potential benefit outweighs the potential risk to the unborn child. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>women of childbearing potential have to use
effective contraception during treatment and for at least three further months
after the last injection of Eylea.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='layout-grid-mode:line'>The systemic use of VEGF inhibitors,
substances similar to those contained in Eylea, is potentially related to the
risk of</span><span lang=EN-GB> blood clots blocking blood vessels (arterial
thromboembolic events) which may lead to heart attack or stroke. There is a theoretical
risk of such events following injection of Eylea into the eye. </span><span
lang=EN-GB style='color:black'>There are limited data on safety in treating
patients with CRVO, BRVO, DME and myopic CNV who have had a stroke or a
mini-stroke (transient ischaemic attack) or a heart attack within the last 6
months. If any of these apply to you, Eylea will be given with caution. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is only
limited experience in the treatment of </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients with DME due to type I diabetes.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diabetics with very high average blood sugar
values (HbA1c over 12%).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diabetics with an eye disease caused by diabetes
called proliferative diabetic retinopathy.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
experience in the treatment of </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients with acute infections.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients with other eye conditions such as a
detachment of the retina or a hole in the macula.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diabetics with uncontrolled high blood pressure.
</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>non-Asian patients with myopic CNV.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients previously treated for myopic CNV.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients with damage outside the central part of
the macula (extrafoveal lesions) for myopic CNV.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If any of the
above applies to you, your doctor will consider this lack of information when
treating you with Eylea.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>The use of Eylea in children or adolescents
under&nbsp;18 has not been studied because wet AMD, CRVO, BRVO, DME and myopic
CNV occur mainly in adults. Therefore, its use in this age group is not
relevant.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other medicines and Eylea</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor if you are using, have recently used or might use
any other medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB
style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Women of childbearing
potential have to use effective contraception during treatment and for at least
three further months after the last injection of Eylea.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>- There is no experience of using
Eylea in pregnant women. Eylea should not be used during pregnancy unless the
potential benefit outweighs the potential risk to the unborn child. If you are
pregnant or planning to become pregnant, discuss this with your doctor before
treatment with Eylea.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>- </span><span lang=EN-GB style='font-size:11.0pt'>Eylea is
not recommended during breast-feeding as it is not known whether Eylea passes
into human milk. Ask your doctor for advice before starting Eylea treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>After your injection with Eylea, you may experience some temporary
visual disturbances. Do not drive or use machines as long as these last.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Important information about some of the ingredients of Eylea</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg)
per dosage unit, that is to say essentially 'sodium-free.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>How you will be given Eylea</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>A doctor experienced in giving eye injections will inject Eylea into
your eye under aseptic (clean and sterile) conditions. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The recommended dose is 2&nbsp;mg aflibercept (50&nbsp;microlitres).
</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Eylea is given as an injection into your eye (intravitreal
injection). </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Before the injection your doctor will use a disinfectant eyewash to
clean your eye carefully to prevent infection. Your doctor will also give you a
local anaesthetic to reduce or prevent any pain you might have with the
injection. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>wet AMD</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Patients with wet AMD will be treated with one injection per month
for three consecutive doses, followed by another injection after a further two
months. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Your doctor will then decide whether the treatment interval between
injections may be kept at every two months or be gradually extended in 2- or
4-weekly intervals if your condition has been stable. If your condition
worsens, the interval between injections can be shortened, but to not less than
every two months in the first year of treatment. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Unless you experience any problems or are advised differently by
your doctor, there is no need for you to see your doctor between the injections.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><u><span
lang=EN-GB>Macular oedema secondary to RVO (branch RVO or central RVO)</span></u></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Your doctor will determine the most
appropriate treatment schedule for you. You will start your treatment with a
series of monthly Eylea injections. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The interval between two injections should
not be shorter than one month.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Your doctor may decide to stop treatment
with Eylea, if you are not benefiting from continued treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Your treatment will continue with
&nbsp;monthly injections until your condition is stable. Three or more monthly
injections may be needed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Your doctor will monitor your response to
treatment and may continue your treatment by gradually increasing the interval
between your injections to maintain a stable condition. If your condition
starts to worsen with a longer treatment interval, your doctor will shorten the
interval accordingly.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Based on your response to treatment your doctor will decide on the
schedule for follow up examinations and treatments. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><u><span
lang=EN-GB>Diabetic macular oedema (DME)</span></u></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Patients with DME will be treated with one injection per month for
the first five consecutive doses followed by one injection every two months
thereafter. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Unless you experience any problems or are advised differently by
your doctor, there is no need for you to see your doctor between the
injections.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>After the first 12 months of treatment with Eylea, the treatment
interval may be extended based on your doctors examination. </span><span
lang=EN-GB>Your doctor will decide on the schedule for follow up examinations.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Your doctor may decide to stop treatment with Eylea if it is
determined that you are not benefiting from continued treatment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><u><span
lang=EN-GB>Myopic CNV</span></u></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Patients with myopic CNV will be treated with one single injection.
You will receive further injections only if your doctors examinations reveal
that your condition has not improved.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The interval between two injections should
not be shorter than one month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If your condition goes away and then comes back, your doctor may
re-start the treatment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Your doctor will decide on the schedule for follow up examinations.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If a dose of Eylea is missed</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Make a new appointment for an examination and injection.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Stopping treatment with Eylea</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Consult your doctor before stopping the treatment. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4. Possible side effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Allergic reactions</span></b><span
lang=EN-GB> (hypersensitivity) could potentially occur. <b>These may be serious
and require that you contact your doctor immediately.</b></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>With administration of Eylea, there may be some side effects affecting
the eyes which are due to the injection procedure. Some of these may be <b>serious</b>
and include <b>blindness</b>,<b> a</b> <b>serious</b> <b>infection or</b> <b>inflammation
inside the eye</b> (endophthalmitis),<b> </b></span><b><span lang=EN-GB>detachment,
tear or bleeding of the light-sensitive layer at the back of the eye </span></b><span
lang=EN-GB style='layout-grid-mode:line'>(retinal detachment or tear), </span><b><span
lang=EN-GB>clouding of the lens</span></b><span lang=EN-GB> (cataract), <b>bleeding
in the eye</b> (vitreous haemorrhage), <b>detachment of the gel-like substance
inside the eye from the retina</b> (vitreous detachment) and <b>increase of
pressure inside the eye</b>, see section 2. These serious side effects affecting
the eyes occurred in less than 1 in 1,900 injections in clinical studies.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you experience a sudden decrease in
vision, or an increase in pain and redness in your eye after your injection, <b>contact
your doctor immediately</b>. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>List of side effects reported</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>The following is a list of the side effects
reported to be possibly related to the injection procedure or to the medicine.
Please do not get alarmed, you might not experience any of these. Always
discuss any suspected side effects with your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Very common side effects</span></b><span lang=EN-GB> <i>(may affect
more than 1 in 10 people):</i></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>deterioration of
eyesight </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>bleeding in the
back of the eye (retinal haemorrhage)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>bloodshot eye
caused by bleeding from small blood vessels in the outer layers of the eye </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>eye pain</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black;layout-grid-mode:line'>Common</span></b><b><span lang=EN-GB
style='layout-grid-mode:line'> side effects </span></b><i><span lang=EN-GB>(may
affect up to 1 in 10 people):</span></i></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>detachment or tear of one of the layers in the
back of the eye, resulting in flashes of light with floaters sometimes
progressing to a loss of vision (retinal pigment epithelial tear*/detachment,
retinal detachment/tear)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>degeneration of the retina (causing disturbed
vision)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bleeding in the eye (vitreous haemorrhage)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>certain forms of clouding of the lens (cataract)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>damage to the front layer of the eyeball (the
cornea) </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>increase in eye
pressure </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>moving spots in
vision (floaters)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>detachment of the gel-like substance inside the
eye from the retina (vitreous detachment, </span><span lang=EN-GB>resulting in
flashes of light with floaters</span><span lang=EN-GB>)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a feeling of having something in the eye</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased tear production</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of the eyelid </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bleeding at the injection site</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='color:black;layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>redness of the eye </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>* Conditions
known to be associated with wet AMD; observed in wet AMD patients only.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black;layout-grid-mode:line'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black;layout-grid-mode:line'>U</span></b><b><span lang=EN-GB
style='layout-grid-mode:line'>ncommon side effects </span></b><i><span
lang=EN-GB>(may affect up to 1 in 100 people):</span></i></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>allergic reactions (hypersensitivity)**</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>serious inflammation or infection inside the eye
(endophthalmitis)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation in the iris or other parts of the
eye (iritis, uveitis, iridocyclitis, anterior chamber flare)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormal sensation in the eye</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>eyelid irritation</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of the front layer of the eyeball
(cornea)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;layout-grid-mode:line'>** Allergic reactions like rash,
itching (pruritus), hives (urticaria), and a few cases of severe allergy
(anaphylactic/anaphylactoid) reactions were reported.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black;layout-grid-mode:line'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black;layout-grid-mode:line'>Rare</span></b><b><span lang=EN-GB
style='layout-grid-mode:line'> side effects </span></b><i><span lang=EN-GB>(may
affect up to 1 in 1,000 people):</span></i></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blindness</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>clouding of the
lens due to injury (traumatic cataract)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>inflammation of </span><span
lang=EN-GB>the gel-like substance inside the eye</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>pus in the eye </span></p>

<p class=MsoNormal style='margin-left:21.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Para0s style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif;layout-grid-mode:line'>In
the clinical trials, there was an increased incidence of bleeding from small
blood vessels in the outer layers of the eye (conjunctival haemorrhage) in
patients with wet AMD receiving blood thinners. This increased incidence was
comparable between patients treated with ranibizumab and Eylea.</span></p>

<p class=Para0s style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif;layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>The systemic use of VEGF inhibitors, substances
similar to those contained in Eylea, is potentially related to the risk of blood
clots blocking blood vessels (arterial thromboembolic events<span
style='color:black'>)</span> <span style='color:black'>which may lead to </span>heart
attack or stroke. There is a theoretical risk of such events following
injection of Eylea into the eye.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As with all
therapeutic proteins, there is a possibility for an immune reaction (formation
of antibodies) with Eylea. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB style='color:black;layout-grid-mode:line'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you get any side effects, talk to your doctor. This includes any
possible side effects not listed in this leaflet.</span><span lang=EN-GB> </span><span
lang=EN-GB>You can also report side effects directly </span><span lang=EN-GB>via
<span style='background:silver'>the national reporting system listed </span></span><span
lang=EN-GB style='color:black;background:silver'>in </span><span lang=EN-GB
style='background:silver'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a>.</span><span lang=EN-GB> By reporting side effects, you can help provide
more information on the safety of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5. How to store Eylea</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this medicine out of the sight and reach of
children.</span></p>

<p class=MsoNormal style='margin-left:30.0pt;text-indent:-30.0pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use this medicine after the expiry date
which is stated on the carton and label after EXP. The expiry date refers to
the last day of that month.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Store in a refrigerator (2C to 8C). Do not
freeze.</span></p>

<p class=MsoNormal style='margin-left:30.0pt;text-indent:-30.0pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The unopened blister may be stored outside the
refrigerator below 25&nbsp;C for up to 24&nbsp;hours.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Store in the original package in order to
protect from light.</span></p>

<p class=MsoNormal style='margin-left:30.0pt;text-indent:-30.0pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not throw away any medicines via wastewater
or household waste. Ask your pharmacist how to throw away any medicines you no
longer use. These measures will help protect the environment.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.75in;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>6. </span><span lang=EN-GB>Contents of the pack
and other information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What Eylea contains </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal;
page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is: aflibercept. One
pre-filled syringe contains 90&nbsp;microlitres, equivalent to 3.6&nbsp;mg
aflibercept. One pre-filled syringe delivers a dose of 2&nbsp;mg aflibercept in
50&nbsp;microlitres. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are: polysorbate&nbsp;20
(E&nbsp;432), sodium dihydrogen phosphate monohydrate </span><span lang=EN-GB>(for
pH adjustment)</span><span lang=EN-GB>, disodium hydrogen phosphate
heptahydrate (</span><span lang=EN-GB>for pH adjustment)</span><span
lang=EN-GB>, sodium chloride, sucrose, water for injections.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What Eylea looks like and contents of the pack</span></b></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Eylea is a</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>
solution for injection (injection) in a pre-filled syringe
(3.6&nbsp;mg/90&nbsp;microlitres). The solution is colourless to pale yellow.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Pack size of 1.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Bayer AG</span></p>

<p class=MsoNormal><span lang=EN-GB>51368 Leverkusen</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Bayer AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mllerstrae 178</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>13353 Berlin</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Germany</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-family:"Tms Rmn",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=DE>Belgi / Belgique / Belgien</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=DE>Bayer SA-NV</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Tl/Tel: +32-(0)2-535 63 11</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>UAB Bayer</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Tel: +370-5-233 68 68</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>&#1041;&#1072;&#1081;&#1077;&#1088;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>&#1058;&#1077;&#1083;: +359-(0)2-</span><span lang=EN-GB
  style='color:black'>424 72 80</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=DE>Luxembourg / Luxemburg</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=DE>Bayer SA-NV</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=DE>Tl/Tel: +32-(0)2-535 63 11</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=DE>&#268;esk
  republika</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Bayer s.r.o.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +420-266
  101 111</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB>Magyarorszg</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Bayer Hungria KFT</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +36-1-487 4100</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Bayer A/S</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Tlf: +45-45 235 000</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Alfred Gera
  and Sons Ltd.</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Tel: +356-21 44 62 05</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Bayer Vital GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Tel:
  +49-(0)214-30 513 48</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=DE>Nederland</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=DE>Bayer B.V.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Tel:
  +31(0)297-28 06 66</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer O</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +372-655
  85 65</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer AS</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tlf: +47-23
  13 05 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer
  &#917;&#955;&#955;&#940;&#962; &#913;&#914;&#917;&#917;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&#932;&#951;&#955;: +30-210-618
  75 00</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=DE>sterreich</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Bayer Austria
  Ges. m. b. H.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +43-(0)1-711 460</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Espaa</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer
  Hispania S.L.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +34-93-495 65 00</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Polska</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer Sp. z
  o.o.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +48-22-572 35 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Bayer
  HealthCare</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tl (N
  vert): +33-(0)800 87 54 54</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Portugal</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer Portugal,
  Lda.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +351-21-416 42 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=DE>Hrvatska</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=DE>Bayer d.o.o.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +
  385-(0)1-6599 900</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Romnia</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>SC Bayer SRL </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +40-(0)21-528 59 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer Limited</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +353-(0)1-216 3300</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer d. o.
  o.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +386-(0)1-58 14 400</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>sland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Icepharma hf.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Smi:
  +354-540 80 00</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Slovensk
  republika</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer, spol.
  s r.o.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +421-(0)2-59 21 31 11</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Italia</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer S.p.A.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +39-02-3978 1</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=DE>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Bayer Oy</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Puh/Tel:
  +358-(0)20-78521 </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>NOVAGEM
  Limited</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&#932;&#951;&#955;:
  +357-22-48 38 58</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer AB</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +46-(0)8-580 223 00 </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>SIA Bayer</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +371-67
  84 55 63</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer plc</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +44-(0)118
  206 3000</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in </span></b><span lang=EN-GB>{MM/YYYY}
</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency website: </span><span lang=EN-GB style='color:blue'><a
href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span><span
lang=EN-GB style='color:black'>. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&lt;--------------------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal style='margin-right:-1.4pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:-1.85pt;margin-bottom:.0001pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:-1.85pt;margin-bottom:.0001pt;line-height:normal'><b><span
lang=EN-GB>The following information is intended for healthcare professionals
only:</span></b></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The pre-filled
syringe should only be used <b>for the treatment of a single eye.</b></span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Do not open the sterile
pre-filled blister outside the clean administration room.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The solution should be inspected visually
for any foreign particulate matter and/or discolouration or any variation in
physical appearance prior to administration. In the event of either being
observed, discard the medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The unopened
blister may be stored outside the refrigerator below 25&nbsp;C for up to
24&nbsp;hours. After opening the blister, proceed under aseptic conditions.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>For the
intravitreal injection, a 30&nbsp;G x  inch injection needle should be used.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><b><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Instructions for
use of pre-filled syringe:</span></i></b></p>

<p class=GlobalBayerBodyText style='margin:0in'><b><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=651
 style='width:488.2pt;border-collapse:collapse'>
 <tr style='height:41.35pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:41.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>1.</span></p>
  </td>
  <td width=617 colspan=2 valign=top style='width:462.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:41.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When ready to
  administer Eylea, open the carton and remove the sterilised blister.
  Carefully peel open the blister ensuring the sterility of its contents. Keep
  the syringe in the sterile tray until you are ready for assembly.</span></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>2.</span></p>
  </td>
  <td width=617 colspan=2 valign=top style='width:462.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>Using aseptic technique, remove the
  syringe from the sterilised blister.</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:157.35pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:157.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>3.</span></p>
  </td>
  <td width=323 valign=top style='width:241.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:157.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>To remove the
  syringe cap, hold the syringe in one hand while using the other hand to grasp
  the syringe cap with the thumb and fore finger. Please note: You should twist
  off (do not snap off) the syringe cap. </span></p>
  </td>
  <td width=294 valign=top style='width:220.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:157.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><img border=0 width=214 height=214
  src="Eylea_IB_007_files/image027.jpg"></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>4.</span></p>
  </td>
  <td width=617 colspan=2 valign=top style='width:462.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>To avoid compromising the sterility of
  the product, do not pull back on the plunger.</span></p>
  </td>
 </tr>
 <tr style='height:158.2pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:158.2pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>5.</span></p>
  </td>
  <td width=323 valign=top style='width:241.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:158.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Using aseptic
  technique, firmly twist the injection needle onto the Luer-lock syringe tip.</span></p>
  </td>
  <td width=294 valign=top style='width:220.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:158.2pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB><img border=0 width=214 height=195
  src="Eylea_IB_007_files/image028.jpg"></span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=617 colspan=2 valign=top style='width:462.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:150.35pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:150.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>6.</span></p>
  </td>
  <td width=323 valign=top style='width:241.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:150.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Holding the
  syringe with the needle pointing up, check the syringe for bubbles. If there
  are bubbles, gently tap the syringe with your finger until the bubbles rise
  to the top.</span></p>
  </td>
  <td width=294 valign=top style='width:220.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:150.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB><img border=0 width=213 height=213
  src="Eylea_IB_007_files/image029.jpg"></span></p>
  </td>
 </tr>
 <tr style='height:50.45pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.45pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>7.</span></p>
  </td>
  <td width=617 colspan=2 valign=top style='width:462.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.45pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Eliminate all bubbles and expel excess medicinal product by slowly
  depressing the plunger rod to align the cylindrical base of the plunger dome
  edge with the black dosing line on the syringe (equivalent to
  50&nbsp;microlitres).</span></p>
  </td>
 </tr>
 <tr style='height:179.9pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:179.9pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=323 valign=top style='width:241.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:179.9pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><img border=0 width=212
  height=212 src="Eylea_IB_007_files/image030.jpg"></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=294 valign=top style='width:220.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:179.9pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span style='position:relative;
  z-index:251656192'><span style='position:absolute;left:-3px;top:-32979px;
  width:180px;height:1px'><img width=180 height=1
  src="Eylea_IB_007_files/image031.gif"></span></span><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal>&nbsp;</p>
  <br clear=ALL>
  <p class=MsoNormal><img border=0 width=81 height=81
  src="Eylea_IB_007_files/image032.gif"></p>
  </td>
 </tr>
 <tr style='height:50.45pt'>
  <td width=34 valign=top style='width:25.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.45pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>8. </span></p>
  </td>
  <td width=617 colspan=2 valign=top style='width:462.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.45pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The pre-filled
  syringe is for single use only. Extraction of multiple doses from a
  pre-filled syringe may increase the risk of contamination and subsequent
  infection.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
  medicinal product or waste material should be disposed of in accordance with
  local requirements.</span></p>
  </td>
 </tr>
</table>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package Leaflet: Information for the patient</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB style='color:black'>Eylea 40&nbsp;mg/mL solution for injection in a
vial</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB style='color:black'>aflibercept</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you are given this medicine because it contains
important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor. This includes any possible side effects not listed in this leaflet. See
section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. What Eylea is and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. What you need to know before you are given
Eylea </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. How you will be given Eylea </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Possible side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5. How to store Eylea </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What Eylea is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Eylea is a solution which is injected into the eye to treat eye
conditions in adults called </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>neovascular (wet) age-related macular
degeneration (wet AMD), </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>impaired vision due to macular oedema secondary
to retinal vein occlusion (branch RVO (BRVO) or central RVO (CRVO)),</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>impaired vision due to diabetic macular oedema
(DME),</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>impaired vision due to myopic choroidal
neovascularisation (myopic CNV).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Aflibercept, the active substance in Eylea, blocks the activity of a
group of factors, known as Vascular Endothelial Growth Factor A (VEGF-A) and
Placental Growth Factor (PlGF). </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In patients with wet AMD and myopic CNV, these factors, in excess are
involved in the abnormal formation of new blood vessels in the eye. These new
blood vessels can cause the leak of blood components into the eye and eventual
damage to tissues in the eye responsible for vision. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In patients with CRVO, a blockage occurs in the main blood vessel
that transports blood away from the retina. VEGF levels are elevated in
response causing the leakage of fluid into the retina and thereby causing a swelling
of the macula, (the portion of the retina responsible for fine vision), which
is called macular oedema. When the macula swells with fluid, central vision
becomes blurry.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In patients with BRVO, one or more branches of the main blood vessel
that transports blood away from the retina is blocked. VEGF levels are elevated
in response causing the leakage of fluid into the retina and thereby causing
macular oedema.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Diabetic macular oedema is a swelling of the retina occurring in
patients with diabetes due to leaking of fluid from blood vessels within the
macula. The macula is the portion of retina responsible for fine vision. When
the macula swells with fluid, central vision becomes blurry.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Eylea has been shown to stop the growth of new abnormal blood
vessels in the eye </span><span lang=EN-GB>which often leak fluid or bleed</span><span
lang=EN-GB>. Eylea can help to stabilise, and in many cases, improve the vision
loss related to wet AMD, CRVO, BRVO, DME and myopic CNV.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What you need to know before you are
given Eylea</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>You will not be given Eylea</span></b></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to aflibercept or any of the
other ingredients of this medicine (listed in section&nbsp;6&nbsp;).</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have an active or suspected infection in
or around the eye (ocular or periocular infection).</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have severe inflammation of the eye
(indicated by pain or redness). </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Talk to your
doctor before you are given Eylea:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have glaucoma.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a history of seeing flashes of light
or floaters and if you have a sudden increase of size and number of floaters.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if surgery was performed or is planned on your
eye within the previous or next four weeks.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a severe form of CRVO or BRVO
(ischaemic CRVO or BRVO), treatment with Eylea is not recommended.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Furthermore, it is important for you to know that:</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>the safety and efficacy of Eylea when
administered to both eyes at the same time has not been <span style='color:
black'>studied </span></span><span lang=EN-GB style='color:black'>and if used
in this way may lead to an increased risk of experiencing side effects.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>injections with Eylea may</span><span
lang=EN-GB> cause an increase in eye pressure (intraocular pressure) in some
patients within 60&nbsp;minutes of the injection. </span><span lang=EN-GB>Your
doctor will monitor this after each injection.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you develop an infection or inflammation
inside the eye (endophthalmitis) or other complications, you may have eye pain
or increased discomfort, worsening eye redness, blurred or decreased vision,
and increased sensitivity to light. It is important to have any symptoms
diagnosed and treated as soon as possible. </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>your doctor will check whether you have other
risk factors that may increase the chance of a tear or detachment of one of the
layers at the back of the eye (retinal detachment or tear, and retinal pigment
epithelial detachment or tear), in which case Eylea must be given with caution.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Eylea should not be used in pregnancy unless the
potential benefit outweighs the potential risk to the unborn child. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>women of childbearing potential have to use
effective contraception during treatment and for at least three further months
after the last injection of Eylea.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='layout-grid-mode:line'>The systemic use of VEGF inhibitors,
substances similar to those contained in Eylea, is potentially related to the
risk of</span><span lang=EN-GB> blood clots blocking blood vessels (arterial
thromboembolic events) which may lead to heart attack or stroke. There is a
theoretical risk of such events following injection of Eylea into the eye. </span><span
lang=EN-GB style='color:black'>There are limited data on safety in treating
patients with CRVO, BRVO, DME and myopic CNV who have had a stroke or a
mini-stroke (transient ischaemic attack) or a heart attack within the last 6
months. If any of these apply to you, Eylea will be given with caution. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is only
limited experience in the treatment of </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients with DME due to type I diabetes.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diabetics with very high average blood sugar
values (HbA1c over 12%).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diabetics with an eye disease caused by diabetes
called proliferative diabetic retinopathy.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
experience in the treatment of </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients with acute infections.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients with other eye conditions such as a
detachment of the retina or a hole in the macula.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diabetics with uncontrolled high blood pressure.
</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>non-Asian patients with myopic CNV.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients previously treated for myopic CNV.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients with damage<span style='color:red'> </span>outside
the central part of the macula (extrafoveal lesions) for myopic CNV.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If any of the
above applies to you, your doctor will consider this lack of information when
treating you with Eylea.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>The use of Eylea in children or adolescents
under&nbsp;18 has not been studied because wet AMD, CRVO, BRVO, DME and myopic
CNV occur mainly in adults. Therefore, its use in this age group is not
relevant.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other medicines and Eylea</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor if you are using, have recently used or might use
any other medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=BayerBodyTextFull style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB
style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Women of childbearing
potential have to use effective contraception during treatment and for at least
three further months after the last injection of Eylea.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>- There is no experience of using
Eylea in pregnant women. Eylea should not be used during pregnancy unless the
potential benefit outweighs the potential risk to the unborn child. If you are
pregnant or planning to become pregnant, discuss this with your doctor before
treatment with Eylea.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>- </span><span lang=EN-GB style='font-size:11.0pt'>Eylea is
not recommended during breast-feeding as it is not known whether Eylea passes
into human milk. Ask your doctor for advice before starting Eylea treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>After your injection with Eylea, you may experience some temporary
visual disturbances. Do not drive or use machines as long as these last.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Important information about some of the ingredients of Eylea</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per
dosage unit, that is to say essentially sodium-free.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>How you will be given Eylea</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>A doctor experienced in giving eye injections will inject Eylea into
your eye under aseptic (clean and sterile) conditions. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The recommended dose is 2&nbsp;mg aflibercept (50&nbsp;microlitres).
</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Eylea is given as an injection into your eye (intravitreal
injection). </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Before the injection your doctor will use a disinfectant eyewash to
clean your eye carefully to prevent infection. Your doctor will also give you a
local anaesthetic to reduce or prevent any pain you might have with the
injection. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>wet AMD</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Patients with wet AMD will be treated with one injection per month
for three consecutive doses, followed by another injection after a further two
months. </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Your doctor will then decide whether the treatment interval between
injections may be kept at every two months or be gradually extended in 2- or
4-weekly intervals if your condition has been stable. If your condition
worsens, the interval between injections can be shortened, but to not less than
every two months in the first year of treatment. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Unless you experience any problems or are advised differently by
your doctor, there is no need for you to see your doctor between the
injections.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><u><span
lang=EN-GB>Macular oedema secondary to RVO (branch RVO or central RVO)</span></u></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Your doctor will determine the most
appropriate treatment schedule for you. You will start your treatment with a
series of monthly Eylea injections. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The interval between two injections should
not be shorter than one month.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Your doctor may decide to stop treatment
with Eylea, if you are not benefiting from continued treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Your treatment will continue with
&nbsp;monthly injections until your condition is stable. Three or more monthly
injections may be needed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Your doctor will monitor your response to
treatment and may continue your treatment by gradually increasing the interval
between your injections to maintain a stable condition. If your condition
starts to worsen with a longer treatment interval, your doctor will shorten the
interval accordingly.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Based on your response to treatment your doctor will decide on the
schedule for follow up examinations and treatments. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><u><span
lang=EN-GB>Diabetic macular oedema (DME)</span></u></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Patients with DME will be treated with one injection per month for
the first five consecutive doses followed by one injection every two months
thereafter. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Unless you experience any problems or are advised differently by
your doctor, there is no need for you to see your doctor between the
injections.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>After the first 12 months of treatment with Eylea, the treatment
interval may be extended based on your doctors examination. </span><span
lang=EN-GB>Your doctor will decide on the schedule for follow up examinations.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Your doctor may decide to stop treatment with Eylea if it is
determined that you are not benefiting from continued treatment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><u><span
lang=EN-GB>Myopic CNV</span></u></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Patients with myopic CNV will be treated with one single injection.
You will receive further injections only if your doctors examinations reveal
that your condition has not improved.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The interval between two injections should
not be shorter than one month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If your condition goes away and then comes back, your doctor may
re-start the treatment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Your doctor will decide on the schedule for follow up examinations.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If a dose of Eylea is missed</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Make a new appointment for an examination and injection.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Stopping treatment with Eylea</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Consult your doctor before stopping the treatment. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4. Possible side
effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Like all medicines, this medicine can cause side
effects, although not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Allergic reactions</span></b><span
lang=EN-GB> (hypersensitivity) could potentially occur. <b>These may be serious
and require that you contact your doctor immediately.</b></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>With administration of Eylea, there may be some side effects affecting
the eyes which are due to the injection procedure. Some of these may be <b>serious</b>
and include <b>blindness</b>,<b> a serious infection or</b> <b>inflammation
inside the eye</b> (endophthalmitis),<b> </b></span><b><span lang=EN-GB>detachment,
tear or bleeding of the light-sensitive layer at the back of the eye </span></b><span
lang=EN-GB style='layout-grid-mode:line'>(retinal detachment or tear), </span><b><span
lang=EN-GB>clouding of the lens</span></b><span lang=EN-GB> (cataract), <b>bleeding
in the eye </b>(vitreous haemorrhage), <b>detachment of the gel-like substance
inside the eye from the retina</b> (vitreous detachment) and <b>increase of
pressure inside the eye</b>, see section 2. These serious side effects affecting
the eyes occurred in less than 1 in 1,900 injections in clinical studies.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you experience a sudden decrease in
vision, or an increase in pain and redness in your eye after your injection, <b>contact
your doctor immediately</b>. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>List of side effects reported</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>The following is a list of the side effects
reported to be possibly related to the injection procedure or to the medicine.
Please do not get alarmed, you might not experience any of these. Always
discuss any suspected side effects with your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Very common side effects</span></b><span lang=EN-GB> <i>(may affect
more than 1 in 10 people):</i></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>deterioration of
eyesight </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>bleeding in the
back of the eye (retinal haemorrhage)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>bloodshot eye
caused by bleeding from small blood vessels in the outer layers of the eye </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>eye pain</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black;layout-grid-mode:line'>Common</span></b><b><span lang=EN-GB
style='layout-grid-mode:line'> side effects </span></b><i><span lang=EN-GB>(may
affect up to 1 in 10 people):</span></i></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>detachment or tear of one of the layers in the
back of the eye, resulting in flashes of light with floaters sometimes
progressing to a loss of vision (retinal pigment epithelial tear*/detachment,
retinal detachment/tear)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>degeneration of the retina (causing disturbed
vision)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bleeding in the eye (vitreous haemorrhage)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>certain forms of clouding of the lens (cataract)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>damage to the front layer of the eyeball (the cornea)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>increase in eye
pressure </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>moving spots in
vision (floaters)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>detachment of the gel-like substance inside the
eye from the retina (vitreous detachment, </span><span lang=EN-GB>resulting in
flashes of light with floaters</span><span lang=EN-GB>)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a feeling of having something in the eye</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased tear production</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of the eyelid </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bleeding at the injection site</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>redness of the eye </span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB>* Conditions known to be associated with wet AMD;
observed in wet AMD patients only.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black;layout-grid-mode:line'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB style='color:black;layout-grid-mode:line'>U</span></b><b><span
lang=EN-GB style='layout-grid-mode:line'>ncommon side effects </span></b><i><span
lang=EN-GB>(may affect up to 1 in 100 people):</span></i></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>allergic reactions (hypersensitivity)**</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>serious inflammation or infection inside the eye
(endophthalmitis)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation in the iris or other parts of the
eye (iritis, uveitis, iridocyclitis, anterior chamber flare)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormal sensation in the eye</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>eyelid irritation</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of the front layer of the eyeball
(cornea)</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black;layout-grid-mode:line'>** Allergic reactions like
rash, itching (pruritus), hives (urticaria), and a few cases of severe allergy
(anaphylactic/anaphylactoid) reactions were reported.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black;layout-grid-mode:line'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black;layout-grid-mode:line'>Rare</span></b><b><span lang=EN-GB
style='layout-grid-mode:line'> side effects </span></b><i><span lang=EN-GB>(may
affect up to 1 in 1,000 people):</span></i></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blindness</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>clouding of the
lens due to injury (traumatic cataract)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>inflammation of </span><span
lang=EN-GB>the gel-like substance inside the eye</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='layout-grid-mode:line'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='layout-grid-mode:line'>pus in the eye </span></p>

<p class=MsoNormal style='margin-left:21.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Para0s style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif;layout-grid-mode:line'>In
the clinical trials, there was an increased incidence of bleeding from small
blood vessels in the outer layers of the eye (conjunctival haemorrhage) in
patients with wet AMD receiving blood thinners. This increased incidence was
comparable between patients treated with ranibizumab and Eylea.</span></p>

<p class=Para0s style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif;layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>The systemic use of VEGF inhibitors, substances
similar to those contained in Eylea, is potentially related to the risk of blood
clots blocking blood vessels (arterial thromboembolic events<span
style='color:black'>)</span> <span style='color:black'>which may lead to </span>heart
attack or stroke. There is a theoretical risk of such events following
injection of Eylea into the eye.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As with all
therapeutic proteins, there is a possibility for an immune reaction (formation
of antibodies) with Eylea. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB style='color:black;layout-grid-mode:line'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you get any side effects, talk to your doctor. This includes any
possible side effects not listed in this leaflet.</span><span lang=EN-GB> </span><span
lang=EN-GB>You can also report side effects directly via <span
style='background:silver'>the national reporting system listed <span
style='color:black'>in </span></span></span><span lang=EN-GB style='background:
silver'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a>.</span><span lang=EN-GB> By reporting side effects, you can help provide
more information on the safety of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5. How to store Eylea</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this medicine out of the sight and reach of
children.</span></p>

<p class=MsoNormal style='margin-left:30.0pt;text-indent:-30.0pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use this medicine after the expiry date
which is stated on the carton and label after EXP. The expiry date refers to
the last day of that month.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Store in a refrigerator (2C - 8C). Do not
freeze.</span></p>

<p class=MsoNormal style='margin-left:30.0pt;text-indent:-30.0pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The unopened vial may be stored outside the
refrigerator below 25C for up to 24&nbsp;&nbsp;hours.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;line-height:
normal;page-break-after:avoid'><a name="_Hlk34659085"><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Store in the original package</span></a><span
lang=EN-GB> in order to protect from light.</span></p>

<p class=MsoNormal style='margin-left:30.0pt;text-indent:-30.0pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not throw away any medicines via wastewater or
household waste. Ask your pharmacist how to throw away any medicines you no
longer use. These measures will help protect the environment.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.75in;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>6. </span><span lang=EN-GB>Contents of the
pack and other information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What Eylea contains </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal;
page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is: aflibercept. One vial
contains 100&nbsp;microlitres, equivalent to 4&nbsp;mg aflibercept. One vial
delivers a dose of 2&nbsp;mg aflibercept in 50&nbsp;microlitres.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are: polysorbate&nbsp;20
(E&nbsp;432), sodium dihydrogen phosphate monohydrate </span><span lang=EN-GB>(for
pH adjustment)</span><span lang=EN-GB>, disodium hydrogen phosphate
heptahydrate </span><span lang=EN-GB>(for pH adjustment)</span><span
lang=EN-GB>, sodium chloride, sucrose, water for injections.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What Eylea looks like and contents of the pack</span></b></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Eylea is a</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>
solution for injection (injection) in a vial (4&nbsp;mg/100&nbsp;microlitres).
The solution is colourless to pale yellow.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Pack size of 1 vial
+ 1 filter needle.</span></p>

<p class=BayerBodyTextFull style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Bayer AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>51368 Leverkusen</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Manufacturer </span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Bayer AG </span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Mllerstrae 178 </span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>13353 Berlin </span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-family:"Tms Rmn",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=DE>Belgi / Belgique / Belgien</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=DE>Bayer SA-NV</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Tl/Tel: +32-(0)2-535 63 11</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>UAB Bayer</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Tel: +370-5-233 68 68</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>&#1041;&#1072;&#1081;&#1077;&#1088;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>&#1058;&#1077;&#1083;: +359-(0)2-</span><span lang=EN-GB
  style='color:black'>424 72 80</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=DE>Luxembourg / Luxemburg</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=DE>Bayer SA-NV</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=DE>Tl/Tel: +32-(0)2-535 63 11</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=DE>&#268;esk
  republika</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Bayer s.r.o.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +420-266
  101 111</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB>Magyarorszg</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Bayer Hungria KFT</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +36-1-487 4100</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Bayer A/S</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Tlf: +45-45 235 000</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Alfred Gera
  and Sons Ltd.</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Tel: +356-21 44 62 05</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Bayer Vital GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Tel:
  +49-(0)214-30 513 48</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=DE>Nederland</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=DE>Bayer B.V.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Tel:
  +31(0)297-28 06 66</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer O</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +372-655
  85 65</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer AS</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tlf: +47-23
  13 05 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer
  &#917;&#955;&#955;&#940;&#962; &#913;&#914;&#917;&#917;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&#932;&#951;&#955;: +30-210-618
  75 00</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=DE>sterreich</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Bayer Austria
  Ges. m. b. H.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +43-(0)1-711 460</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Espaa</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer Hispania
  S.L.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +34-93-495 65 00</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Polska</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer Sp. z
  o.o.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +48-22-572 35 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Bayer
  HealthCare</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tl (N
  vert): +33-(0)800 87 54 54</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Portugal</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer
  Portugal, Lda.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +351-21-416 42 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=DE>Hrvatska</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=DE>Bayer d.o.o.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +
  385-(0)1-6599 900</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Romnia</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>SC Bayer SRL </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +40-(0)21-528 59 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer Limited</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +353-(0)1-216 3300</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer d. o.
  o.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +386-(0)1-58 14 400</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>sland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Icepharma hf.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Smi:
  +354-540 80 00</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Slovensk
  republika</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer, spol.
  s r.o.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +421-(0)2-59 21 31 11</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Italia</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer S.p.A.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +39-02-3978 1</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=DE>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Bayer Oy</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Puh/Tel:
  +358-(0)20-78521 </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>NOVAGEM
  Limited</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&#932;&#951;&#955;:
  +357-22-48 38 58</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer AB</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel:
  +46-(0)8-580 223 00 </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>SIA Bayer</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +371-67
  84 55 63</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Bayer plc</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +44-(0)118
  206 3000</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=326 valign=top style='width:244.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in </span></b><span lang=EN-GB>{MM/YYYY}
</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency website: </span><span lang=EN-GB style='color:blue'><a
href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span><span
lang=EN-GB style='color:black'>. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&lt;--------------------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal style='margin-right:-1.4pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:-1.85pt;margin-bottom:.0001pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:-1.85pt;margin-bottom:.0001pt;line-height:normal'><b><span
lang=EN-GB>The following information is intended for healthcare professionals
only:</span></b></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The vial should only be used <b>for the treatment of a single eye.</b></span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The solution should be inspected visually for any foreign
particulate matter and/or discolouration or any variation in physical
appearance prior to administration. In the event of either being observed,
discard the medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The unopened vial
may be stored outside the refrigerator below 25&nbsp;C for up to
24&nbsp;hours. After opening the vial, proceed under aseptic conditions.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>For the
intravitreal injection, a 30 G x </span> <span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>inch injection needle should be
used.</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><i><span lang=EN-GB>Instructions for use of
vial:</span></i></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=642
 style='width:481.85pt;border-collapse:collapse'>
 <tr style='height:148.45pt'>
  <td width=35 valign=top style='width:26.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:148.45pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>1.</span></p>
  </td>
  <td width=347 valign=top style='width:260.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:148.45pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Remove the
  plastic cap and disinfect the outer part of the rubber stopper of the vial.</span></p>
  </td>
  <td width=260 valign=top style='width:195.3pt;padding:0in 5.4pt 0in 5.4pt;
  height:148.45pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB><img border=0
  width=234 height=194 id="Picture 32" src="Eylea_IB_007_files/image033.gif"></span></p>
  </td>
 </tr>
 <tr style='height:157.35pt'>
  <td width=35 valign=top style='width:26.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:157.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>2.</span></p>
  </td>
  <td width=347 valign=top style='width:260.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:157.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Attach the
  18&nbsp;G, 5-micron filter needle supplied in the carton to a 1&nbsp;mL
  sterile Luer-lock syringe.</span></p>
  </td>
  <td width=260 valign=top style='width:195.3pt;padding:0in 5.4pt 0in 5.4pt;
  height:157.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB><img border=0
  width=234 height=201 id="Picture 33" src="Eylea_IB_007_files/image034.gif"></span></p>
  </td>
 </tr>
 <tr>
  <td width=35 valign=top style='width:26.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>3.</span></p>
  </td>
  <td width=607 colspan=2 valign=top style='width:455.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Push the
  filter needle into the centre of the vial stopper until the needle is
  completely inserted into the vial and the tip touches the bottom or bottom
  edge of the vial.</span></p>
  </td>
 </tr>
 <tr style='height:150.05pt'>
  <td width=35 valign=top style='width:26.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:150.05pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>4.</span></p>
  </td>
  <td width=347 valign=top style='width:260.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:150.05pt'>
  <p class=MsoNormal><span lang=EN-GB>Using aseptic technique withdraw all of
  the Eylea vial contents into the syringe, keeping the vial in an upright
  position, slightly inclined to ease complete withdrawal. To deter the
  introduction of air, ensure the bevel of the filter needle is submerged into
  the liquid. Continue to tilt the vial during withdrawal keeping the bevel of
  the filter needle submerged in the liquid</span><span lang=EN-GB>.</span></p>
  </td>
  <td width=260 valign=top style='width:195.3pt;padding:0in 5.4pt 0in 5.4pt;
  height:150.05pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:29.55pt'>
  <td width=35 valign=top style='width:26.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:29.55pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=607 colspan=2 valign=top style='width:455.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:29.55pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:#990099'><img border=0 width=241 height=212
  src="Eylea_IB_007_files/image035.jpg"> <img border=0
  width=241 height=213 src="Eylea_IB_007_files/image036.jpg"></span></p>
  </td>
 </tr>
 <tr style='height:29.55pt'>
  <td width=35 valign=top style='width:26.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:29.55pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>5.</span></p>
  </td>
  <td width=607 colspan=2 valign=top style='width:455.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:29.55pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ensure that
  the plunger rod is drawn sufficiently back when emptying the vial in order to
  completely empty the filter needle.</span></p>
  </td>
 </tr>
 <tr style='height:30.05pt'>
  <td width=35 valign=top style='width:26.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:30.05pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>6.</span></p>
  </td>
  <td width=607 colspan=2 valign=top style='width:455.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:30.05pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Remove the
  filter needle and properly dispose of it.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Note: Filter
  needle is not to be used for intravitreal injection.</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:149.4pt'>
  <td width=35 valign=top style='width:26.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:149.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>7.</span></p>
  </td>
  <td width=347 valign=top style='width:260.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:149.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Using aseptic
  technique, firmly twist a 30&nbsp;G x&nbsp;&nbsp;inch injection needle onto
  the Luer-lock syringe tip.</span></p>
  </td>
  <td width=260 valign=top style='width:195.3pt;padding:0in 5.4pt 0in 5.4pt;
  height:149.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB><img border=0 width=234 height=188
  id="Picture 35" src="Eylea_IB_007_files/image037.gif"></span></p>
  </td>
 </tr>
 <tr style='height:20.85pt'>
  <td width=35 valign=top style='width:26.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:20.85pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=607 colspan=2 valign=top style='width:455.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:20.85pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:142.5pt'>
  <td width=35 valign=top style='width:26.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:142.5pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>8.</span></p>
  </td>
  <td width=347 valign=top style='width:260.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:142.5pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Holding the
  syringe with the needle pointing up, check the syringe for bubbles. If there
  are bubbles, gently tap the syringe with your finger until the bubbles rise
  to the top.</span></p>
  </td>
  <td width=260 valign=top style='width:195.3pt;padding:0in 5.4pt 0in 5.4pt;
  height:142.5pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB><img border=0 width=235 height=199
  src="Eylea_IB_007_files/image038.jpg"></span></p>
  </td>
 </tr>
 <tr style='height:33.85pt'>
  <td width=35 valign=top style='width:26.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:33.85pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>9.</span></p>
  </td>
  <td width=607 colspan=2 valign=top style='width:455.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:33.85pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Eliminate all
  bubbles and expel excess medicinal product by slowly depressing the plunger
  so that the plunger tip aligns with the line that marks 0.05&nbsp;mL on the
  syringe.</span></p>
  </td>
 </tr>
 <tr style='height:169.3pt'>
  <td width=35 valign=top style='width:26.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:169.3pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=347 valign=top style='width:260.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:169.3pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB><img border=0 width=231 height=215
  src="Eylea_IB_007_files/image039.jpg"></span></p>
  </td>
  <td width=260 valign=top style='width:195.3pt;padding:0in 5.4pt 0in 5.4pt;
  height:169.3pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB><img border=0 width=240 height=219
  src="Eylea_IB_007_files/image040.jpg"></span></p>
  </td>
 </tr>
 <tr style='height:29.95pt'>
  <td width=35 valign=top style='width:26.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:29.95pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><span lang=EN-GB>10.</span></p>
  </td>
  <td width=607 colspan=2 valign=top style='width:455.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:29.95pt'>
  <p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>The vial is for
  single use only. Extraction of multiple doses from a single vial may increase
  the risk of contamination and subsequesnt infection.</span></p>
  <p class=MsoNormal style='margin-left:1.5pt;text-indent:-1.5pt;line-height:
  normal'><span lang=EN-GB>Any unused medicinal product or waste material
  should be disposed of in accordance with local requirements.</span></p>
  </td>
 </tr>
</table>

<p class=GlobalBayerBodyText style='margin:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
line-height:normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
line-height:normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
line-height:normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
line-height:normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
line-height:normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:7.0pt;margin-left:6.35pt;text-align:center;line-height:14.0pt;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:7.0pt;margin-left:6.35pt;text-align:center;line-height:14.0pt;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:7.0pt;margin-left:6.35pt;text-align:center;line-height:14.0pt;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:7.0pt;margin-left:6.35pt;text-align:center;line-height:14.0pt;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:7.0pt;margin-left:6.35pt;text-align:center;line-height:14.0pt;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:7.0pt;margin-left:6.35pt;text-align:center;line-height:14.0pt;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:7.0pt;margin-left:6.35pt;text-align:center;line-height:14.0pt;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:7.0pt;margin-left:6.35pt;text-align:center;line-height:14.0pt;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:7.0pt;margin-left:6.35pt;text-align:center;line-height:14.0pt;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:7.0pt;margin-left:6.35pt;text-align:center;line-height:14.0pt;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:7.0pt;margin-left:6.35pt;text-align:center;line-height:14.0pt;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:7.0pt;margin-left:6.35pt;text-align:center;line-height:14.0pt;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:7.0pt;margin-left:6.35pt;text-align:center;line-height:14.0pt;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:7.0pt;margin-left:6.35pt;text-align:center;line-height:14.0pt;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:7.0pt;margin-left:6.35pt;text-align:center;line-height:14.0pt;
text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

</div>

</body>

</html>
